Money Talk Sundayz: Recent Episodes
Stevenson Benoit
Become a Paid Subscriber: https://anchor.fm/moneytalksundayz/subscribe
Money Talk Sundayz is a weekly podcast started by the Investment Bros as they document their journey to their first $100K in the market. Join the bros as they discuss stocks, crypto, swing trading, options, and more.
Hello, listeners! Welcome back to Money Talk Sundayz, the podcast that brings economic events from around the world into focus. I'm your host, Stevie bee, and today we're going to tackle a critical issue that's hitting headlines: the decision of Saudi Arabia and other oil producing countries to cut oil production by a million barrels per day. We'll explore why this impacts the economy, drives up the price of gas, and its effect on the stock market. Don’t forget to like, share, and subscribe! Cue the music!
To begin with, let's talk about oil. Oil is a non-renewable resource, and it's a crucial component of our global economy. It powers our vehicles, heats our homes, and even plays a role in producing products like plastics and synthetic materials. It's an economic lifeblood, so to speak. That means when the flow of this lifeblood slows, it has significant ripple effects.
Now, Saudi Arabia, along with other oil-producing nations, have agreed to cut their oil production by a million barrels per day. Why does this matter? Well, economics is essentially the study of supply and demand. When supply decreases and demand stays the same or even increases, prices go up. That's exactly what's happening with oil right now. Less oil production means less supply. But our demand hasn't decreased; we still need oil to fuel our cars, heat our homes, and manufacture goods.
So, you might be wondering, why would these countries cut production? The answer lies in their status as the dominant players in the global oil market. By limiting the supply, they have the power to manipulate the prices and increase their revenue. While this may seem like a smart move for these countries, it can cause hardship for nations dependent on oil imports and everyday people at the gas pump.
When oil prices rise, the cost of producing goods and services that rely on oil also increases. Think about the transport sector. Trucks, trains, and ships all use oil-based fuel. So, when the price of oil goes up, the cost to transport goods increases. Companies often pass these costs onto the consumer, leading to a rise in the cost of goods.
But the impact isn't only at the consumer level; it's also felt in the broader economy. High oil prices can lead to inflation, reducing the purchasing power of consumers, which can then slow economic growth. At the same time, it can create economic uncertainty, leading to decreased investment in sectors heavily dependent on oil.
Zooming in on the impact on gas prices. The price you pay at the pump is directly linked to the price of oil. When oil prices rise, gas companies must pay more to refine crude oil into gasoline. These increased costs inevitably get passed down to consumers, leading to higher prices at the gas pump. So, the decision of Saudi Arabia and other oil producers to cut production will almost certainly be felt in your wallet next time you fill up your tank.
This situation underscores the importance of diversifying energy sources. If we, as a global society, were less dependent on oil, production cuts like this would have less impact on our economies and our daily lives. Investing in renewable energy sources not only addresses the immediate issue of volatile oil prices but also contributes to a more sustainable and environmentally friendly future.
Now, let's turn our attention to the world of investing, where oil stocks represent shares in oil companies. The fortunes of these stocks are deeply tied to the price of the oil, the company's profitability, and the overall health of the energy sector. When oil production diminishes and oil prices go up, oil companies generally record higher profits, providing a positive push to their stock prices.
Send in a voice message: https://podcasters.spotify.com/pod/show/moneytalksundayz/message
Hello, everyone! Welcome back to The Money Talk Sundayz Podcast where we untangle the complex world of finance and economics, one thread at a time. I'm your host, Stevie Bee, and today we're discussing an important topic that has been making the headlines recently: the strong jobs market report and its effect on the Federal Reserve’s decision on raising interest rates.
Don’t forget to hit that like, share, and subscribe button. For those that heeded my call on Nvidia, congratulations. You’re in the money! Let’s move on.
Now, I know this sounds like it will be quite jargon-heavy, but don't worry! We're going to break it down together.
First, let's talk about the Federal Reserve, or the Fed, as it's often called. The Fed is the central banking system of the United States, responsible for managing the country's money supply and maintaining the stability of its financial system. One of the primary tools they use to do this is by manipulating interest rates.
Interest rates are like the price of money. When you borrow money, you pay interest; when you save money, you earn interest. The Fed can raise or lower these rates to stimulate or slow down the economy, respectively.
Now, onto the jobs market report. This is a monthly announcement released by the Bureau of Labor Statistics. It provides crucial data on the state of employment in the country, indicating things like job creation, the unemployment rate, and wage growth.
Now the million dollar question is: why would the Federal Reserve raise interest rates based on a stronger jobs market report?
Well, the relationship between the two is fundamentally about managing the health of the economy. When the jobs market report indicates high employment rates and solid job growth, it's usually a sign that the economy is doing well. More people working means more income being earned and, consequently, more spending. This increased spending fuels economic growth.
However, there's a delicate balance to be struck here. Too much economic growth too quickly can lead to inflation. Inflation is when the price of goods and services increases, eroding the purchasing power of money.
So, imagine this: the economy is humming along nicely, job growth is strong, and wages are rising. That means more people have money to spend. If the supply of goods and services doesn't keep up with this increased demand, prices will rise — that's inflation.
Now, this is where the Fed steps in with its interest rate lever. To keep inflation in check, the Fed may raise interest rates. Higher interest rates make borrowing more expensive, which can curb spending and slow down the economy. In a way, it's like tapping the brakes on an overheating engine.
So, in essence, a stronger jobs market report can signal a robust economy, but it also raises the specter of inflation. By adjusting interest rates, the Federal Reserve aims to maintain a healthy balance between economic growth and price stability.
If we remember several months ago, the Federal Reserve stated that in order to cool inflation they would need to raise interest rates, so much so to the point where millions of people would end up unemployed. A strong jobs market report is counter-productive forcing the Feds to reverse course on decreasing the amount of the interest rate as well as possibly increasing the frequency and length of increases going forward.
Now, it's important to remember that while all these dynamics are often textbook scenarios, in reality, the Fed takes into consideration a myriad of other economic indicators and global events to decide its monetary policy. A stronger jobs market report is a significant piece of the puzzle, but it's still just one piece.
Send in a voice message: https://podcasters.spotify.com/pod/show/moneytalksundayz/message
Hello everyone, and welcome to another episode of "Money Talk Sundayz." I'm your host, Stevie Bee, and today we're going to explore a seeming paradox in our economy. Don’t forget to like, share, and subscribe. Cue the music.
You've probably heard the news: employment rates are at an all-time high. But interestingly, Americans are not necessarily feeling wealthier. How can this be? Let's dive into it.
Let's start with a fundamental understanding. A high employment rate, while generally considered a good sign for the economy, does not automatically translate into overall wealth or prosperity for individuals. Why is that?
The first reason is that the quality of jobs matters as much, if not more, than the quantity. You see, having a high employment rate is great, but if most of those jobs are low-paying, or what economists refer to as 'low-quality jobs', then it's not necessarily beneficial for individuals. Low-quality jobs often lack benefits like healthcare, retirement plans, or paid time off. This means that while more people are working, they may still be struggling to make ends meet.
Secondly, the cost of living has been rising across many parts of the country, particularly in areas like housing, healthcare, and education. This has been outpacing wage growth, meaning that while people might be earning more, their expenses are increasing even faster. So, even though employment rates are up, Americans may have less disposable income and feel poorer as a result.
Another factor is income inequality. In recent years, the wealth gap has widened significantly. Many of the jobs being created are at either the very top or bottom of the wage scale, leaving fewer opportunities for middle-income jobs. This means more people are working, but the majority aren't earning as much as they need to truly prosper.
The nature of employment is also changing. We're seeing an increase in gig economy jobs, which often don't offer the same stability or benefits as traditional full-time employment. These types of jobs can contribute to a high employment rate but may not provide a livable wage or any long-term financial security.
So, how can we address these issues? It's a complex problem with no easy solutions, but some suggestions include promoting policies that encourage higher wages and better working conditions, investing in education and training to prepare workers for higher-quality jobs, and tackling the high costs in areas like housing and healthcare that put so much financial strain on individuals.
Thanks for joining us on today’s episode of "Money Talk Sundayz." It's important to remember that while a high employment rate is generally good news, we must look deeper to understand the full picture of our economic health. In the next episode I’m going to discuss how the latest jobs report will affect the Federal Reserve’s decision on raising interest rates further. That's it for today's episode. Until then, stay curious, keep questioning, and remember - economics is about more than numbers; it's about people.
Send in a voice message: https://podcasters.spotify.com/pod/show/moneytalksundayz/message
MemeCoins: Viable Trade Asset or Waste of TimeHello, and welcome back to Money Talk Sundayz, the podcast where we delve deep into the world of digital currencies. Today, we're taking a plunge into the colorful, whimsical, and potentially lucrative world of memecoins. You've probably heard the term, and you're wondering why these memecoins are raking in huge profits.Memecoins, for the uninitiated, are a subset of cryptocurrencies that emerged from internet memes or jokes. They might have started as fun and games, but the financial potential they've unlocked is no laughing matter.So, why the surge? First off, it's about the community. The strength of memecoins is often derived from the power of their communities. People band together, united by a common interest, a joke, or a meme, and that creates a sense of camaraderie that is often lacking in other cryptocurrencies. This active community engagement fosters a loyal user base that not only invests but also advocates for the coin, driving its value up.Secondly, we can't ignore the power of social media. In today's digital era, a viral tweet or a trending TikTok can have more influence on an asset's value than traditional market factors. Memecoins, by nature, are viral material. They're catchy, they're fun, and they're easy to share, which makes them incredibly susceptible to these viral trends.Next, we have the appeal of accessibility and affordability. Many of these memecoins are priced incredibly low compared to established giants like Bitcoin. This means that potential investors can buy millions, or even billions, of units with a relatively modest investment. The idea of owning a huge number of coins, coupled with the dream of those coins one day reaching even a fraction of the value of a Bitcoin, can be a powerful motivator.Lastly, let's talk about the 'David versus Goliath' narrative. The world of finance has often been seen as the playground of the elite. Cryptocurrency as a whole has challenged that, and memecoins take it a step further. They represent a defiance of traditional financial norms, an underdog story in the world of digital currency that people love to root for.Now, it's important to note that with high returns come high risks. Memecoins can be extremely volatile. While some see massive returns, others can and do lose their investment. This is why it's crucial to only invest money you can afford to lose, and to do your research before diving in.In conclusion, memecoins might have started as a joke, but they're having the last laugh. Their surging popularity and potential for high returns make them an intriguing, if risky, element of the cryptocurrency market. It's a fascinating space to watch, and as always, we'll be right here, keeping you up to date with all the latest developments.That's it for this episode of Money Talk Sundayz.' Stay tuned for our next episode, where we'll discuss the environmental impact of crypto mining. Until then, keep those wallets secure, and remember, in the world of cryptocurrency, knowledge is your most valuable asset."
--- Send in a voice message: https://podcasters.spotify.com/pod/show/moneytalksundayz/message
Welcome back to Money Talk Sundayz, the podcast where we make sense of the whirlwind world of cryptocurrency. I'm your host, Stevie Bee, and today we’re talking about a coin that's making waves in the market - PepeCoin. Over the past few months, we've seen an incredible surge in PepeCoin’s value. And today, we'll break down why that is.First, we need to understand what PepeCoin is. PepeCoin, like many other cryptocurrencies, is a decentralized digital currency that operates on blockchain technology. It was initially associated with the meme culture, particularly the 'Pepe the Frog' meme, and has now evolved into a prominent crypto asset.The surge in PepeCoin’s value can be attributed to a number of factors.First, the rise of meme culture in the financial sector has been a significant driving force. This trend was first seen with Dogecoin, another meme-inspired cryptocurrency. The success of Dogecoin seemed to indicate to investors that meme-driven currencies could indeed hold substantial value. As meme culture continues to grow and permeate different areas of life, it's no surprise that this phenomenon would have a significant impact on the crypto market.Secondly, PepeCoin has been embraced by the NFT or Non-Fungible Token market. NFTs, unique digital assets stored on the blockchain, have gained significant popularity recently. The creators of PepeCoin have cleverly leveraged this trend by launching a series of Pepe-themed NFTs. These digital collectibles have spurred interest in PepeCoin, contributing to its rise in value.Thirdly, let's talk community. The PepeCoin community, often referred to as 'Pepe-nauts', has been key in promoting the coin. This community has grown exponentially, bolstered by social media platforms and internet forums. Through grassroots marketing efforts, they've managed to generate buzz around PepeCoin, and when it comes to cryptocurrencies, buzz often translates to value.Finally, we can't ignore the general bullish trend in the crypto market. As more investors warm up to the idea of cryptocurrencies as legitimate investment vehicles, we've seen an overall increase in the value of many digital coins. PepeCoin has benefited from this larger trend.That said, as with any investment, it's important to exercise caution. Cryptocurrencies are known for their volatility, and while the rise of PepeCoin is impressive, it's also subject to sudden dips. Always ensure you're investing money you're willing to lose, and if you're new to the game, consider consulting with a financial advisor.It's an exciting time in the world of cryptocurrency, and PepeCoin is no exception. Whether it's the appeal of the meme, the integration with NFTs, the power of its community, or the overall bullish crypto market, it's clear that PepeCoin has captured the attention of investors around the world. As we move forward, it will be fascinating to see where this journey takes us.That's all for this episode of Money Talk Sundayz. Remember to stay informed, stay curious, and most importantly, stay secure in your crypto adventures.
--- Send in a voice message: https://podcasters.spotify.com/pod/show/moneytalksundayz/message
Hello, and welcome to today's episode of 'Money Talk Sundayz'. I'm your host, Stevie Bee, and today we're diving into a topic that's been making headlines all around the world: the stock market and its seemingly unshakeable relationship with the U.S. debt ceiling.Now, if you're a seasoned investor, you're likely aware of the turmoil that ensues every time this topic resurfaces. If you're new to the scene, don't worry. By the end of this podcast, you'll have a clearer understanding of why this little thing called the debt ceiling is causing such a big stir.First things first, what is the debt ceiling? Well, simply put, it's the maximum amount of money that the U.S. government can borrow. Now, why would the government need to borrow money? To fund a myriad of things, from military operations to social services, infrastructure, and everything in between.However, there's a catch. The debt ceiling needs to be increased periodically to keep up with the spending demands of a growing economy. Without this increase, the government can default on its debts, causing economic uncertainty and a ripple effect that can send waves across global markets.Now, let's connect the dots between this debt ceiling and the stock market.When there's uncertainty around the debt ceiling, investors get jittery. The possibility of a government default sends shivers down their spines. It's important to remember that the stock market is, in essence, a reflection of future expectations. When investors are faced with a potential default, they predict a bleak future, leading to a sell-off of stocks, which in turn causes the market to struggle.The stock market thrives on stability and predictability. The back-and-forth around the debt ceiling creates an environment of uncertainty. Investors cannot plan for the future if they're unsure whether the government will default on its obligations or not.Moreover, if the debt ceiling is not increased and the U.S. defaults, the credit rating of the country may be downgraded. This downgrade can increase borrowing costs, not just for the government, but for corporations as well. This can directly impact their profitability, and by extension, their stock prices.The debt ceiling also plays a significant role in fiscal policy. If the ceiling isn't raised, government spending will need to be cut dramatically. This could lead to a slowdown in economic growth, another factor that could negatively impact the stock market.In conclusion, until the debt ceiling issue is resolved, the stock market will struggle to rally. The uncertainty and potential negative consequences of a default create an environment that's not conducive to a thriving stock market.It's important to keep this in mind as you navigate your investment journey. Remember, investing is not just about picking the right stocks. It's also about understanding the macroeconomic factors that can influence the performance of those stocks.And with that, we've reached the end of today's episode. Thanks for joining me on Money Talk Sundayz. As always, invest smart and stay informed. Happy Trading.
--- Send in a voice message: https://podcasters.spotify.com/pod/show/moneytalksundayz/message
Hello, everyone, and welcome back to Money Talk Sundayz, where we discuss intriguing and sometimes, counterintuitive topics in finance. I’m your host, Stevie Bee. Today, we're delving into a concept that may seem unusual to some, trading against the S&P 500. Yes, you heard it right! Going against one of the most trusted and widely followed indexes in the world.Before we start, I must clarify that this isn't investment advice but an exploration of a diverse approach in the financial markets.The S&P 500 is often hailed as the holy grail of indexes. It comprises 500 of the largest companies listed on U.S. stock exchanges, essentially providing a snapshot of the U.S. economy. It's stable, reliable, and has a long history of delivering steady returns. So why would anyone consider trading against it?First, let's clarify what trading against the S&P 500 means. It's not necessarily about short selling the entire index. Instead, it involves strategies such as taking positions in assets that are inversely correlated to the S&P 500, or buying into sectors or companies that are currently underrepresented or not included in the index.One reason for trading against the S&P 500 is diversification. While the S&P 500 includes a broad range of companies, it's heavily skewed towards the largest ones. The top 50 companies make up over 50% of the index's value. Hence, if you're only following the S&P 500, your investments are highly concentrated in a few big players, leaving you exposed to sector-specific or company-specific risks. By trading against the index, you can diversify into other sectors, smaller companies, or different asset classes that can offer opportunities for alpha, or risk-adjusted outperformance.Another reason is the potential for higher returns. The S&P 500 has historically provided steady, but not spectacular, returns. In bull markets, it's common for certain sectors or asset classes to significantly outperform the S&P 500. For example, during the tech boom of the late 1990s, tech stocks massively outperformed the broader market. Similarly, during the housing boom of the mid-2000s, real estate-related stocks and assets outperformed. Trading against the S&P 500 allows you to seek these higher returns.Lastly, trading against the S&P 500 can provide a hedge against market downturns. When the market crashes, the S&P 500 usually falls with it. But some assets, such as gold or certain defensive stocks, often perform well during these periods. By trading against the S&P 500, you can include such assets in your portfolio, providing a hedge against market volatility.Now, trading against the S&P 500 is not without risks. It requires a thorough understanding of market dynamics, careful risk management, and a willingness to accept potential losses. But with careful planning and execution, it can provide diversification, the potential for higher returns, and a hedge against market downturns.And that's it for today's episode. Remember, the world of finance is not black and white. It's a rainbow of opportunities. Don't limit yourself to the standard paths. Be curious, be bold, explore, and you might just find a pot of gold at the end of your financial rainbow.Until next time, this is your host, Stevie Bee, signing off. Keep exploring, folks!
--- Send in a voice message: https://podcasters.spotify.com/pod/show/moneytalksundayz/message
Welcome, listeners! You're tuning in to Money Talk Sundayz, where we journey through the fascinating world of finance, economics, and global markets. I'm your host, Stevie Bee, and in today's episode, we're diving into a topic that's been making headlines: how the BRICS nations are competing with the US Dollar and the stock market. So grab your passports, and let's get started!Before we discuss the competition, let's establish some context. BRICS is an acronym that stands for Brazil, Russia, India, China, and South Africa. These five countries, often referred to as emerging economies, have been collaborating to strengthen their collective economic power and reduce their dependence on the US Dollar.One of the most significant ways the BRICS nations are challenging the US Dollar's dominance is by trading in their local currencies. By doing so, they are reducing their reliance on the dollar as a reserve currency and promoting their own currencies for international trade. This move has the potential to create a more diversified global financial system and reduce the influence of the United States on the global economy.For example, China has been promoting the use of the yuan in international trade through various initiatives, including the Belt and Road Initiative and the Asian Infrastructure Investment Bank. Meanwhile, Russia has been gradually reducing its dollar holdings in its foreign reserves, opting instead for gold and other currencies like the euro and yuan.Another significant aspect of the BRICS countries' challenge to the US Dollar is the establishment of new financial institutions. The most notable example is the New Development Bank (NDB), which was founded by the BRICS nations in 2014. The NDB's primary goal is to finance infrastructure projects in developing countries, providing an alternative to existing institutions like the World Bank and the International Monetary Fund.By establishing their own financial institutions, the BRICS countries are creating a parallel system to that of the US Dollar-dominated world. This move could potentially weaken the influence of the United States in global financial decision-making and encourage a more balanced distribution of power.Now, let's talk about how the BRICS nations are competing with the stock market. The BRICS countries have been making significant strides in developing their own stock exchanges and promoting investment in their local markets.The BRICS Exchanges Alliance, a collaboration between the stock exchanges of the five BRICS nations, aims to increase investment in these emerging markets by offering a platform for cross-listing and trading of stocks. This alliance allows investors to access new markets, diversify their portfolios, and mitigate risks. Moreover, it provides an alternative to investing in the established stock markets of developed countries, such as the United States.As the BRICS nations continue to collaborate and develop their financial infrastructure, we can expect a gradual shift in the global economic landscape. While the US Dollar and the stock market may still hold significant influence, the rise of alternative financial systems and institutions will likely challenge their dominance.This competition has the potential to reshape the global economy in ways that could promote more equitable distribution of power and resources. However, it also comes with risks, such as increased volatility in currency markets and the potential for economic conflicts between nations.--- Send in a voice message: https://podcasters.spotify.com/pod/show/moneytalksundayz/message
Hello, and welcome to today's episode of the "Money Talk Sundayz" podcast. Today we’ll be discussing pressing economic issues and their potential impact on our daily lives. I'm your host, Stevie Bee, and in this episode, we'll be discussing the looming debt default, how it could lead to the loss of 8 million jobs, and its potential to sink the stock market. So, without further ado, let's dive right into it.The concept of a debt default refers to a situation where a borrower fails to meet their financial obligations. This could occur on a personal, corporate, or even governmental level. A sovereign debt default, which is what we're focusing on today, happens when a government is unable to make payments on its debt, leading to potentially catastrophic consequences for the economy.As we speak, the world is facing the threat of a massive debt default. The precarious financial situation we find ourselves in is the result of a combination of factors, including unsustainable public debt, economic stagnation, and political gridlock. These factors have created a perfect storm that could ultimately lead to the loss of millions of jobs and a sharp downturn in the stock market.Let's first discuss the potential job loss that could stem from a debt default. As the government struggles to meet its financial obligations, public spending will inevitably be cut. This will have a domino effect, as reduced spending will impact various industries and sectors that rely on government support, leading to the loss of millions of jobs.We're talking about a massive loss of 8 million jobs across various sectors, such as infrastructure, education, healthcare, and defense. The ripple effect of these job losses will be felt across the economy, with reduced consumer spending and a decline in overall economic activity. This, in turn, will lead to further job losses, creating a vicious cycle of unemployment and economic stagnation.Now, let's move on to the potential impact on the stock market. A debt default by the government can have a devastating effect on investor confidence. The fear of not receiving timely interest payments, or worse, losing the principal amount of their investments, can cause investors to flee the market, resulting in a significant drop in stock prices.As the stock market tumbles, the wealth of millions of investors, both large and small, will be wiped out. The loss of wealth will not only impact individual investors but will also affect institutional investors such as pension funds and mutual funds, potentially leading to a crisis in the financial sector.It's important to note that a debt default doesn't just impact the government's ability to borrow in the future. It can also lead to a downgrade in the country's credit rating, making it even more difficult and expensive for the government to borrow funds, further exacerbating the economic crisis.The good news is that this debt default and its catastrophic consequences are not inevitable. Governments, policymakers, and financial institutions can take steps to prevent or mitigate the impact of a potential default. This could include implementing responsible fiscal policies, addressing structural issues in the economy, and promoting economic growth through investment in infrastructure and job creation.It's crucial for governments to work together with the private sector and international organizations to address the issues that have led to the current crisis. By taking decisive and coordinated action, we can avert the worst-case scenario of a debt default, massive job losses, and a stock market crash.--- Send in a voice message: https://podcasters.spotify.com/pod/show/moneytalksundayz/message
Being an IT junkie as well as someone who dabbles in the market does not make me an SME or subject matter expert. That however doesn’t stop my coworkers asking for my opinion on market related topics from Tesla to SalesForce and more. The latest craze out now is ChatGPT and how this AI is revolutionizing education, the workplace, and more. As someone who is always trying to find an edge in the market I tested out how this AI could be useful in investing. Truthfully, it was hit or miss trying to get the desired output BUT a recent article posted yesterday March 25th showed me what I was doing wrong. Now while this firm did not necessarily use ChatGPT specifically, the AI that they did use came up with 5 stocks that has been outperforming the S&P 500 consistently. Here are those stocks.Welcome to Money Talk Sundayz. I’m your host Stevie Bee. Hit that like, share, and subscribe button. Make sure you ding that notification bell to get alerted to new drops. Last weekend I did not drop an episode. I was on vacation. I was on a cruise with my family, and we had a good time. Can’t say it was restful since it was a very active vacay, but it was a welcome disconnect from the day to day drudgery of life. Anyway if you’ve made it this far, you’re curious to hear what stocks were recommended by this AI to weather further market downside. So without further ado… Stock #1 is: Realty IncomeTicket symbol O, Realty Income has a market cap of $41 billion. Realty is one of the most consistent dividend payers in the markets. It is currently down more than 5.5% this quarter and is facing it’s fourth quarterly decline. Back when Covid was surging around the globe causing mass shutdowns, many investors fretted over physical retail locations and office spaces. This led to a monumental selloff in the REIT space and Realty Income was caught up in the wave. Even after a bounce back of the markets, O has not achieved new all-time highs. Despite the relatively poor price action over the past few months and few years, Realty Income stock holds a number of positives.First, the company pays a monthly dividend and has an annual yield of 5.1%. It has also raised its payout in 102 consecutive quarters — or more than 25 years straight. That alone makes this stock attractive for certain income-oriented investors.Unfortunately, the FED is still raising interest rates causing investors to cash out. If this pattern continues, be ready to catch the dip at around $55-56 range. Why? This was a big support level for several quarters after the initial covid-19 selloff. It’s also the 50% retracement from the 2022 high down to the 2020 low. Lastly, this zone contains the 2022 low.So if we get a dip down to this area, it’s possible we get another bounce.If the selling persists, we could have a test of the $51 to $52 area. Should we test this zone, it would be the lowest price Realty Income stock has traded at since May 2020. In this zone we have the 61.8% retracement and gap-fill level.Lastly, the 78.6% retracement and 200-month moving average currently sit near the $45 area, which stands out as another potential support zone. Let’s keep an eye on this stock and set your alerts accordingly. The 2nd stock recommended by this AI is Buckle with a market cap of $1.8 billion. Ticket symbol BKE, Buckle has a 1 year low of $26.50 and a 1 year high of $50.35. The firm's fifty day simple moving average is $41.34 and its 200 day simple moving average is $40.04.BKE last announced its earnings results on Friday, March 10th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Buckle had a net margin of 18.93% and a return on equity of 65.52%. The business had revenue of $401.80 million for the quarter, compared to analyst estimates of $386.36 million. During the same quarter in the previous year, the firm posted $1.69 earnings per share. Buckle's revenue was up 5.5% compared to the same quarter last year.Buckle also recently announced a quarterly dividend, which will be paid on Friday, April 28th. Investors of record on Friday, April 14th will be given a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a yield of 4.03%. The ex-dividend date is Thursday, April 13th. Buckle's dividend payout ratio (DPR) is currently 27.29%.If you’re not familiar with Buckle, BKE engages in retailing of casual apparel, footwear, and accessories for men and women. It offers brands such as BKE, Buckle Black, Red by BKE, Daytrip denim, Gimmicks, Gilded Intent, FITZ + EDDI, Willow & Root denim, Outpost Makers, Departwest, Reclaim, Nova Industries, and Veece. The company was founded by David Hirschfeld in 1948 and is headquartered in Kearney, NE.The most economically advantageous stock option promoted by the AI is Crawford and Company. With ticker symbol CRD, Crawford & company is a solid choice for "trend" investing. Here’s why. A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. CRD.A is quite a good fit in this regard, gaining 53.6% over this period. CRD.A is currently trading at 87% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout. Based on the fundamentals, the stock is in the top 5% of more than 400 stocks reviewed based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements.Investors should note CRD has a P/B ratio of 2.90. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 3.34. Over the past year, CRD.A's P/B has been as high as 2.92 and as low as 1.39, with a median of 1.93. This shows that currently the company is likely being undervalued right now.What do you think about these AI picks? Is it spot on or wildly missing the mark. Let me know in the comment section. I’m curious to hear what you think about this. Also, if you’re using AI such as ChatGPT to relative success in the market let me know in the comment section. We’re all trying to eat. Each one, reach one and teach one, ya heard. I’m your Investment Bro Stevie Bee signing off for Money Talk Sundayz. Happy trading germs. --- Send in a voice message: https://podcasters.spotify.com/pod/show/moneytalksundayz/message
The risks of failing banks in the American economy is a topic I want to discuss with you today because it concerns all of us. Banks play a significant role in our economy by offering services including lending, financing, and investing. Our financial system depends on them, but when they falter, there may be dire repercussions.The effect of failing banks on the US economy is best illustrated by the financial crisis of 2008. Major banks like Lehman Brothers and Bear Stearns failing set off a domino effect that resulted in a severe recession, massive job losses, and a sharp decline in the stock market. While the government had to intervene with significant bailouts to stop the collapse of the whole financial system, millions of People lost their homes, their jobs, and their savings.A bank failure may set off a chain reaction that quickly spreads throughout the economy. A liquidity crisis brought on by failing banks may result in a credit crunch and a reduction in the quantity of credit accessible to both individuals and companies. This may result in a sizable drop in consumer spending, which could have an effect on overall economic growth.In addition, the stock market may suffer significantly from bank failure. Stock values significantly decline when banks fail because investors lose faith in the market. A stock market catastrophe could result from this, setting off a domino effect that would be disastrous for the economy.As you may already be aware, the Silicon Valley Bank has announced its closure, which has had a significant impact on the stock market and the world of cryptocurrency.The Silicon Valley Bank was founded in 1983 to offer financial services to the technology sector, which has fueled the expansion of the world economy. The financial markets have been rocked by the bank's announcement that it is closing, though. It's no secret that Silicon Valley was instrumental in the development of the technology industry, and many of these businesses have benefited from the bank's services.The stock market is one of the areas where the closure has had the most profound impact. Several of the top technological companies in the world have relied on the financial services provided by Silicon Valley Bank. The technology sector is a crucial part of the stock market. Many of these businesses could experience financial difficulties as a result of the bank's liquidation, which would cause their stock prices to fall.The world of cryptocurrencies has also been impacted by the Silicon Valley Bank's demise. The bank's liquidation has left a hole that will be difficult to fill because it was one of the main financial partners for several of the top bitcoin exchanges. As a result, cryptocurrency traders might have trouble getting access to the banking services they need to purchase and sell cryptocurrencies.SVB has been a key banking partner for Ripple for several years, facilitating its cross-border payment solutions for customers around the world. Ripple has used SVB's services to hold and transfer funds in various currencies, including U.S. dollars, euros, and British pounds. SVB has also been instrumental in helping Ripple navigate the complex regulatory landscape for digital currencies and blockchain technology.SVB closing down could potentially have a negative impact on Ripple's ability to conduct its business. Ripple would need to quickly find alternative banking partners to provide the same level of service that SVB has offered. However, this may not be easy, as not all banks are comfortable with dealing with digital currencies and the associated regulatory risks.Aside from that, during the past few years, Ripple has had to cope with legal and regulatory challenges. Accusing Ripple of selling unregistered securities in the form of its XRP cryptocurrency, the U.S. Securities and Exchange Commission (SEC) launched a complaint against the company in December 2020. In the midst of a legal battle, Ripple has refuted the accusat--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
What’s up Bros Nation. It’s Stevie Bee and welcome to another episode of Money Talk Sundayz. This episode is all about side hustles and some of the best side hustles you can do in 2023 with little to no startup costs. In this day and age you're going to need at least one side hustle to help offset the rising costs of inflation. Have you seen the prices of eggs lately? It seems insane but it's not really that insane to actually have a side hustle. Back in 2020 a study showed that 45% of Americans had a side hustle with the percentage increasing every single year. One out of every 10 people that had a side hustle profited over one thousand dollars per month. That is pretty good that one out of every 10 people Americans had a side hustle that made over a thousand dollars a month. How could an extra grand a month help you? Keep it locked on Money Talk Sundayz for more. Subscribe: https://linktr.ee/moneytalksundayzWelcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping. Now let’s get into it. Add up to $300 a month in passive income storing other people's stuffDo you have extra space around the house and want to make money off it? Perhaps you have an unused driveway, garage, basement, shed, or parking spot. If it’s just sitting there wasting away, you could turn that unused space into passive income every single month… without ever lifting a finger. All you have to do is go to neighbor.com and sign up to be a host. It’s like an AirBNB of storage. Neighbor is a website that lets you rent out your unused space to make extra money on autopilot. You can turn your garage, spare room, or even closet into a profitable side hustle that earns several hundred dollars a month. Seriously. You just sign up on their site, list what space you have available, and people in your city can rent out your unused space to store their stuff, while paying you a premium for the storage.The entire process works seamlessly and money is deposited into your account automatically. You don’t even need to move anything — your renters will move their stuff in (and out) on their own, while you collect a sweet paycheck month after month. Neighbor takes the work out of collecting payments from your renter! Oh, and you’re protected by up to $1 million in liability insurance too. Sign up today to see how much you could earn. Being a Virtual AssistantAs companies grow in size, it becomes increasingly difficult to stay on top of the daily tasks necessary to keep the business running. When employees wear many hats in a fast-paced environment, it can be tricky keeping operations and administrative needs running smoothly. But hiring full-time, on site support staff isn’t always an option, either – and that’s where your services can come in. Thanks to the disruptive force of the Coronavirus pandemic, remote work has been normalized and in many cases preferred to the traditional brick and mortar ways of yesterday. Business Wire estimates that virtual assistants’ market size alone will reach $25.6 billion by 2025. You can work as a virtual assistant from anywhere in the world on a laptop, making it a good side hustle for digital nomads or full-time travelers. As more people are launching digital businesses, there is an incredible demand for people to help run them.There are no set tasks that virtual assistants perform, and assignments can vary depending on the employer. Some of the most common tasks given to virtual assistants include the following: administrative work, ie. scheduling meetings and booking travel etc., bookkeeping, customer service, data entry, personal assistant, social media production and more. If you are proficient in any--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
OpenAI introduced ChatGPT on November 30, and since then, it has demonstrated its ability to perform a variety of jobs, including writing stock stories, layoff emails, and even messages for dating apps. It is an illustration of generative AI, which is educated on enormous amounts of data and may produce text-based or even visual responses. Like any new fancy toy, the need to replicate and monetize is booming and many tech companies are scrambling to be the next best thing in the market. So who stands to gain the most for the next generation in tech and will this help resurrect a an ailing sector? Lets find out in today’s episode of Money Talk Sundayz. Subscribe: https://linktr.ee/moneytalksundayzWelcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping.The rumor mill has gone into overdrive, and Microsoft is reportedly investing $10 billion in OpenAI. OpenAI is not listed on open markets, but public stocks related to artificial intelligence have been benefiting from the trend.ChatGPT, the lazy man’s key to adequacy is here and everyone is catching the buzz. Since the phenom burst into the public eye, copycats have been popping up left and right clamoring for a piece of the pie. It goes without saying that some of these imitators will be more successful than others. Others still will try to expand on the capabilities of this AI and make it more all-encompassing. One thing they have in common is the parts under the hood that they will need to get the engine running. It is for this reason, these 5 stocks are making major moves in the market currently. NvidiaThe artificial intelligence mania is ingrained in Nvidia, which is best known for designing and manufacturing graphics processing chips. The company's technology is used for numerous AI integrations, from self-driving vehicles to robotics.Jensen Huang, the company's creator and CEO, has become significantly wealthier as a result of the Nvidia stock boom; according to Bloomberg data, his worth has increased by more than $5 billion so far this year.Also optimistic is Wall Street. According to recent estimates from Citigroup analysts, a surge in ChatGPT usage may result in $3 billion to $11 billion in sales for Nvidia over the course of the next year. According to the bank, Nvidia's ChatGPT might be a significant computational demand driver.Nvidia's new chips, according to Wells Fargo and Bank of America analysts, are positioned to benefit from the increased compute demands of ChatGPT and other generative AI tools.AmbarellaAnother chip manufacturer that caters to the AI sector is Ambarella. It creates semiconductors for use in anything from cellphones to in-car entertainment systems.Also, it specializes in "system on a chip" semiconductors, which enable artificial intelligence computing by fusing several core processors onto a single logic board.Ambarella chips are utilized in autonomous driving systems, and the company recently collaborated with Continental, a German auto supplier, on an autonomous driving project.MobileyeIntel created Mobileye as a spinoff company that specializes in semiconductors and cameras for driver assistance and self-driving vehicles. Among its clients are GM, Ford, and VW. The company's SuperVision system is designed to be nearly entirely autonomous, and its Chauffeur product is intended to turn a car into a Level 4 self-driven vehicle.The corporation announced a positive sales outlook for 2023 after exceeding quarterly expectations. CEO Amnon Shashua bragged about bookings of almost $17 billion that go all the way until 2030.On a conference call with analysts, he stated, "We expect Su--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
Genius Group Limited, through its subsidiaries, provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company operates through two segments, Education and Campus. Its courses, products, and services form a full entrepreneur education curriculum together with a full suite of tools for students. Why am I telling you this? It is also the top stock mover for the week with a one-week change of over 400%. In most cases, and also my initial reaction after seeing that, I would consider shorting the stock the following week because generally after a quick surge retail investors sell off to recoup some of their profits. I was planning to short the stock until I stumbled across some interesting information. Here’s why I changed my mind on shorting the stock. Subscribe: https://linktr.ee/moneytalksundayzWelcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping.Naked shorting is the illegal practice of short selling shares that have not been affirmatively determined to exist. Normally, before selling a stock short, traders must either borrow it or verify that it may be borrowed. Therefore, the term "naked shorting" refers to short pressure on a company that may be greater than the market's tradable shares.By repeating that process again and again, bad actors can generate massive profits and manipulate a stock’s price lower, with an ultimate goal of driving a company to bankruptcy, at which point all the equity is wiped out and the naked shorts no longer need to be covered.Due to regulatory gaps and differences between paper and electronic trading platforms, naked shorting persists even though it was rendered illegal following the financial crisis of 2008–2009.This in and of itself is not novel. In reality, WallStreetBets and meme stocks became popular as a result of firms engaging in this strategy. Popular meme stocks GameStop and AMC are just two examples of businesses that were under pressure; once retail investors discovered what was going on, they came together to support their beloved businesses.Enter Genius Group Limited. Shares of Genius Group skyrocketed 290% on Thursday alone after they appointed a former FBI director to investigate naked short selling of its stock while also issuing a special dividend to help flush out the crooks. Volume of 197.76 million shares traded crushed the 65-day average of just 634,17.Timothy Murphy, a former deputy director of the F.B.I. and current board member, will serve as the task force's leader. It will consist of Roger Hamilton, the CEO of Genius Group, and Richard Berman, who is also a Genius Group Director and serves as the committee's chair.After the financial crisis, the Securities and Exchange Commission (SEC) prohibited naked short selling in the US in 2008. Only naked shorting is prohibited; other forms of short selling are not included. Before this restriction, the SEC changed Regulation SHO to reduce the possibility of naked shorting by closing 2007 loopholes that certain brokers and dealers had used. The publication of lists that monitor equities with exceptionally high trends in failing to deliver (FTD) shares is mandated by Regulation SHO.As mentioned previously, the news sent the share price up over 200% on Thursday and an additional 59% on Friday. About 270 million shares traded in Thursday’s trading session, another indicator of wrongdoing according to CEO Roger Hamilton given that the company’s float is just 10.9 million shares. Genius Group has proof that some people and/or businesses sold but failed to deliver a "substantial" am--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
Crypto can’t seem to catch a break with the latest offender Celsius Network literally raw dogging its customers sans lube. What happened this time? Stay tuned. Subscribe: https://linktr.ee/moneytalksundayzWelcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping. The cryptocurrency that Celsius Network LLC account holders deposited into Earn program accounts prior to the cryptocurrency lending company filing for Chapter 11 belongs to Celsius, and it is permitted to sell $18 million worth of those assets to continue funding its bankruptcy, a New York bankruptcy judge ruled on Wednesday.U.S. Bankruptcy Judge Martin Glenn stated in a 45-page written opinion that he based his judgment on Celsius' "unambiguous terms of use."According to the Court, the terms of use of Celsius "unambiguously transfer title and ownership of Earn assets deposited into Earn accounts from accounts holders to the debtors," creating "a genuine, enforceable contract" between Celsius and its account holders.Once Celsius filed its Chapter 11 petition, the opinion stated that the cryptocurrency deposits were property of the bankruptcy estates.Judge Glenn continued, "The court does not take lightly the implications of this judgement on ordinary persons, many of whom invested large funds into the Celsius platform.The decision has an impact on over 600,000 accounts that, as of July 10, 2022, a few days before Celsius and six affiliates sought bankruptcy protection, contained cryptocurrency assets worth almost $4.2 billion.It was in response to a motion Celsius made in September asking for permission to sell some of the stablecoin cryptocurrency in order to continue its bankruptcy cases.After multiple parties expressed concerns, Celsius in November requested a court order establishing ownership of the cryptocurrency assets used in the Earn program.Celsius offered its members the possibility to earn rewards on deposits of different digital assets including bitcoin and ether before it filed for bankruptcy.Customers could deposit cryptocurrency through Earn accounts, which Celsius would then sweep into its main accounts and use to generate revenue. Customers who had these Earn accounts received rewards in the form of extra cryptocurrency, a practice that attracted regulatory attention.According to Celsius, the conditions of usage of the company's earnings program explicitly state that participants are giving up their ownership rights to their assets in return for the incentives.Federal and state officials contested the legality of the user agreement at a six-hour hearing convened by Judge Glenn in December on the crypto ownership arguments. Some objectors said that the agreement's eight different versions and phrasing caused confusion.The motion received answers from nearly 30 creditors, 14 states, the committee of unsecured creditors, and the U.S. Trustee's Office, according to the opinion.As of September 2022, Earn program accounts have almost $23 million in stablecoin, according to the opinion. Judge Glenn authorized Celsius to sell a portion for about $18 million to cover ongoing administrative costs.According to the court's ruling on Wednesday, other Celsius programs including the Custody program, Withhold accounts, and the Borrow program do not have their assets determined as belonging to them.The rights of any state or state authorities on whether Celsius broke state securities laws by promoting unregistered securities are not decided by the court's findings, according to Judge Glenn.An inquiry for comments was not immediately answered by Celsius's representatives.Josh A. Sussberg, Patrick J. Nash Jr.--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
Crypto is in the news again for all the wrong reasons but this time it is not for loss of crypto assets or fraud. Rather, it is the lack of fraud prevention and safeguards that has landed this well-known crypto firm in hot water. What company is it and what did they do? Let’s discuss. Subscribe: https://linktr.ee/moneytalksundayzWelcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping. Following the discovery of "serious failings" in Coinbase Inc.'s anti-money laundering compliance regime, New York's financial services regulator struck a settlement with Coinbase Inc., one of the largest cryptocurrency exchanges, for $100 million, the agency announced on Wednesday.According to the agreement with the New York State Department of Financial Services, Coinbase must pay the state a $50 million fine. As part of the settlement, Coinbase, a California-based company with licenses in New York, would also put $50 million into bolstering its compliance program over the following two years.DFS Superintendent Adrienne A. Harris stated in a statement that "it is essential that all financial institutions protect their systems from bad actors, and the department's expectations with respect to consumer protection, cybersecurity, and anti-money laundering programs are just as stringent for cryptocurrency companies as they are for traditional financial services institutions."According to Harris, "Coinbase failed to develop and sustain a practical compliance program that could keep up with its expansion." Because of this breakdown, the Coinbase platform was potentially exposed to illegal conduct, necessitating rapid departmental action, including the installation of an independent monitor.Following the failure of FTX Trading Ltd., lawmakers, regulators, and law enforcement are putting pressure on the cryptocurrency business, which led to Wednesday's settlement. The settlement with DFS, according to Coinbase, is an important step in its commitment to "continuous improvement, our engagement with key regulators, and our push for greater compliance in the crypto space — for ourselves and others." Coinbase claims to have more than 108 million verified users and $101 billion in assets on its website.In a statement released on Wednesday, Coinbase Chief Legal Officer Paul Grewal said the company has made significant improvements in relation to its past failings and "remains committed to being a leader and role model in the crypto space, including partnering with regulators when it comes to compliance."We think we've invested more in compliance than any other cryptocurrency exchange in the world, and we want our users to feel secure using our services, Grewal added.The consent order issued on Wednesday states that DFS examined Coinbase in 2020 for the time frame of July 1, 2018, through December 31, 2019, and discovered serious flaws in a number of compliance areas, including its customer due diligence procedures and its screening program for the Office of Foreign Assets Control of the U.S. Treasury Department. The department also discovered that since 2017, Coinbase had been conducting insufficient yearly anti-money laundering risk assessments.According to the settlement order, the department compelled Coinbase to employ a third-party consultant to evaluate its compliance program and provide areas for improvement. As a result, Coinbase adopted a remediation plan to strengthen its compliance program.According to the ruling, the agency launched an enforcement inquiry into the compliance problems identified during the 2020 exam in 2021. The examination revealed weaknesses in Coinbase's compliance and --- Send in a voice message: https://anchor.fm/moneytalksundayz/message
The first trading day of 2022, January 3, seemed to be no different from the previous days in the stock market upswing that started while Barack Obama was still in office. The S&P 500 reached a new peak. The stock of Tesla, the firm that revolutionized the auto industry and made many investors wealthy, increased 13.5 percent, almost reaching its all-time high.
Subscribe: https://linktr.ee/moneytalksundayz
Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping.
That Monday, it turned out, marked the end of a market that had gone primarily in one direction for more than ten years, with the S&P 500 gaining by more than 600% since March 2009.
Just two days later, the Federal Reserve released the minutes from its previous meeting, a common occurrence on Wall Street. These minutes showed that the central bank's decision-makers were so concerned about inflation that they considered possibly needing to speed up the rate of interest rate increases.
The S&P 500 fell 1.9 percent as a result of how severely investors reacted, and a market sell-off that started later in the year set the tone for the remainder of the year.
Financial markets have seen a generational transition in the past year as a result of the Fed's repeated interest rate increases in an effort to stem the worst inflation in decades. Its efforts are starting to bear fruit: The rate of price growth has recently slowed.
But the Fed's dramatic measures to slow the largest economy in the world have had far-reaching effects.
The year marked the conclusion of a period of low interest rates that made borrowing affordable and encouraged investors to take risks in search of rich returns on the stocks of emerging tech companies, cryptocurrencies, and debt markets.
Both the S&P 500 and Tesla have fallen from the heights they hit on January 3. The S&P 500 had a worse finish on Friday and down 19.4% for the year, which was its worst annual performance since 2008. Since the collapse of cryptocurrency behemoths like FTX, debt has become more expensive.
However, the Federal Reserve has stated that its work is far from done even as the American economy appears to be headed for a probable recession. Even while inflation is beginning to decline, it is still far too high, and future increases in interest rates portend more suffering.
#work #growth #future #tech #podcast #money #economy #cryptocurrency #trading #markets #bank #stockmarket
--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
Ripple (XRP), Bitcoin (BTC), Ethereum (ETH), SUSHISWAP (SUSHI) & More Crypto to Watch in 2023 Cryptocurrency had a significant drop from its recent highs at the beginning of 2022. Since then, the cryptocurrency market has lost billions of dollars. For instance, Bitcoin is currently consolidating around $16K after recently trading at close to $70K per coin. 2023 while not experiencing the same decline, crypto is in the dumps. LBRY had its judgement revealed a couple months back. Ripple is still locked in battle with the SEC. What can we expect from crypto this week and further on into the new year. Stay tuned. Subscribe: https://linktr.ee/moneytalksundayz Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping. It is evidently difficult to pinpoint precisely which cryptocurrency will see the next boom. We can still discover possible rivals that are taking advantage of recent innovations like decentralized finance and digital payment systems. The market for cryptocurrencies began 2023 with the protracted negative circumstances that have characterized the sector over the past year continuing. Nevertheless, a few digital assets stand out as having the potential to generate tremendous growth despite the depressing economic climate. The top five cryptocurrencies that could see a sizable bull run are as follows: Ethereum 1. (ETH) Despite the fact that Ethereum has probably already beyond the limit where it can expand by 5,000%, it still has a lot of room to grow. It was the first blockchain to incorporate smart contracts, which programmers may utilize to create decentralized apps (dApps). 2. XRP The XRP ecosystem has always been active since its creation. On May 22, 2014, XRP started trading at $0.00268621, and in the eight years since then, it has grown by a staggering 12727%. SushiSwap 3. (SUSHI) Automated market makers, which are decentralized exchanges built on smart contracts, significantly increased in size in 2021. SushiSwap (SUSHI), though there are other AMMs accessible, might be the one most poised for a huge breakout. Bitcoin 4. (BTC) The top cryptocurrency is still in a consolidation phase despite having lost more than 70% of its value after reaching an all-time high of about $69,000. Price predictions indicate that BTC may correct more this month and trade around $15,500, but it is likely that the price will keep falling. Shiba Inu 5. (SHIB) Despite being the first meme coin to enter the cryptocurrency market, Dogecoin now has a lot of competition. Shiba Inu is perhaps one of the best cryptocurrencies for those wishing to diversify their portfolio with other meme coins in light of this.
--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
Market Declines, $TESLA Stock Fluctuates, SW Airlines, 2023 Wrap Up
The markets have had a difficult year, and the future seems even gloomier.
But there are a number of reasons to remain upbeat in the new year, according to investor Kari Firestone. When trading got underway on Wednesday morning, the main averages had barely altered. 3 points were added to the Dow Jones Industrial Average. The Nasdaq Composite opened marginally down while the S&P 500 opened barely above the flat line. On Wednesday, stocks declined as investors made preparations for 2023 and the conclusion of a dismal year.
150 points, or 0.5%, were lost by the Dow Jones Industrial Average. S&P 500 and Nasdaq Composite both experienced declines of 0.6% and 0.8%, respectively.
Louis Navellier, the founder and chief investment officer of the growth investing firm Navellier & Associates, stated that stocks ultimately collectively clawed into the green but that it did not hold. After a lackluster start to the official Santa Claus rally, the market is doing its best to stay afloat on minimal volume. Since the hardest-hit industries are engaging in some bottom fishing, there has been some regression to the mean. #growth #investment #future #investing #trading #tesla #airlines #markets
--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
If you've been following this channel since last year than you know I've been a huge proponent for VXRT. Truthfully, I backed Vaxart initially because I sold my Moderna shares early and lost out on some major profits. VXRT was very promising and leading the pack w/ their Covid vaccine pill that was supposed to be revolutionary. The biggest hurdle for Vaxart was time. Time eventually won out and lockdowns and restrictive Covid protocols around the world eased up. VXRT was even in Phase 2 of their clinical trials for their vaccine pill candidate. Now w/ Covid not as big of a deal as it was, what's next for Vaxart? Let's discuss. Subscribe: https://linktr.ee/moneytalksundayzThanks for checking out Money Talk Sundayz. I'm your host Stevie Bee. Hit that like, share and subscribe button and feel free to drop any comments in the comment section below. Again, take one second to hit that like and subscribe button. It'll help the channel out more than you know and it keeps this movement going. Thanks again. On to VXRT. I'm big on VXRT. Even after the disappointment of the company not getting their pill out in time for it to be relevant for most and shares tanking, I still believe in VXRT. Vaxart has many other products they are championing and that in itself can't be ignored. BUT, Vaxart was behind the curve on this one and paid dearly. Furthermore, investors in VXRT paid even more so. Let's breakdown the case for VXRT. Vaxart is still dealing w/ their lawsuit. In said lawsuit, plaintiffs allege a “pump and dump” scheme to inflate the value of Vaxart stock by falsely representing that Vaxart was in a position to profit from development of a COVID-19 vaccine through participation in Operation Warp Speed. According to plaintiffs, the alleged stock price inflation allowed hedge fund Armistice Capital, which controlled Vaxart, to reap approximately a quarter of a billion dollars in profit during the class period by selling shares of Vaxart.On December 9, plaintiffs in lawsuit filed a Corrected Second Amended Consolidated Class Action Complaint. The complaint alleges numerous instances of misleading disclosures followed quickly by Armistice Capital sales of Vaxart stock. The class period runs from June 15, 2020 to August 19, 2020 inclusive, and includes a subclass (under Section 20A) of the Securities Exchange Act comprised of those “who purchased or otherwise acquired Vaxart securities contemporaneously with Defendants Armistice, Boyd and Maher’s sales of Vaxart securities on or about June 26 and 29, 2020.”Court documents state that Vaxart, and all the individual defendants except two, have entered into a partial settlement for $12,015,000. A hearing for approval of the settlement is scheduled for January 12, 2023. If the settlement is approved, only the claims against Armistice Capital, LLC and two individual defendants: Steven Boyd and Keith Maher will remain.Dovetailing with the dates of the subclass is the allegation that on June 26, 2020 “Defendants delivered the master stroke of their carefully calculated deception to create the pop in the stock pice they expected. Specifically, the Armistice Defendants caused Vaxart to issue a press release headlined: ‘Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed.” Plaintiffs further allege that “The press release also noted that Vaxart ‘has been selected to participate in a non-human primate (NHP) challenge study, organized and funded by Operation Warp Speed’ — language that was plainly calculated to give the Defendants at least some basis to later claim that they had adequately disclosed their ‘selection’ was only for the NHP study.”With that being said, a settlement has been proposed w/ "all the individual defendants except two". While that settlement agreement is pending a judge's approval there is still a case out there for VXRT and the proposed pump and dump that transpired to inflate the value of the stock. Recently, the company reported--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
Dow Jones Futures Drop: Powell Gains Are Wiped Out by Market Rally as Apple, Exxon, and Tesla DropEarly on Wednesday, Dow Jones futures, S&P 500 futures, and Nasdaq futures all decreased. As the EV behemoth provided another price incentive in China, Tesla stock fell.Subscribe: https://linktr.ee/moneytalksundayzApple (AAPL) and Exxon Mobil (XOM) broke below crucial levels on Tuesday, while Amazon.com (AMZN) and Tesla (TSLA) are starting to move near bear market lows, giving the stock market rally another difficult session.The S&P 500 and other important indices were rounding major gains made last Wednesday after Fed Chairman Jerome Powell's speech by testing or undercutting key levels.Several significant one-day gains during this stock market rise have been followed by pullbacks. This has made it challenging for stocks flashing buy signals to advance. Investors should keep an eye out for equities that are poised to rise, but now is not the time to increase exposure.UnitedHealth Group (UNH), United Rentals (URI), and United Airlines (UAL) are all trading in close proximity to buy points.IBD Leaderboard lists the stock of UAL, whereas Leaderboard watchlist lists the stock of URI. The IBD 50 list includes United Airlines, Charles Schwab, and UNH stock. The IBD Stock Of The Day on Tuesday was United Rentals.MongoDB (MDB), a provider of database software, rose early on Wednesday on a surprising profit. Over the past year, MDB stock has fallen precipitously.Mobileye (MBLY), a manufacturer of driver-assistance systems, outperformed expectations in its maiden report following its IPO in late October. The MBLY stock fluctuated.When the close-out company Ollie's Bargain Outlet (OLLI) underperformed on earnings and sales, its stock fell.In comparison to fair value, Dow Jones futures declined by 0.3%. Nasdaq 100 futures dropped 1%, while S&P 500 futures dropped 0.6%.The yield on the 10-year Treasury increased by 4 basis points to 3.55%.Futures for crude oil tacked upward. Costs of natural gas increased by 3%. The U.S. consented to ship the U.K. additional LNG.As anticipated, China revoked additional Covid regulations; nonetheless, trade data were weaker than anticipated. The previously rising Hang Seng in Hong Kong dropped 3.2%.Keep in mind that overnight trade in Dow futures and other markets may not necessarily reflect real trading during the following normal stock market session.After Tuesday's opening, the stock market rally quickly declined. It continued to move lower throughout the day before marginally reversing course around the close.Tuesday's stock market activity saw a 1% decline in the Dow Jones Industrial Average. S&P 500 index losses were 1.4%. The Nasdaq composite fell 2% in value. The Russell 2000 small-cap index fell 1.5%.Prices for U.S. crude oil fell 3.5% to $74.25 a barrel.The 10-year Treasury yield decreased 9 basis points to 3.51%, returning to levels not far from those seen on September 20.There may be a breakdown in the inverse link between Treasury yields and the stock market. In contrast to lowering inflation pressures, a lower 10-year Treasury yield may increasingly represent greater recession risks. Concerns about a recession are also indicated by the yield curve, which keeps inverting further.A component of the Dow Jones, S&P 500, and Nasdaq composite, Apple stock fell 2.5% to 142.91, returning it to below its 50-day line. The price of XOM shares dropped 2.8%, falling below both a buy target and its 50-day line. The price of oil, gasoline, and natural gas are all falling, which is hurting Exxon stock.Amazon stock fell 3% to 88.25, moving in on its bear bottom of 85.87 set on November 9.Despite being off intraday lows, Tesla shares lost 1.4% to 179.82 on Tuesday after falling 6.4% on Monday. TSLA is approaching 52-week lows, but it still has a ways to go before it reaches the 166.19 level.In addition to the existing 4,000 yuan insurance subsidy, Tesla is also providi--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
Risk of a Bitcoin price collapse rises as BTC tries to recover $18,000Leveraged long margin traders are playing with fire, and given that BTC is now battling at $17,000, they might get burned sooner rather than later.After the November report on American producer prices revealed a 7.4% increase vs 2021, the bitcoin price had a conflicting response on December 9. The information revealed that wholesale prices were still rising and that inflation might linger longer than what investors had initially thought. Investors are still paying attention to oil prices, with WTI crude hitting a new yearly low on December 8 at $71.10.Subscribe: https://linktr.ee/moneytalksundayzThe United States Dollar Index (DXY), which gauges the strength of the dollar against a selection of the most popular foreign currencies, maintained the 104.50 level, although on December 4 it traded at a 5-month low of 104.10. This shows a lack of faith in the US Federal Reserve's capacity to control inflation without significantly worsening the economy.Regulator ambiguity might have been a major factor in restricting Bitcoin's potential rise. New guidelines that could require publicly traded corporations to disclose their exposure to crypto assets were released by the Securities and Exchange Commission (SEC) of the United States on December 8.The recent crisis in the crypto asset market has "created widespread disruption," according to the SEC's Division of Corporation Finance, and U.S. corporations may be required to make disclosures under federal securities laws if these events potentially have an impact on their operations.To better appreciate how professional traders are positioned in the present market environment, let's look at derivatives measures.Due to the ability for investors to borrow bitcoin to leverage their positions, margin markets reveal how experienced traders are positioned.For instance, borrowing stablecoins to buy Bitcoin can raise exposure. Borrowers of Bitcoin, on the other hand, can only short the cryptocurrency because they are betting on it falling in value. The balance between margin longs and shorts isn't necessarily equal, unlike with futures contracts.According to the aforementioned chart, OKX traders' margin lending ratio grew between December 4 and December 9, indicating that even after numerous unsuccessful efforts to break over the $17,300 resistance, professional traders raised the leverage on their long positions.The indicator is currently at 35, favoring stablecoin borrowing by a significant margin and showing that shorts are hesitant to create bearish leveraged positions.In order to determine whether Bitcoin will eventually give in to the unfavorable newsflow, traders need study the options markets. When arbitrage desks and market makers overcharge for upside or downside protection, the 25% delta skew is a telltale sign.When fear is prominent, the indicator will turn positive because the premium for protective put options is larger than the premium for risky call options. It compares similar call (buy) and put (sell) options.Therefore, if traders anticipate a decline in the price of Bitcoin, the skew indicator will rise above 10%. Generalized excitement, however, exhibits a negative 10% skew.The 25% delta skew improved between Dec. 4 and Dec. 9, as shown above, indicating that options traders were less risk-averse about unexpected price drops. However, because market makers are less involved in providing downside protection at the current 15%, the delta skew indicates that investors are still apprehensive.On the one hand, it appears positive that open interest did not rise as Bitcoin touched the intraday bottom on December 9. However, excessive margin usage suggests that purchasers may be compelled to cut positions amid unexpected downside moves.Leverage margin longs are at greater risk as time passes before Bitcoin reclaims $18,000. It is still crucial for traditional markets to estab--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
Salesforce Plagued by Leadership Changes; Time to Buy?In spite of mixed guidance for CRM stock, Salesforce (CRM) announced earnings for the quarter that ended in October that exceeded expectations. Salesforce shares fell when the business announced that Bret Taylor, a co-chief executive, would be leaving in addition to other management changes.Subscribe: https://linktr.ee/moneytalksundayzTaylor will continue to serve as co-CEO until December 31, 2023, after serving for nearly a year. According to Salesforce, Taylor plans to pursue his business interests. The company's only CEO, Marc Benioff, will continue to lead it.According to a study by Truist Securities analyst Terry Tillman, "We anticipate this revelation will raise issues and constitute a surprise decision for investors that could take time to comprehend."The most recent change in management for CRM stock is Taylor's exit.According to Wedbush analyst Daniel Ives, "The Street will perceive this as a stunner with Taylor one of the mainstays in the CRM strategy even though Benioff remains the core hearts and lungs of the Salesforce story."Added him: "With Taylor's departure, we can anticipate Benioff stepping up his M&A efforts in the cloud market as more private and public suppliers struggle against a softer macroenvironment. With CRM in a great position to significantly expand its product footprint over the coming years, this is all about the competition with Microsoft (MSFT) for market share in the cloud and collaboration area."Brian Millham was appointed president and chief operating officer of Salesforce on August 8. Former president and chief revenue officer Gavin Patterson was promoted to chief strategy officer. Early in November, Patterson quit the organization.Separately, Stewart Butterfield, the CEO of Slack, revealed he would be leaving Salesforce in January, according to Business Insider.A few days after Salesforce announced that co-CEO Bret Taylor would resign from his position, the article claims that Butterfield informed staff that the resignation had nothing to do with that announcement."For the record, this has nothing to do with Bret leaving. The planning process has been ongoing for a while! merely odd timing "He allegedly wrote something in a private Slack channel.Salesforce's 52-week range includes a high of $270.57 and a low of $135.71.According to Benzinga Pro, the stock was down 5.96% at $135.93 at the time of writing.On sales of $6.86 billion, Salesforce recorded a profit of $1.27 per share, including investment gains. Salesforce was predicted to report earnings of $1.22 per share on sales of $7.83 billion by CRM stock analysts.The maker of enterprise software reported that current remaining performance obligations, or CRPO bookings, increased 11% to $20.9 billion from $21 billion projections. Deferred revenue and order backlog are added together to form CRPO bookings.In comparison to predictions of $1.34 per share for CRM stock, the business expects earnings per share for the current quarter ending in January to range between $1.35 and $1.37. In addition, versus predictions of $8.03 billion, the software manufacturer predicts revenue of $7.98 billion at the midpoint of range.Due to the generally poor performance of software growth firms, CRM stock has declined by around 39% in 2022.According to IBD Stock Checkup, Salesforce stock has a Relative Strength Rating of 24 out of a maximum potential 99.Is it a good idea to purchase Salesforce right now?A shareholder's perception of two basic trends often determines whether or not to purchase CRM stock. One is an increase in corporate investment in digital transformation initiatives. The second is Salesforce.com's propensity for making significant acquisitions, such as its acquisition of Slack Technologies, a provider of software for office collaboration.The general performance of software growth stocks is one issue for the Salesforce stock.The iShares Expanded T--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
After a stronger-than-anticipated jobs data for November sparked concerns about how quickly the Federal Reserve could slow its escalating interest rate hikes, U.S. markets recovered to close nearly where they had started. The S&P 500 lost 0.1% of its value at the close after falling as much as 1.2% earlier in the day. The Dow Jones Industrial Average barely managed a 0.1% gain, while the Nasdaq composite reduced its deficit by losing 0.2%. The indices all saw weekly increases. Since last month, stocks have been rising as investors hoped that the worst of the country's high inflation may already be behind us. Which stocks fared the best and worst during the storm? Stay tuned for another episode of Money Talk Sundayz. Subscribe: https://linktr.ee/moneytalksundayz Vapotherm, Inc. is in first place with a one-week change of 101.22%. Vapotherm, ticker symbol VAPO, ended Friday's trading session with a stock price of 1.62 and a volume of 2,282,509. After-hours trading has seen a 1.85% gain in VAPO. A medical technology firm called Vapotherm, Inc. concentrates on the creation and marketing of specialized high velocity treatment solutions that are used to treat patients of all ages who are experiencing respiratory distress both domestically and abroad. A small-bore nasal interface is used by the company's precision flow systems, which include Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox. These systems deliver heated, humidified, and oxygenated air to patients at a high velocity. Vapotherm's (VAPO) stock price increased by 51.69% over the most recent trading day. As the company's stock price climbed by nearly 140% over the previous week, this is a continuance of momentum. Why? Some significant deals that were revealed in regulatory filings have received favorable reactions from investors. — Company director Anthony L. Arnerich acquired 100,000 shares at $0.76 each — Company SVP and CFO John Landry acquired 45,000 shares at $0.76 each; 90,000 shares at $0.7899 each; 13,550 shares at $0.7948 each; and 3,400 shares at $0.755 each — Company director James Liken acquired 75,000 shares at $0.7645 each
--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
Genesis warns of a potential bankruptcy without funding.
This is a big thing because it comes from Bloomberg. The parent business, Digital Currency Group, a titan in the field, and the Silence from digital currency groups might be destroyed by Genesis, the largest Bitcoin OTC desk and a significant lender. Why is Genesis spooking the Bitcoin market overall, and how did we get here? Five days have passed since Genesis Global Trading's lending unit stopped accepting withdrawals and new loan applications following its announcement last week that it would do so in light of the ftx collapse state of play. As a result of the company's eerie silence, it is now possible to speculate about the general health of the company as well as that of its parent company Digital Currency Group and sister unit Grayscale Investments.
Subscribe: https://linktr.ee/moneytalksundayz
--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
Following the fallout from its peer FTX's bankruptcy earlier this month, Binance has established a fund to rebuild the cryptocurrency sector, involving a $1 billion pledge from the industry titan.Subscribe: https://linktr.ee/moneytalksundayzThe Industry Recovery Initiative (IRI) fund would be open and accessible on a public address and last roughly six months, according to a blog post published by Binance late on Thursday.As a major player in the cryptocurrency market, Binance stated that it is its duty to take the initiative in defending customers and reviving the sector.This occurs after Changpeng Zhao, the founder of Binance, admitted to Bloomberg on Thursday that he had delayed posting about FTX.In order to "ensure transparency," the business emphasized that the IRI is not an investment fund and that anyone wishing to make an investment through the IRI application procedure must set aside pledged funds in public addresses.The fund has a flexible organizational structure since it anticipates that "unique situations will require tailored solutions"; it can be financed through tokens, fiat currency, stock, convertible instruments, loans, credit lines, etc.In response to conventional financial institutions that would not be able to transmit money to a public address, Binance stated that it is open to "exploring other deal formats."Companies seeking assistance have already submitted over 150 applications. Applications will be open for evaluation by each co-investor in the fund on a deal-by-deal basis.In the beginning, Binance will devote $1 billion to "IRI-themed investment possibilities," with a potential rise to $2 billion if necessary.Zhao clarified in a tweet that the $1 billion investment is roughly split across three tokens: Binance Coin, Bitcoin Binance USD, and Binance USD.So far, a number of businesses have contributed to the fund, totaling $50 million.Jump Crypto, Polygon Ventures, Aptos Labs, Animoca Brands, GSR, Kronos, and Brooker Group are a few of them.Binance continued, "We anticipate more participants to sign up soon."Industry peers have reacted to the announcement largely favorably.The goal of this new initiative, according to the organization, is to help the most innovative, high-caliber businesses and initiatives created by the brightest entrepreneurs and technologists but who, through no fault of their own, are currently experiencing serious, immediate financial challenges.As the weekly chart exhibits a distinct indicator of strength, bitcoin may follow stocks on a "huge bull run."It's time to abandon the bear market narrative, according to the most recent analysis from a number of well-known cryptocurrency names.Despite the fact that everyone is predicting a new macro BTC price low, probably near $12,000, fresh viewpoints necessitate a change of heart.There are three new reasons to switch to a positive position on Bitcoin at its present price of close to two-year lows, whether it be because of macro or simply plain old Bitcoin price cycles.The first theory comes from macro analyst Henrik Zeberg and involves a macro market catalyst.In a tweet from November 24, Zeberg argued that Bitcoin was still behaving similarly to other risky investments, but "not like gold."There is still no reason to give up on the notion that it will return, even though the FTX controversy has lessened the link between BTC and stocks.A last rise throughout the risk asset market might push BTC/USD over $100,000, according to Zeberg, who believes that rising tides raise all boats."Unlike gold, bitcoin moves as a risk asset. "Final rally before Deflationary Bust!" he tweeted. "When SPX bursts higher in Blow-Off Top into 5700 - 6000 target region - Bitcoin should hit 90k - 110k!"--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
After less than three months in business, a bank startup funded by billionaire Donald Trump supporter Peter Thiel and marketed as "anti-woke" for "pro-freedom" Americans is closing its doors. Subscribe: https://linktr.ee/moneytalksundayz The bank, GloriFi, burned through $50 million in investment funds, fired off the majority of its personnel on Monday, and informed employees that it would be closing down, according to the first story from The Wall Street Journal. Last Friday, hoped-for funds that would have kept the operation going fell through. The website of GloriFi advised users that "We will be cancelling all accounts registered to date." Savings accounts closed on December 6, and checking accounts on Friday. For customers who find Wall Street too liberal, GloriFi had been promoted as an alternative conservative banking system. According to a Journal profile of the business earlier this year, Toby Neugebauer, an entrepreneur and significant GOP donor, and his business partner Nick Ayers, the chief of staff for former Vice President Mike Pence, claimed that a sizable market of plumbers, electricians, and police officers were fed up with big banks that didn't share their values. According to the Journal, GloriFi promoted capitalism, family, law enforcement, and the freedom to "love of God and nation" along with offering bank accounts, credit cards, and plans to offer mortgages and insurance. According to Rolling Stone, Neugebauer also promoted ideas like credit cards fashioned out of shell casings, reductions on homeowners insurance, and help with legal costs for people who use firearms for self-defense. Candace Owens, a right-wing broadcaster, served as the company spokesman. Along with Thiel, the business attracted investors including Ken Griffin, the founder of Citadel, and Kelly Loeffler, a former Georgia Republican senator. However, within months, GloriFi missed launch dates, alleging poor technology and vendor issues, and, according to news accounts, investors' money was almost completely gone. According to a statement on the business' website, "financial issues due to initial missteps, the failing economy, reputational attacks, and numerous unfavorable stories took their toll."
--- Send in a voice message: https://anchor.fm/moneytalksundayz/message
For those of you not familiar with Cathie Wood, she built her reputation on going against the grain, the norm and leading her ARK firm in the same manner. Her tech stock ETF, ARKK took a major hit during this market recession and is currently trading at 36.51. Recent market turns have done little to sway her however and continues to be the trailblazer scooping up these 2 stocks under $5 each. Let’s discuss.
Subscribe: https://linktr.ee/moneytalksundayz
Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping.
The great Cathie Wood has gone shopping in this heavily discounted market. Black Friday really has come early as she scoops up these 2 stocks under $5. Each one has a substantial upside potential.
The first stock is ATAI. ATAI is at the forefront of what could be a new paradigm in treating mental health disorders – it is testing the use of psychedelics for medicinal purposes.
The company’s business model is differentiated; it operates via a decentralized platform that purchases and runs clinical programs with small affiliate companies formed around the pipeline candidates. All can access shared funds, with the capital allocated per needs.
ATAI currently has 8 candidates aimed at treating depression, anxiety, schizophrenia and substance abuse.
Leading the way is PCN-101/R-ketamine, indicated as a therapy for treatment resistant depression (TRD). Then there is RL-007, which targets cognitive impairment associated with schizophrenia. Both of these drugs are currently in phase 2 studies.
Further back in development, the pipeline includes GRX-917 (deuterated etifoxine), which is being developed for generalized anxiety disorder (GAD), and for which the company recently announced positive preliminary pharmacokinetics and pharmacodynamics results from a Phase 1 study. Positive preliminary results of the single ascending dose (SAD) portion of the Phase 1 testing of KUR-101 (deuterated mitragynine) indicated to treat opioid use disorder (OUD) were also recently announced.
Shares of ATAI are currently down 64% YTD. In the 3rd quarter, Cathie copped a whopping 6,133,914 now valued over 17.61 million. The average price target for ATAI is between $26 and 27. The highest projected price target for the stock is $50. It is suggested that shares of ATAI will soar over 818% over the course of the next 12 months. ATAI is currently trading at 3.07.
Note to self… cop some ATAI tomorrow…. Stat!
Send in a voice message: https://anchor.fm/moneytalksundayz/message
FTX is extending the crypto winter. Although closing higher on Friday, the major indexes are down for the week after several days of bumpy trading. The S&P 500 rose 0.5% after wavering between small gains and losses for much of the day. The Dow Jones Industrial Average rose 0.6% and the Nasdaq composite ended essentially flat after swinging between a 1% gain and an 0.8% drop. Big retailers made strong gains after posting positive quarterly results. The FED continues to fight inflation and hints at higher interest rates than expected to cool inflation. All in all, it’s been another dicey week for investors. Who won big? Let’s find out. Subscribe: https://linktr.ee/moneytalksundayz Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping. Coming in at number 1 with a one-week change of 272.29% is SatixFy Communications Ltd. Ticker symbol SATX, Satixfy closed Friday with a stock price of 42.85 with a trading volume of 1,950,032. In after-hours trading, SATX has dipped 17.12%. SatixFy Communications Ltd. develops end-to-end next-generation satellite communications systems. The company offers satellite payloads, user terminals, and modems. Its products include modems that feature software defined radio; fully electronically steered multi beam antennas; and very small aperture terminals and multi-beam fully electronically steered antenna arrays for various mobile applications and services. Over the last five sessions, the vertically integrated communications systems provider skyrocketed more than 400%. Having only made its public market debut last month via a reverse merger with special-purpose acquisition company (SPAC) Endurance Acquisition Corp., SATX stock represents a youthful investment vehicle. Nevertheless, it already owns a remarkable breadth of chart mobility, featuring a 52-week range between $7.39 to $79.20. Shares of the satellite communications company started the week around $11.50 per share, then surged to nearly $40 per share on Tuesday. They had sunk below $21 on Wednesday and once again shot higher by the end of the week. The volatility is not tied to any real news. Investor speculation and supposedly momentum-driven algorithmic trading appears to the driving factor. In 2nd place we have Elevate Credit, Inc. boasting a one-week-change of 94.62%. It closed trading Friday at 1.81 with a trading volume of 1,463,962. Elevate, ticker symbol ELVT, provides online credit solutions to non-prime consumers in the United States. The company offers unsecured online installment loans, lines of credit, and credit cards. Its products include Rise, an installment loan product; Elastic, a line of credit product; and Today Card, a credit card product. Recently it was announced that ELVT was to be acquired by Park Cities Asset Management, an alternative asset manager focused on providing flexible debt solutions. Park Cities will acquire Elevate for $1.87 per share in an all-cash transaction at an implied value of $67 million. Pursuant to the terms of the merger agreement, 7% of shares and shares underlying equity awards held by certain members of Elevate management are permitted to rollover into equity of the acquiring entity. This purchase is now being investigated by Kahn Swick & Foti, LLC and the former attorney general of Louisiana, Charles C. Foti, Jr. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you’re invested in this stock keep tabs on the proceedings of the investigation. Rounding out the top 5 we have GlycoMimetics, Inc., Atento S.A., and 4D Molecular Therapeutics, Inc. Glyco, ticker s
Send in a voice message: https://anchor.fm/moneytalksundayz/message
LBRY Loses SEC Lawsuit, Ripple Effects
Crypto startup LBRY violated securities laws by selling its native LBC tokens without registering with the U.S. Securities and Exchange Commission. That is according to New Hampshire Judge Paul Barbadoro. The SEC sued LBRY back in March of last year claiming LBC tokens were securities and that the startup had violated securities laws by selling them without registering with the agency. So what’s next for LBRY and consequently Ripple and the XRPArmy? Stay tuned. This is Money Talk Sundayz midweek edition.
Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping.
Subscribe: https://linktr.ee/moneytalksundayz
As I mentioned during the opening, the SEC sued LBRY over their LBC tokens claiming they were being sold without being registered with the agency first. LBRY countered saying their tokens were not securities and that the SEC did not give it fair notice that its sale of LBC was subject to securities laws, thus violating the company’s right to due process.
The judge overseeing the lawsuit, Barbadoro of the District Court for the District of New Hampshire ruled Monday that “no reasonable trier of fact could reject the SEC’s contention that LBRY offered LBC as a security, and LBRY does not have a triable defense that it lacked fair notice.”
After the ruling LBRY took to Twitter tweeting “We lost. Sorry everyone. We’re going to lick our wounds for a little bit but we’re not giving up.” LBRY founder Jeremy Kauffman stated, "The SEC vs LBRY case establishes a precedent that threatens the entire US cryptocurrency industry. Under the SEC vs LBRY standard, almost every cryptocurrency, including Ethereum and Doge, are securities. The future of cryptocurrency in the US now rests in with an organization even worse than the SEC: the United States Congress.”
This ruling as we know can have wide ranging implications on the rest of the crypto industry. Notably, Ripple Labs is in a heated contest of their own with the SEC. Ripple Labs and two of its executives, who have been charged with selling $1.3 billion in unregistered securities. Much like LBRY, Ripple Labs’ defense has hinged on its claim that its native token XRP is not a security, and that, by failing to provide clarity on whether XRP was a security, the SEC did not provide fair notice that Ripple Labs’ conduct was unlawful.
As the time for Summary Judgement is approaching fast, the XRPArmy appears to be pretty confident of the lawsuit turning in favour of the company.
According to Andrew Rossow, an attorney and adjunct law professor, the court’s ruling used the Howey Test, a test which helps to define what is and what isn’t a security in the US. Per Rossow, although the test was used, it missed the mark in a key area.
“The Court missed the mark in identifying a distinction that possibly speaks to a further clarification of what a ‘reasonable expectation of profits’ means under Howey, as it applies to projects such as LBRY,” Rossow said.
“That distinction separates what I believe to be LBRY’s recognition that it is a ‘work in progress,’” Rossow added, “and while it does want to see its investors make a return on their investment, that the only way that will happen is if others believe the project to have the utility as the company has presented it.”
This same test was applied in the Ripple lawsuit. Attorney John E Deaton said that the LBRY’s lawyers did not challenge Howey’s 2nd Prong test which required a common enterprise. Meanwhile, in Ripple’s case, the common enterprise was challenged. Further, the expert witness for SEC argued the common enterprise is the entire Ripple ecosystem including
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Shares tanked Thursday after the DuPont deal fell through. Rogers was set to be absorbed by chemical industry bellwether DuPont in a $5.2 billion deal that would have valued Rogers at $277 per share -- nearly 50% above its share price at that point. Those hopes were dashed on Tuesday after market hours when DuPont announced it was pulling out of the arrangement due to the inability "to obtain timely clearance from all the required regulators" (China, specifically). Subscribe: https://linktr.ee/moneytalksundayz Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping.
Send in a voice message: https://anchor.fm/moneytalksundayz/message
MTS: Top 5 Stock Movers - HUDI, SNTG, RYAM, ARAV, & MMAT Stocks rallied this past Friday and yet still finished the week lower amid a cloudy outlook about what the latest payroll numbers mean for future rate hikes. The Dow climbed 1.26% to close at 32,403.22. The S&P 500 grew 1.36% settling at 3,770.55 and Nasdaq rose 1.28% closing at 10,475.25. Despite these gains the averages capped off the week with losses. Hawkish comments from Fed Chairman Jerome Powell on Wednesday increased worries that the central bank could keep boosting interest rates for longer than previously expected and put further pressure on stocks. Fed officials on Friday echoed Powell’s comments about potentially decreasing the size of rate hikes but needing to continue to raise rates for a longer period of time and potentially above the 4.6 percent level the central bank penciled in at its September meeting. In light of this news, which stocks had the most growth? Let’s find out in today’s episode of Money Talk Sundayz. Subscribe: https://linktr.ee/moneytalksundayz Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping. Coming in at the number 4 spot is Aravive, Inc. Ticker symbol ARAV, Aravive had a one-week-change of 66.36% closing trading at 1.81. ARAV is a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. Rounding out the top 5 is a goodie from last year and you’ve probably seen in the intro, Meta Materials. Ticker symbol MMAT, Meta had a one-week-change of 63.11% closing trading Friday at 1.62. For those that don’t know, MMAT invents, designs, develops, and manufactures various functional materials and nanocomposites. Its products include metaAIR, a laser glare protection eyewear; NANOWEB, a transparent conductive film; holoOPTIX, a holographic optical element; glucoWISE, a non-invasive glucose measurement device; and metaSURFACE, which allows an enhancement in signal to noise ratio of up to 40 times for magnetic resonance imaging scans. MMAT is up over 120% this month following an MOU and purchase order with DuPont Teijin Films and Mitsubishi Electric Europe worth $4.3 million. The partnerships seeks to improve traditional lithium-ion batteries by reducing their dependence on copper. Meta will utilize its PLASMAfusion technology, which adds thin layers of copper on the sides of a polyester substrate. This can reduce the weight of the current collector by up to 80%, which increases energy density and battery life. DuPont will supply the polyester substrates, while Mitsubishi will contribute automation technology and interface to machine builders. The batteries created in this process can be used for electric vehicles (EVs) and other purposes. Are you invested in any of these stocks? If so, when did you jump in and what prompted you to buy into that stock? I’m curious as to how certain signals get out. What I really want to know… with so many different stocks out there, how do you really know which ones are getting ready to pop… especially if you’ve never heard of the stock before? I need a program to scan the whole market and pick up triggers and alert me. Alas I’m your boy Stevie Bee signing off for Money Talk Sundayz.
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Midweek Check-In: Plays of the Week; DUO, HTCR, AGLE, ARKK
My plays of the week.
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Recession talks have reignited following reports the economy posted positive GDP growth for the third quarter. This is the first increase in 2022 and a remarkable about face after half a year of contraction and recession fears. If you remember the episode of Money Talk Sundayz I did at that time I said….
Subscribe: https://linktr.ee/moneytalksundayz
Thank you, ladies and gentlemen. I said it then and I will say it again now… despite posting negative GDP growth, the TREND of the negative growth was going in the right direction and lo and behold our economy has grown at a rate of 2.6 percent in the third quarter. In the face of recession deniers and propagandists.
“The irony is, we’re seeing the strongest growth of the year when things are actually slowing,” said Diane Swonk, chief economist at KPMG. “There are some real cracks in the foundation. Housing is contracting. The consumer is slowing. GDP is growing, but not for all of the right reasons.”
The market had mixed reactions to this news but obviously most of it was favorable. This goes in line with the FED reducing the amount of the rate hike in December from .75 to .50. But don’t celebrate just yet. This GDP growth wasn’t for all the right reasons so therefore you can expect another dip the following quarter. For now, these stocks are the biggest movers this week.
Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping.
Coming in at number 1 with a one-week change of 139.89% is Fangdd Network Group Ltd. Ticker symbol DUO, DUO closed Friday with a stock price of 1.94 with a trading volume of 4,166,372. Fangdd Network Group Ltd., an investment holding company, provides real estate information services through online platforms in the People's Republic of China. It operates Property Cloud, a software as a service solution for real estate sellers. The company also operates platforms for real estate agents, including Duoduo Sales, which offers real estate agents with instant access to marketplace functionalities and allows them to conduct transactions on the go.
Just last week DUO announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated October 20, 2022, notifying the Company that it is not in compliance with the minimum market value requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(1)(C) requires companies to maintain a minimum market value of publicly held shares of at least US$5 million, and Listing Rule 5810(c)(3)(D) provides that a failure to meet the market value requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the market value of the Company for the 30 consecutive business days from September 8, 2022 to October 19, 2022, the Company no longer meets the minimum market value requirement. They have been given 180 calendar days to turn it around and this week they did.
In 2nd place we have ESSA Pharma Inc. boasting a one-week-change of 134.21%. It closed trading Friday at 4.41 with a trading volume of 18,461,487. ESSA, ticker symbol EPIX, is a clinical-stage pharmaceutical company that focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc.
EPIX stock rocketed Wednesday thanks in part to results o
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Another Fed rate hike looms around the corner but that didn’t stop the Dow from jumping almost 750 points as overall stocks closed sharply higher Friday. Speculation indicates that the Fed may be considering smaller rate hikes after November. Don’t get it confused. The Fed is still discontent on how effective the recent hikes have been on tamping down inflation. While the U.S. central bank appears set to again lift its benchmark rate by three-quarters of a percentage point at its policy meeting in early November, there may be some debate among Fed officials over whether to hike rates by 50 basis points in December.
All three major U.S. stock benchmarks scored their biggest weekly percentage gains since June as investors continued to assess companies’ earnings results from the third quarter. The Dow Jones Industrial Average rose 4.9%, the S&P 500 climbed 4.7% and the Nasdaq Composite advanced 5.2%.
Subscribe: https://linktr.ee/moneytalksundayz
Since things have gone so well this past week, let’s take a look at the biggest movers on Wall Street.
Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping.
Coming in at number 1 with a one-week change of 109.04% is Haudi International Group Co., LTD. Ticker symbol HUDI, HUDI closed Friday with a stock price of 58.92 with a trading volume of 219,696. HUDI develops, manufactures, markets, and sells industrial stainless steel seamless pipes, tubes, bars, and plates in the People's Republic of China. The company's products are used in oil and gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, electricity, automobile, naval architecture, paper mill, and mechanical industries. It also exports its products to 20 countries, including the United States, Mexico, and Thailand.
What’s particularly interesting is that HUDI opened trading at 31.01 and peaked at 65.56 before closing at 58.92. The materials sector as whole climbed 2.8% off the strength of HUDI and Metalla Royalty & Streaming Ltd. The Materials sector includes chemicals, construction materials, containers and packaging, metals and mining, and paper and forest products. The Materials sector is very sensitive to fluctuations in the global economy, the U.S. dollar, and inflationary pressures.
In 2nd place we have Cabaletta Bio, Inc. boasting a one-week-change of 95.48%. It closed trading Friday at 1.80 with a trading volume of 7,239,448. Cabaletta, ticker symbol CABA, is a clinical-stage biotechnology company out of Philly that focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.
Five insiders purchased shares of Cabaletta Bio (CABA, Financial) during the past month. The total number of shares purchased was 346,000. CABA has several positive investing signs which include no long-term debt and an equity-to-asset ratio that is outperforming more than 90% of its global competitors.
According to reports, the reason for the surge in CABA stock is that investors are responding to regulatory findings showing a number of insider stock buys. Company President and CEO Steven Nichtberger acquired 141,873 shares for $0.9939 each. Company President of Science & Technology Gwendolyn Binder acquired 20,000 shares for $0.9947 each. Company director Mark Simon acquired 118,000 shares for $0.977 each and 7,000 shares for $0.9764 each (by spouse).
Send in a voice message: https://anchor.fm/moneytalksundayz/message
There have been more warnings of a "lost decade" of returns for the stock market in recent months, but the chances of that actually happening appear less likely given this year's massive 25% decline. With falling stock markets come falling valuations. This is showing to be more appealing for long-term investors. The long-term forecasts are said to be the best they’ve been in over two years but the short-term outlook is dicier than ever. In the midst of this there are stocks making huge gains and others taking huge losses. Let’s discuss this weeks’ top movers.
Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping.
Coming in at number 1 with an awesome one-week change of 106.58% is Laser Photonics Corporation. Ticker symbol LASE, LASE closed Friday with a stock price of 4.91 with a trading volume of 25,713,268. LASE is a vertically integrated manufacturing company for photonics-based industrial products and solutions, primarily disruptive laser cleaning technologies.
Laser Photonics gapped up for the second day in a row Friday before falling to fill most of the second empty trading range. The stock also gapped up to open the Oct. 11 session.
The higher open on Oct. 11 came after Laser Photonics announced it received an order from the U.S. Navy for its LPC-1000CTH CleanTech Laser Blasting System. On Thursday, news that Coca Cola Co has started to use Laser Photonics’ CleanTech Handheld Laser Blasting system in the beverage giant's manufacturing facilities further boosted the stock.
Laser Photonics went public on Sept. 30 at an opening price of $5.05, and after two weeks of trading below the IPO price, the stock reached back up above the level on Friday.
In 2nd place we have Immunic, Inc. boasting a one-week-change of 89.39%. It closed trading Friday at 10.03 with a trading volume of 7,282,351. Immunic, ticker symbol IMUX, is a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.
The company announced it has entered into a securities purchase with select accredited investors and certain existing investors to issue and sell an aggregate of 8,696,552 shares of its common stock at a price of $4.35 per share, reflecting a 10% premium to the closing price on October 7, 2022 on NASDAQ, and pre-funded warrants to purchase up to an aggregate of 5,096,552 shares of Common Stock at a purchase price of $4.34 per pre-funded warrant share, through a private investment in public equity ("PIPE") financing.
According to analysts, the average rating for IMUX stock is "Buy." The 12-month stock price forecast is 23.46, which is an increase of 133.90% from the latest price.
Rounding out the top 5 we have Applied DNA Sciences, Inc., Vigil Nueroscience, Inc., and Wunong Net Technology Company Limited. APDN is up 87.6% closing at 2.38 with a trading volume of 3,306,642. VIGL is up 86.54% with a closing price of 15.97 and a trading volume of 21,664. WNW is up 85.64% closing at 1.71 with a trading volume of 1,150,980.
Top 5 biggest losers for the week are: Relmada Therapeutics, Inc., ticker symbol RLMD dropping 82.08%. Zhong Yang Financial Group Limited is down 70.75%. T2 Biosystems, Inc. is down 54.80%. Quanergy Systems, Inc. is down 53.08%. NeuroMetrix, Inc. is down 42.14%.
Are you invested in any of these stocks? If so, when did you jump in and what
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Crypto has taken a shellacking over the course of the year with flagship BTC priced at 19,123.10 and ETH at 1,283.04. Both down considerably from their peak high almost a year ago. With speculation swirling about whether crypto will have a return to form, there is one cryptocurrency that many are banking on… literally. Ripple Labs Inc has been locked in battle with the SEC for nearly 2 years over their XRP coin. The outcome of this battle is said to have far reaching effects on the crypto industry as a whole and the life of XRP. The latest revelation in this battle is a Wednesday filing by I-Remit, a payment processor, siding with Ripple Labs. Let’s discuss.
Welcome to Money Talk Sundayz. I’m your host Stevie Bee. You know the deal, when you pop in drop a like share and subscribe if you haven’t done so. You can subscribe to the podcast on all your favorite streaming platforms. Moving on.
As I mentioned I-Remit is siding with Ripple and XRP urging a New York federal judge to side with Ripple Labs Inc. in its efforts to beat a U.S. Securities and Exchange Commission enforcement action, arguing the fact that I-Remit customers use Ripple's digital token to send money abroad cuts against the SEC's claim that the token is an unregistered security. The payment processor argued that the SEC is wrong in its belief that Ripple's digital token, XRP, is an investment contract and that "the principal reason for anyone to buy XRP was to speculate on it as an investment."
I-Remit is one of many companies using XRP for cross-border fund transfers daily. That should be proof XRP is not a security and holders of the coin should not expect the value to increase over time according to I-Remit.
"The way in which entities like I-Remit use XRP on a daily basis undermines the SEC's theory of the case," the brief states. "XRP provides a digital currency with benefits not achievable through traditional governmental currencies. XRP is best understood as a means of value exchange, not an investment. It should not be regulated as an investment under the Securities Act."
Despite the enforcement actions of the SEC, more than 100 banks have joined RippleNet, the network that allows the processing of cross-border payments in real-time and with little cost. 6 of the biggest banks on the Ripple’s network are PNC Bank, Santander Bank, Standard Chartered Bank, Cuallix, Skandinaviska Enskilda Banken (SEB), and Mitsubishi UFG. Additionally, many foreign central banks have aligned themselves with Ripple.
The Canadian Imperial Bank of Commerce (CIBC) and Israel’s Bank Leumi, recognized small business banks, are now using the Ripple payment network for cross-border transactions as a result of their alliance with the National Australia Bank.
The large Australian bank stated: “We’re excited to be working with CIBC and have already partnered with them in using Ripple’s blockchain technology to complete international payments transfers between our banks as a proof of concept.”
In spite of these breakthroughs and monumental adoption of Ripple, the SEC maintains Ripple's CEO Brad Garlinghouse and chairman Christian Larsen were reckless in believing that XRP would not be considered a security by regulators and that Ripple had "fair notice" that XRP would be subject to the SEC's jurisdiction.
According to Ripple the enforcement action came after nearly a decade of regulatory uncertainty surrounding cryptocurrencies, and that the SEC failed to demonstrate that XRP is a security while other decentralized digital assets, such as bitcoin and ether, are not.
In January, Ripple won access to a small slice of a trove of SEC documents the agency claimed were privileged. U.S. Magistrate Judge Sarah Netburn ordered the SEC to give Ripple a selection of handwritten notes agency staffers took during certain meetings with third parties unrelated to Ripple, as well as an emailed draft of a June 14, 2018, conference speech in which SEC Division of Corporation Finance Director
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Leaked PayPal AUP Rattles Retail Investors
We’ve all used it at least and some more than others. An early bird to the world of FinTech, PayPal once cornered the market for online payments but now shares the space with many other companies like Affirm and Chase’s Zelle. While providing assurances of protected, secured, and encrypted payment processing, it appears under the hood PayPal has something to hide. Let’s dive in. Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping. PayPal. This past Friday PayPal’s latest Acceptable Use Policy leaked online, and its contents set the internet ablaze. Notably, PayPal has the intentions of imposing financial penalties on customers who violate this new policy. The financial penalty… $2,500 for any and all misinformation about the company. Simply put, you the customer and user of PayPal services, if found guilty of multiple acts of misinformation, will be fined $2,500 per instance. “You are independently responsible for complying with all applicable laws in all of your actions related to your use of PayPal's services, regardless of the purpose of the use," the document, called "Acceptable Use of Policy," said. “Violation of this Acceptable Use Policy constitutes a violation of the PayPal User Agreement and may subject you to damages, including liquidated damages of 2,500.00 U.S. dollars per violation, which may be debited directly from your PayPal account(s)," the company added. This AUP was purportedly to go into effect sometime next month based on the memo being marked, “Last Updated on November 3, 2022.” Today is Sunday October 9th, 2022, and this memo was last updated in the future. Already a shady move on behalf of PayPal. The company is already having a string of problems. Its stock price has fallen 52.2% since January. The market value has decreased by nearly $114 billion during that period to $104.3 billion. The FED’s ongoing war on inflation is also taking its toll on the company. The aggressive increase in interest rates by the Federal Reserve is leading to a slowdown in economic activity… activity that the company directly benefits from. Since the company’s core source of income is the fees, they charge consumers to use the platform, when the volume of transactions decreases, so do PayPal revenue. Let’s not forget about crypto. Crypto as a whole has shed billions of dollars in value. How does this correlate with PayPal? Well, the company was one of the first to offer to buy and sell Bitcoin and Ethereum. Crypto peaked in November of last year and since then has pretty much survived on fumes. This disinterest in trading crypto has led to a sharp decline in trading volume and the withdrawal of retail investors. So, PayPal has enough on their plate. To go and create another headache for themselves is bewildering. Co-Founders Elon Musk and David Marcus agree saying the new policy goes against everything they believe in. The company has since issued a statement after a crescendo of criticism cascaded on them. PayPal said the new policy information was an error. "An AUP [Acceptable Use Policy] notice recently went out in error that included incorrect information," a PayPal spokesperson said in an emailed statement. "PayPal is not fining people for misinformation and this language was never intended to be inserted in our policy. Our teams are working to correct our policy pages. We’re sorry for the confusion this has caused." The only error I see here is that the memo leaked before implementation. As a regular consumer I find it hard to believe that a future dated AUP included “incorrect information”. I wholeheartedly believe that
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Top Stock Movers for the Week; PEGY, TOPS, FAZE & More
Stocks are destined to continue to fall further in anticipation of another Fed rate hike. It’s all but inevitable that the market will be collateral damage in the fight against inflation. For the week most stock indexes were up almost 1% but for the month they are all down including the Nasdaq which is down in the double digits. Despite the continued assault on wall street, some stocks managed to make huge gains this week. This is our top stock gainers for the week. Bumper footage. Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping. Coming in at number 1 with a ridiculous one-week change of 315.56% is Pineapple Holdings. Ticker symbol PEGY closed at 3.80 Friday with a trading volume at a whopping 14,122,766 shares. Pineapple Holdings, Inc. provides photovoltaic solar energy systems to residential homeowners in the United States. It offers a range of installation services, including design, engineering, procurement, permitting, construction, grid connection, warranty, monitoring, and maintenance of residential solar energy systems. The company also offers battery storage products and energy management control devices on solar systems that are paired with batteries. So why is PEGY moving? On the surface, it’s hard to say. It’s been a relatively light news cycle. The only thing I can see is that recent storms and rising utility bills are forcing people to unplug from the mainframe and go green. Keep an eye on this one going forward for sure. I can see this company expanding into European markets as winter descends on a region dealing with a fuel shortage. In 2nd place we have Top Ships Inc with a one-week-change of 116.29%. TOPS closed trading at $7 and had a staggering trading volume of 22,966,322. Top Ships Inc. owns and operates tanker vessels worldwide. The company's medium range tanker vessels transport crude oil, petroleum products, and bulk liquid chemicals. As of December 31, 2020, it had a fleet with a total capacity of 1,435,000 deadweight tonnes (dwt) consisting of one 50,000 dwt product/chemical tanker, five 157,000 dwt Suezmax tankers, two 300,000 dwt very large crude carriers, and two 50,000 dwt product tankers. Shares of TOPS traded higher Friday after the company announced the day before that they would be terminating the equity distribution agreement for the recent sale of the company’s common shares. The equity distribution agreement was for up to an aggregate amount of $19.7 million with Maxim Group LLC in an at-the-market equity offering program. The company will make no further sales under the at-the-market offering. Net proceeds from sales under the at-the-market offering amounted to approximately $2.0 million. TOPS is down considerably from their 52-week-high of $33 but so are all of your favorite publicly traded companies like Apple, Google, Tesla and more. I’m not much into the industrials sector but this may be one to watch going forward. Buy low, sell high. That is the motto right? Rounding out the top 5 we have Senti Biosciences, Inc., SAI.TECH Global Corporation, and FingerMotion, Inc. SNTI is up 92.31% on the week with a Friday closing of 4.48. SAI is 78.21% with a closing of 5.01. FNGR is 77.91% with a closing of 7.38. Top 5 biggest losers for the week are: Biohaven Ltd., ticker symbol BHVN dropping 91.60%. KalVista Pharmaceuticals, Inc. (KALV) is down 66.46%. LGL Group is down 51.92%. Blue Apron Holdings is down 43.50%. FaZe Holdings is down 43.18%. A couple weeks ago I was going to do an episode all about FAZE, which I did eventually buy in for a short term, but something more press
Send in a voice message: https://anchor.fm/moneytalksundayz/message
SPRO, AMPX, AIRT, GSUN, SHPH & More; Feds Rate Hike Rocks Markets
The feds aren’t backing down raising interest rates another 0.75 percent this past week in a bid to stifle inflation. The aggressive tactics are slowing down the economy stoking fears of an impending recession. This is the 5th time this year the fed has raised the interest rates increasing the possibility of recession, job losses, higher credit costs and other unknown consequences. With the Fed hitting the brakes on an overheated economy, the main question for many market watchers is how fast Fed Chair Jerome Powell will continue to raise rates and whether that spills over into a recession. Are you surprised? 40% of the US money was printed in the last 2 years. Let’s discuss.
Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping.
With so much of our money having been printed over the course of the last 2 years to deal with the Covid pandemic and the business and economic slowdown, inflation has run unabated. To quell this free-for-all, the fed raised interest rates by another three-quarters of a point, the third time they’ve raised it by this much this year. The Federal Reserve has identified inflation as Public Enemy No. 1 and with this move, there are going to be winners and losers. On to last week’s biggest winners in the market.
Coming in at number 1 with a one-week change of 138.10% is Spero Therapeutics, Inc. SPRO, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
Spero closed out trading Friday at 1.97 with a trading volume of 41,542,091 shares. Shares jumped 168 percent on SPRO’s licensing deal with GSK. This licensing deal is for their experimental antibiotic candidate, tebipenem HBr, used to treat complicated urinary tract infection (“cUTI”), including pyelonephritis, caused by specific microorganisms in adult patients with limited treatment options.
In after-hours trading, SPRO has gone up an additional 3 cents bringing shares to $2 even.
Coming in at number 2 is Amprius Technologies, Inc. AMPX closed trading Friday at 12.94 up 50.71% on the week. In after-hours trading it has fallen off slightly currently hovering at 12.66. AMPX has a trading volume of 13,076,586.
AMPX manufactures and distributes lithium-ion batteries. Its products include silicon nanowire anode lithium-ion batteries. The company serves the aerospace, defense, and electric vehicle industries.
Rounding out the top 5 we have AIR T Inc, Golden Sun Education Group Limited, and Evaxion Biotech A/S. AIRT is up 45.07% with a price of 22.50. GSUN is up 42.37% with a trading price of 52.89. EVAX is up 42.16% with a trading price of 2.91. Respectively their trading volume is 25,447, 1,378,943, and 1,093,718 shares.
Interestingly enough while researching these stocks I came across the biggest losers for the week and guess what… some of our biggest winners from previous weeks have ended up on the top 20 biggest losers for the week last week. While none have broken the top 10 at number 11 should be a familiar stock, SHPH or Shuttle Pharmaceuticals Holdings, Inc. Let me play the clip from last week.
Well just as I mentioned last week, SHPH has cratered and is now at a parsley 5.75 a share down 41.66%. I am definitely game to jump in now and do exactly what I recommended last week and ride the swing up and sell off. Who’s with me?
Another winner from previous weeks is AMTD Digital Inc, ticker symbol HKD. It is currently down 39.41% with a price of 63.59.
It’s good to keep track of how these
Send in a voice message: https://anchor.fm/moneytalksundayz/message
The market closed out the week in a rut. The S&P, Nasdaq, and Russell 200 are down more than 5%, the Dow almost 5%. Bitcoin has dropped by almost 60% year-to-date and is now wobbling around its psychological support of $20,000. Stock prices are tumbling, and bonds are being hit with the deepest losses in decades. While this dumpster fire of a market is reeling from impending rate hikes by the feds, some stocks are still making significant gains. Let’s check out the top gainers from last week after the dust settled.
Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping.
Coming in at number 1 with a one-week change of 118.39% is Akero Therapeutics. AKRO, a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
AKRO closed out trading Friday at 26.02 with a trading volume of 1,225,611 shares. Shares skyrocketed 136.76% during market hours on Sep 13 after the company announced positive top-line data from its phase IIB HARMONY study. The study evaluated the safety and efficacy of efruxifermin (EFX) in patients with pre-cirrhotic non-alcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3).
NASH is a progressive form of non-alcoholic fatty liver disease (NAFLD), characterized by excessive fat buildup in the liver, accompanied by inflammation and fibrosis, which may progress to cirrhosis, liver failure, cancer and death.
Coming in at number 2 is Dawson Geophysical Company. DWSN is up 83.93% closing trading Friday at 2.00 with a trading volume of 77,675.
Dawson Geophysical Company provides onshore seismic data acquisition and processing services in the United States and Canada. The company acquires and processes 2-D, 3-D, and multi-component seismic data for its clients, including oil and gas companies, and independent oil and gas operators, as well as providers of multi-client data libraries.
Dawson Geophysical's short percent of float has risen 50.0% since its last report. The company recently reported that it has 25 thousand shares sold short, which is 0.42% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.3 days to cover their short positions on average.
Rounding out the top 5 we have Zero Fox Holdings, AMTD Digital, and Akouos, Inc. ZFOX is up 74.33% with a closing price of 7.06 and 1,774,082 trading volume. AMTD ticket symbol HKD is up 66.39% with a closing price of 108.00 and trading volume of 1,045,037. AKUS is up 59.15% closing at 5.16 with a trading volume of 270,468.
Are you invested in any of these stocks? If so, when did you jump in and what prompted you to buy into that stock? I’m curious as to how certain signals get out.
Send in a voice message: https://anchor.fm/moneytalksundayz/message
The Dow Jones snapped a 3-week losing streak Friday finally closing in the positive. The S&P and Nasdaq were also up at the time of closing Friday. Tech and chip stocks boosted the overall tech sector more than 2% while several stocks passed key buy points. The stocks making the biggest moves this week come from different sectors but the winningest is biopharmaceuticals. Let’s get to it!
Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping.
Coming in at number 1 with a one-week change of 195.23% is Shuttle Pharmaceuticals Holdings, Inc. Ticker symbol SHPH. It closed Friday at 38.80 up 26.14% on the day. Afterhours it has since slid down to 35.90 for a loss of 2.90.
The stock closed at $14.90 last Friday and then opened this Tuesday at $12.16. It hit its high at $43.80 on Thursday and closed on Friday at $38.80. The stock began trading on Aug. 31 after its initial public offering (IPO). The stock has been on a volatile ride of late. After its IPO, the stock jumped to $84.70, but dropped like a rock, falling to a low of $11.77 last Friday before bouncing back. This week, it rallied on Thursday and Friday.
Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT). Although RT is a proven modality for treating cancers, by developing radiation sensitizers, they aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment, or in combination with surgery, chemotherapy and immunotherapy.
The stock's wild swings have a lot to do with retail investor interest. It's important to note it is hard to gauge the company's worth as it hasn't released a public quarterly report and doesn't yet have any therapies approved by the Food and Drug Administration (FDA). However, the company's pipeline drugs have the potential to serve a large target audience. According to the American Cancer Society, a little over 1.9 million new cancer cases are expected to be diagnosed in the U.S. in 2022, and more than 50% of those patients will receive radiation at some point. The company's pipeline includes two therapies that could treat a wide range of cancers. There isn't much competition in the radiation sensitizer indication, with only one like therapy, Eribtux (Cetuximab), sold in the U.S. by Eli Lilly and by Merck outside the U.S., that has been approved by the FDA.
My suggestion, wait for it to crater again before grabbing up some shares and letting her ride.
In 2nd place we have PIXY, or ShiftPixy, Inc. closing Friday up 151.13%. PIXY ended the day Friday at 34.45, up 3.45. It dropped to 31.14 in after-hours.
ShiftPixy, a gig-economy focused workforce management company, together with its subsidiaries, provides staffing solutions in the United States. It offers employment administrative services, such as payroll processing, human resources consulting, and workers' compensation administration and coverage. The Company also operates human resources information systems platform to assist in customer acquisition for the onboarding of new clients into the company's closed proprietary operating and processing information system.
One of the reasons for the recent rise is because PIXY is planning to spinoff its ShiftPixy Labs business. That’s big news for investors in PIXY stock as the company intends to give them a stake in the spinoff via a special dividend. ShiftPixy will be using Sept. 8 as the record date for shareholders to receive that dividend.
As part of the spinoff, the company said it will transfer ShiftPixy Labs' Virtual Brand d
Send in a voice message: https://anchor.fm/moneytalksundayz/message
The Dow Jones snapped a 3-week losing streak Friday finally closing in the positive. The S&P and Nasdaq were also up at the time of closing Friday. Tech and chip stocks boosted the overall tech sector more than 2% while a number of stocks passed key buy points. Things are looking favorable in the market but the FED is here to change that. For more on this, stay tuned.
Bumper footage.
Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on YouTube, like, share, and subscribe. You can even hit the notification bell to receive the alerts of new videos dropping.
Like I mentioned at the beginning, the Dow Jones snapped a 3-week losing streak to surge back into the positive. Even though it’s resurgence lagged behind the other major indexes it still rose almost 400 points. A major contributing factor is Apple closing in on the key 50-day moving average after gaining 1.9%. Another shining star for the Dow was Salesforce (CRM) rising 3.6%. Caterpillar (CAT) also impressed as it gained 3.5%.
But don’t get it twisted. We are in a bear market. We are in recession territory. We have a long way back to bull market and what we are witnessing is the invariable bounces to the bottom. I say bottom because the FED has all but declared war on inflation and is not backing down regardless of market conditions. Fed Hair Jerome Powell said on Thursday, “History cautions strongly against prematurely loosening policy. I can assure you that my colleagues, and I are strongly committed to this project and we will keep at it until the job is done."
His comments echoed Fed vice chair Lael Brainard's, who spoke at a banking policy conference in New York on Wednesday. "It is especially important to guard against the risk that households and businesses could start to expect inflation to remain above 2% in the longer run," she said.
One by one officials acknowledged the economic and market pain their hiking policy could inflict and then reiterated that for the time being they would keep on with their aggressive regime to fight pervasively high inflation rates.
Certain key factors do indicate the Fed is taking steps in the right direction. Core and headline inflation were softer in July, commodity prices are falling, the dollar is strong, and supply-chain kinks are improving. The labor market is showing early signs of cooling off, and GDP growth is also slowing… but it’s not over yet and the Fed is quick to remind that taming inflation has not been as uniform or as rapid as they would like.
With all this in mind, the market is going to continue to bounce up and down and with the Fed’s latest announcement to proceed with their rate hike this month, expect knee jerk reactions from the market. We are in prime buying territory ladies and gentlemen. We could be in this bear market for the next 6 months to a year before the next bull run. Don’t you want to be in position to capitalize? Stack your chips now. Load up on stocks. You have time. Even if it’s a weekly or biweekly automatic deduction from your bank account like I have set up for some crypto assets, a little bit goes a long way over time. Let’s get it! I’m your host Stevie Bee. This has been Money Talk Sundayz.
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Inflation falls for first time in more than two years, key U.S. gauge shows, due to sinking gas prices. Fed Chair Jerome Powell’s inflation remarks trigger market sell-off. Crude oil prices fall while UK energy bills to rise by 80% in October as regulator announces hike. The market is in flux and while signs of inflation are abating market uncertainties abound. For more on this and next steps to ride the market, stay tuned. This is Money Talk Sundayz.
Welcome to Money Talk Sundayz. I'm your host Stevie Bee. For those tuning in via your favorite streaming platform hit that like and share button. You can also subscribe to the Money Talk Sundayz podcast. The link will be in the description box. For those viewing on youtube, like, share, and subscribe.
Today's show is going to take a different format than previous shows. I wanted to do a deep dive in FAZE, a company that operates lifestyle and media platform in gaming and youth culture. Those plans were quickly shelved when the Fed Chair Jerome Powell essentially sucked the wind out of the sails of the latest market rally by declaring that the U.S. needs a "sustained period of below-trend growth." That will mean some "pain" for households and businesses, he said, but the alternative is "far greater pain."
What does that mean???
The Fed is going to raise interest rates significantly more and keep them there to combat inflation. This news created a market rout on Friday as a mass sell-off began. The Dow Jones Industrial Average skidded 4.2% in last week's stock market trading. The S&P 500 index lost 4%. The Nasdaq composite gave up 4.4%. The small-cap Russell 2000 shed 3%.
Powell's hawkish message wasn't a surprise, but the market did not react well. The Dow Jones, S&P 500 and Nasdaq composite knifed back below their 21-day moving averages and are now not that far away from their 50-day lines — as well as some big round numbers for each of the major indexes.
There are signs that inflation is slowing however, it is these very signs that Jerome Powell is warning us about. He stressed the 1970s lesson for policymakers not to let their guard down quickly. The rate of inflation over the past year dropped to 6.3% from 6.8% in the prior month. The core rate of inflation edged down to 4.6% from 4.8% in the 12 months ended in July. It had touched a 40-year high of 5.3% in February.
So what can we do as investors?
Investors may need to pare exposure, especially if they ramped up in the past few days and are now sitting on some losses. Should the market trend higher fresh buying opportunities will arise, with Apple, Arista and Tesla among the possibilities. But investors should still be cautious, minding the risks of a quick head fake or resistance at the 200-day line. Keep in mind the possibility the market will retreat to the 50-day line, or worse. Depending on what followed, such a move could create a number of setups or a challenging period.
Read your charts and examine the stages. The only constant in life is change and a change is upon us.
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Happy Sunday everyone and welcome to Money Talk Sundayz. If you’re tuning in via spotify, anchor, or from any of the popular podcast streaming platforms I’m your host Stevie Bee. Go ahead and drop a like on your way in the door. Let’s rap money.
Let’s talk about some of the winners of this past week. At the top of the list with the biggest gains for the week is Eargo, ticker symbol, EAR. Eargo, Inc., a medical device company, engages in enhancing the quality of life of people with hearing loss in the United States. The company markets and sells hearing aids. It sells its products direct-to-consumer and through omni-channel. The company was formerly known as Aria Innovations, Inc. and changed its name to Eargo, Inc. in November 2014. Eargo, Inc. was incorporated in 2010 and is headquartered in San Jose, California.
Although this stock traded down $0.23 during trading Friday hitting $2.41 for the week, EAR is still up 111.4% We can agree that the new government ruling allowing for ear aids to be sold over the counter played a part in this stocks’ crazy jump. Considering the jump however, do you buy, sell, or hold? Generally after big gains many investors grab their profits and run causing stock prices to fall. It appears that the profit taking started early Friday so maybe about Tuesday/Wednesday would be a good time to buy if this stock interests you. If you’re already holding, I do see another rebound in the coming weeks before this stock settles.
Coming in at number 2 is Aeglea BioTherapeutics. For the week AGLE is up 75.4% with a current price of $0.91. Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency.
Current price target for this stock is $1.17 with a healthy short interest. Only 1.65% of shares are currently being sold short. Wells Fargo & Company reduced their price target on shares of Aeglea BioTherapeutics from $2.00 to $1.50. Even after rising 85% this past week AGLE shareholders are still down 88% over the past three years. There is room to grow with this one so jump in, swing, and jump out. We’re focused on short term trades while the market works out its volatility.
Rounding out the top 5 is one of our favorite meme stocks, Vinco Ventures aka BBIG. We’ve covered this stock before in our last season. If you haven’t seen or heard it, definitely check it out. BBIG is up 63% for the week closing out trading Friday at $1.45. After BBIG is Hill International or HIL. HIL is up 58% on the week closing at $2.81. Finally, there is Horizon Global or HZN. HZN is up 44.4% closing trading at $2.39.
Horizon Global Corporation engages in the design, manufacture, and distribution of towing, trailering, cargo management, and other related accessory products worldwide. It operates in two segments, Horizon Americas and Horizon Europe-Africa. The company provides towing products, such as hitches/tow bars, fifth wheels, gooseneck hitches, weight distribution systems, brake controllers, wiring harnesses, draw bars, ball mounts, crossbars, security products, and other towing accessories.
These are your top 5 stocks of the previous week ladies and gents. Are you invested in any of these stocks? If so, what is your trading strategy? Let’s chat. This is Stevie Bee and as always bros nation happy trading. See you next week.
Send in a voice message: https://anchor.fm/moneytalksundayz/message
AMRS, NVTA & Other Top Stocks for the Week Happy Sunday everyone and welcome to Money Talk Sundayz. If you’re tuning in via spotify, anchor, or from any of the popular podcast streaming platforms I’m your host Stevie Bee. Go ahead and drop a like on your way in the door. Let’s rap money. The market wrapped up another positive week in trading reaffirming the notion that we are out of the woods and that THE BEST IS YET TO COME!!! Let’s talk about some of the winners of this past week. At the top of the list with the biggest gains for the week is Invitae Corporation (NVTA). The day after the earnings release, the stock shot up 276%, landing at a previously unimaginable $8.63 a share. The CEO's comments on "improvements in several key metrics" were duly noted, but a share-price move of this magnitude is difficult to justify by the data alone. It sits comfortably this Sunday morning at 5.37. According to Stock Analysis NVTA had a positive change of over 125% for the week. Invitae Corp. is a biotechnology company that was created as a subsidiary of Genomic Health in 2010 and then spun-off in 2012. In 2017, Invitae acquired Good Start Genetics and CombiMatrix. In 2020, Invitae announced the acquisition of ArcherDX for $1.4 billion. Following NVTA we have Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives. This stock has seen over 110% positive growth this week closing out the week at 1.73. In after-market it has increased it a little bit more to 1.86. I’m not too familiar with this stock so let’s see what the net says. Aquestive Therapeutics Inc (AQST) is around the top of the Drug Manufacturers - Specialty & Generic industry according to InvestorsObserver. AQST received an overall rating of 64, which means that it scores higher than 64 percent of all stocks. Aquestive Therapeutics Inc also achieved a score of 87 in the Drug Manufacturers - Specialty & Generic industry, putting it above 87 percent of Drug Manufacturers - Specialty & Generic stocks. Drug Manufacturers - Specialty & Generic is ranked 138 out of the 148 industries. Word is investors in this stock from last year are still down 68% in spite of the 40% gains this past week. Knowing that, it’s as good a time as any to go ahead and build your position in this stock if this company interests you. Personally, I’m considering opening a position in this stock to swing short term. Catch the upward bounce you feel me. Rounding out the top 5 in third place we have Twin Vee PowerCats Co. ticker symbol VEEE. In fourth place, Verona Pharma PLC symbol VRNA. In 5th place we have Amyris Inc ticker symbol AMRS. All three had a positive change in the 90th percentile. Do any of these stocks interest you? Did you make money on any of them this week? Let me know in the comments section. Happy Sunday and have a profitable week bros nation.
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Recession: Are We In One or Not w/ Money Talk Sundayz
If it walks like a duck and it quacks like a duck... it must be a donkey!
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Has the Market Bottomed Out & Safe to Invest? Top Stock Movers the Past Week
Has the market bottomed out? Can we start to invest again? Have we staved off inflation? Depending on who you ask it’s either the end of the world or the fruit is ripe for the picking. Welcome to Money Talk Sundayz. I’m your host Stevie Bee. Let’s get to it.
The major averages ended positive for the week coming after the best month for the S&P 500 since November 2020. Almost 2 years! You can say for the last two years we were in pre-recession mode despite the gains various industries have seen. You know how they say by the time you feel thirsty you’re already dehydrated? The same can be said for the market. Over the last several months going back to a year there were all kinds of signals of a “thirsty” market. Inflation is but one signal, the latest of which the media has decided to harp on. Rule of thumb, by the time the media is telling you about it, it’s already too late and corrective action is past due. Hence the over correction that is so common in consumer behavior.
Despite this though, the state of the economy is still the barometer for how the country is doing. Although recent gains across major indices has brought renewed hope, the Nasdaq and S&P are still in the red for the year. The Nasdaq Composite is still down 20% year-to-date and the S&P 500 13%.
Like I said last week I think we’ve been in recession mode and the recent rally is not to be confused with the end of the bear market. Are we trending closer to positive growth? Definitely! Are we out of the woods yet? Definitely not! Inflation is still a real factor limiting the spending power of millions. Higher prices, supply shortages, short staffing, the invasion of technology into the labor force and more will lead to a tightening of the pockets especially for those lower on the totem pole.
It is not all doom and gloom despite the seriousness of the situation. There are still industries and sectors seeing positive gains in contrast to the rest of the market. Take for example the top 5 market movers this past week.
Applied DNA Sciences Inc or APDN saw their shares explode in value after their recent announcement that it had initiated a validation of a monkey pox virus test. In fact, it is up 755% in the past week. If we learned anything during Covid, the first one out the gate gets free reign of the market before a competitor shows up. On Aug 1, the stock was worth only 68 cents. Today it is up to 5.83 with a price target of 11.56. Remember missing out on Moderna? I sure did. I had it before it reached the hundreds and bailed on it. It reached the mid 300s at one point. Take advantage of the circumstances set before you and win. I’m buying in on APDN first thing tomorrow.
Next we have Assure Holdings Corp ticket symbol IONM which is up 160% in the past week followed by QRTEB, MTC, and AMTD. AMTD went bananas this week at one point closing at $1,100. Now beware with AMTD. This is considered a meme stock so just as quickly you can come out with a bag, that bag could be empty by the end of the trading session so traders beware.
All this to say despite a struggling market there are opportunities out there for the aggressive trader. If you’re more of a buy and hold type of guy there are still plenty of options to buy in on and as the market continues to bounce you just average down or up and keep on going.
That’s all I have for Money Talk Sundayz. I hope you found some of this information beneficial. I’m not going to rush this and try to do too much too fast like I did before but I do have some ideas in my head for the future. Patience is a virtue. Until next week, this is Stevie Bee for Money Talk Sundayz. Happy trading!
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Welcome to Money Talk Sundayz market recap. If this is your first time here go ahead and smash that like button and subscribe if you haven’t done so already. Today we’re going to go over some of the biggest gainers over the last week and what to expect from them going into this next trading session. Buckle up ladies and gents, it’s going to be a bumpy ride. Why? Chinese stocks seem to be in play for the next couple weeks. Let’s unpack.
First up we have BEST inc. To be honest with you, I never heard of this stock but after seeing who made the best moves this week and seeing this entity at the top of the chart, I had to take notice and do some digging. It wasn’t easy, I guess being that it’s a China-based holding company. Anyway, this stock rocketed up to $1 on Friday after opening the day’s trading session at roughly around 60 cents. In after hours, it fell 15 cents and is currently sitting at 85 cents a share. It’s last high of $1.11 was reached on Valentine’s Day and has seen a steady decline until the 10th of this month where it began surging. I’m intrigued in this stock for a short-term play. I’m debating a put option or snagging a few shares for the swing upwards. Might do both just to cover my ass. I don’t know what caused this upward swing for this stock and I’ve been doing my googles. If any of you viewers happen to have more info on this stock do share because we here at Money Talk Sundayz want to know more. All we know for now is that BEST Inc is a China-based holding company. The Company mainly conducts its business through its subsidiaries, variable interest entities (VIEs) and VIEs' subsidiaries. The Company operates its business through five segments. The Supply Chain Management Services segment provides warehouse management, order fulfillment services and transportation services to its offline and online enterprise customers. The Express Delivery Services segment provides express services that comprise sorting, line-haul and feeder transportation services to its franchisee service stations. The Freight Delivery Services segment provides freight services that comprise sorting, line-haul, and feeder transportation services mainly to its franchisees. The Store + Services segment deliveries the consumer goods to its convenience store membership customers. The Other Value-added Services segment principally relates to finance leasing services, cross-border logistic services and UCargo transportation services. Analysts are strong buy in the short term for this stock but holding anything longer than a month it’s a strong sell so be wary folks.
What does all that mean? Not a whole lot to us but if we can make money off it then let’s go!
It appears that with Biden’s chat with China’s leader, Xi Jinping , hopes of a truce are manipulating the stocks. If you didn’t already know, Russia’s Vladimir Putin, reached out to China for military aide in his quest to “liberate” Ukraine. Rumor has it that China is trying to create some separation between Russia’s incursion of Ukraine BUT they do remain very close allies in their bid to usurp the West. Shares of several large Chinese stocks traded on U.S. exchanges continued their ascent this week following positive news from Chinese regulators. In fact, Chinese stocks have had their best multiday rally in the 21st century this week.
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Welcome to Money Talk Sundayz. I’m your Investment Bro Stevie Bee. From market pullbacks to covid to death in the family and so much more 2022 has been jam packed with adversity but you know what… all those things are excuses. Even my technical issues with my computer and software issues trying to edit videos in post I just have to deal with it and find a way to push through. So here I am.
Obviously, the markets have been a rollercoaster since the close of 2021 but the Russian invasion of Ukraine has proven to be a major disruptor. It’s also proven to be a great buying opportunity. I took the opportunity to buy into a couple fuel stocks, particularly Shell and Chevron. It made a few bucks but I’m starting at the ground floor with these stocks. I wasn’t invested in them before and ARKKS’s Cathie Woods downplaying of fuel stocks a ways back sure hasn’t aged well.
I also bought into BXRX or Baudax Bio. You know I’m a sucker for biotech stocks. The one thing constant about technology is that is always evolving. Wall Street is positive on Baudax Bio Inc (BXRX). On average, analysts give the stock a Strong Buy rating. The average price target is $44.465, which means analysts expect the stock to add by 2594.85% over the next twelve months.
Baudax Bio Inc (BXRX) stock is trading at $1.65 as of 2:57 PM on Friday, Mar 11, a loss of -$0.15, or -8.51% from the previous closing price of $1.80. The stock has traded between $1.60 and $1.80 so far today. Movin on, you know your boy still die hard VXRT. China just had a resurgence of Covid stating that it’s the worst spike in Covid infections since February of 2020! That being said, we’re getting closer and closer to the end of the latest clinical trials for Vaxart’s covid vaccine pill while other companies such as Pfizer are still pushing their treatment pill. I’ll choose the vaccine pill over the treatment pill but at this point, I’m guessing neither will have as much importance for me after my bout with Covid earlier in the year. Like I said, 2022 is proving to be the craziest year yet.
VXRT stock has decreased by -2.64% in the last month. The company shares reached their 1-month lowest point of $3.91 on 02/24/22. With the stock rallying to its 52-week high on 01/05/22, shares of the company touched a low of $3.91 and a high of $11.11 in 52 weeks. It has reached a new high 2 times so far this year and lost -23.60% or -$1.48 in price. In spite of this, the price is down -56.88% from the 52-week high.
Analysts predict a range of price targets between $7.00 and $18.00, with a median target of $11.50. Taking a look at these predictions, the average price target given by analysts for Vaxart Inc. (VXRT) stock is $12.00.
We outside! Vaccine restrictions are loosening. People are travelling! With increasing fuel costs and rising energy stocks will come airline shares. Considering the rising costs of fuel and the fact that people are going to travel, like I am in a few weeks, airlines are in prime position to rally.
United Airlines announced that employees that didn't get the big shot can return to work.
Send in a voice message: https://anchor.fm/moneytalksundayz/message
What’s up everyone. Thanks for tuning into Money Talkz. We’ve taken a break here at Money Talk Sundayz to spend time with the family. This will be the last episode for 2021 so I hope you all had a merry Christmas and have a safe and enjoyable New Year’s Eve.
I wanted to look back at some of the events this year that spurred Money Talk Sundayz as well as look back at some of the predictions that were made and how they panned out. At first, I was considering doing a top 10 but I don’t want to drag this out too long, so we’ll go with a top 5 for the year. It’ll be a top 5 from the podcast streaming and the top 5 from YouTube. Do expect some overlap and some topics to come up more than once on both platforms. We’re getting the word out!
I started the podcast at the beginning of May but the first post to YouTube was May 16th when we uploaded MTS Episode 2 broken into 3 parts: Part 1 - Dogecoin Isn’t Going Anywhere, Part 2 – Cryptocurrency, and Part 3 – Plays of the Week. Obviously, Doge is not where it once was earlier this year and has struggled to recover.
Every week since the beginning of June at least one episode was posted on YT each week bringing you what we thought the market was doing and plays we were making or suggesting be made. It was a slow grind building the channel and we’re still growing but things didn’t really start making moves until Vaxart came on the radar. For this reason, Vaxart ranks number at the top of our favorite episodes/stocks/coverage etc. You the viewers were just as eager to see VXRT make a breakthrough as I was. For the record I hold more shares of Vaxart than any other stock right now. And I continue to hold and every now and then grab up a few more.
When I run the stats for the lifetime of the channel, our Vaxart coverage appears 8 times in the top 10 most viewed videos for this period. You guys made this happen. The two other stocks that appear in the top 10 are “MMAT Price Jumps on Short Squeeze” and Jaguar Health Inc. (JAGX) Is It a Good Time to Buy?”.
Runner ups go to Atossa Therapeutics and SNDL, both of which I’ve only covered once but made money prior to the inception of the podcast.
Over on the podcast streaming between Apple and Spotify and a host of other streaming services, the numbers are a somewhat different. Taking the top spot was our “BBIG Moon Landing; Vinco Ventures Squeeze on the Way” followed by our “VXRT vs ORMP: Vaxart vs Oramed” episode. When it comes to the streaming services’ top 10 Vaxart is on the list 3 times as opposed to 8 on YT.
Our Ocugen and MARK put episodes were timed perfectly allowing us to secure profits on the hype that was being blown up peoples’ rears. If you timed it along with us congrats and give yourselves a pat on the back.
One big thing that sticks out looking back though is the price prediction for Bitcoin back at the beginning of the year. Experts were predicting that Bitcoin would reach $100K by the end of the year. I was skeptical and voiced it but there were moments that I thought it would do it. But alas, on 12/28/2021 Bitcoin is down currently priced at $47,482.16. And like I always say as Bitcoin goes so does the rest of the crypto arena.
In summary, I just want to thank all of you for subscribing, sharing, liking, commenting and more. 2022 we plan to come back in full force with some plays, some news coverage, and more transparency and chronicling of our journey to $100K. Kyng V will be back. He keeps telling me that so I’m telling you guys that. Investment Bros is still in effect, and we still want you to join the marathon too! Subscribe! Let’s make this money.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Lucid Motors is a buy right now. Why? It’s set to make some big waves in the electric vehicle market. Buyers and investors are already lining up and making reservations. Production and sales around one hundred grand equate to a minimum of 12 billi in revenue potential. The stock prices have fallen in recent weeks to no fault of the company. Attribute it to people taking profits in a soaring company. Now’s your turn to get in and get a piece of the pie. Let’s talk lucid about LCID.
Welcome to Money Talk Sundayz. I’m your investment bro Stevie Bee. Thanks for tuning in. Run that like, share, and subscribe. Let’s pump the YouTube algorithm and squeeze these numbers.
Lucid Motors is an auto manufacturer in the electric vehicle market. They place an exceptionally high priority on efficiency ensuring that their cars maximize their use of the world’s resources sustainably. They seek materials from the most responsible suppliers — with a focus on sustainable standards and the potential for recyclability. Their band new factory is the first purpose-built EV facility in North America — designed expressly for the needs of the consumer and environmentalist alike.
Lucid Motors’ Lucid Air has been named Motor Trend’s Car of the Year for 2022.
Reservations for the Lucid Air, Lucid Motors' first attempt at producing an electric vehicle, are increasing.
Top 3 reasons why LCID is a buy right now:
-
The company has already begun deliveries of their cars to customers while reservations for vehicles are rising.
-
The Lucid Air range of 520 miles is unparalleled and unmatched in the industry. Even by Tesla. No company comes close to this range rating.
-
Production of the Air Sedan has just commenced. LCID will be revealing more details about other new models in the coming weeks.
There are many EV companies that showcase their prototypes and pre-production models, but only a few can show a finished product that is selling. This is where Lucid Motors distinguishes itself in an increasingly crowded field. In October, the electric-vehicle company began making customer deliveries to reservation holders, and reservations are increasing.
The company is currently sitting on 17K reservations for the Air Sedan which is up from 13K reservations in the previous reservation status. With their new facility in Arizona the company is looking to scale up to around 34K cars in the first phase of their build up. At this rate Lucid is on the money to exhaust half of its production capacity just off reservations.
In September, the Lucid Air Dream Edition sedan received the highest EV category range rating from the EPA, 520 miles, beating the nearest competitor by a solid 100 miles. No other EV product on the market comes close to Lucid Motors, which, let's face it, is a pretty good selling point for customers looking to contribute to the EV revolution by purchasing an electric vehicle with their hard-earned money. As a result, the Lucid Air sedan and its various special editions should prove to be best-selling models, resulting in a significant increase in sales once Lucid Motors reaches mass production capacity.
Lucid Motors is currently on track to produce and sell only one primary product: The Lucid Air sedan. But, behind the scenes, the electric-vehicle manufacturer is hard at work on its second project, which will see the introduction of the Gravity luxury SUV. The SUV from Lucid Motors is still in the design phase, and few details have been revealed so far, other than the fact that the new electric-vehicle will be available in 2023.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Just as the title of the episode indicates, Vaxart stock is on the rise after breaking out of the pennant pattern it has been in for some time now. As I mentioned in previous episodes, VXRT’s share price has been getting squeezed between ever narrowing highs and lows for a while and over the last couple days has broken past resistance and is testing a new support level. Bag holders like you and I know that this break above resistance will let the stock to continue to push higher as volume continues to move into the stock. Ready to talk Vaxart? Let’s go.
Welcome to Money Talkz, the gems I drop between the weekly Money Talk Sundayz podcast. I’m your investment bro Stevie Bee. Special shout out to all the new subs. I appreciate all of you. You know the business, run that like, share, and subscribe. If you’re a VXRT holder you definitely want to sub. This is a special edition of our Vaxart Watch.
Let’s get it.
As you can see on the chart, VXRT is making moves and breaking past its resistance level. You know how they say today’s price is not tomorrow’s price? Well yesterday’s resistance is today’s support for Vaxart. Things are trending favorably and now is definitely a time to grab up more shares of Vaxart before you get priced out.
The stock is trading above both the 50-day moving average (which is the green line there) and the 200-day moving average (which is the blue line there), indicating sentiment in the stock looks to be turning bullish. Each of these moving averages may hold as a possible area of support in the future. The Relative Strength Index (RSI) has pushed higher the past few days and now sits at 62 on the indicator. What this means is that buying pressure is strongly outweighing the selling pressure in the stock.
Ignore the FUD (fear, uncertainty, doubt)!!!! Focus on the facts!!! Vaxart is a winner! Moderna CEO has already come out saying that the current vaccines out are less effective against the new Omicron Covid variant. Vaccine resistance could lead to more sickness and hospitalizations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks, and the Australian dollar.
We are anticipating even higher lows for VXRT. Over the next several days expect to see above average trading volume for Vaxart stock. Barring some crazy news expect the stock to remain above the moving averages. Stay bullish bros nation!
In press news, Vaxart, Inc. announced that the company’s vice president, Sean Tucker, will attend and speak at the World Vaccine & Immunotherapy Congress West Coast 2021, being held today. As of this recording it hasn’t happened yet, but I will let Bros Nation know how it goes.
It’s part of an award-winning series of conferences and exhibitions that’s steadily rising to become the world’s largest and most established vaccination events. Vaxart’s CSO will discuss the company’s research program for an oral candidate for the COVID-19 vaccine in the form of tablets. The medicine that needs to be swallowed against coronavirus is the only oral vaccine of its kind against COVID-19, which has immunological potential, which is confirmed. And this is the only vaccine that has been conducting Phase 2 clinical trials since October 2021.
If you haven’t done so, as a shareholder it is in your best interest to go to Vaxart.com and subscribe to their alerts.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
It is the day after Thanksgiving and one of the first things to hit my alerts this morning was the news of a new Covid variant giving everyone pause. Rightfully so, the market’s response to this news was as expected so I had to check on my favorite biotech stock, VXRT. It was already up in premarket and closed the day up a little over 5%. in aftermarket it went up an additional 1% making me several hundred dollars on the day. If you tuned into the Winter is Coming episode on Vaxart you already know that this bump is indicative of what’s to come. In the last VXRT episode covering the squeeze pattern the stock is experiencing I said the stage is set for it to breakout. Are we on the verge of the next bull run? Let’s look at a couple of factors and you be the judge.
Welcome to Money Talk Sundayz. I’m your investment bro Stevie Bee with another installment of our Vaxart Watch. Run that like button. Subscribe and share if you’re feeling even more bullish on VXRT.
Here’s a bit of news I just found out and I haven’t heard or seen much chatter about it. We all know that Vaxart is conducting phase 2 trials of their covid vaccine tablet. What many of you may not have heard however is that the study will also be assessing the viability of the vaccine candidate as a “booster” for those who’ve received the injectable vaccine. Reports stated that the efficacy of the injectable vaccine wanes over time thus the need for a vaccine booster. The company’s Phase II trial is investigating its vaccine as a booster dose in people who have previously received an mRNA vaccine in their primary series. With the need for boosters comes more time for Vaxart to complete their phase 2 study.
The problem with the regular booster shots come from familiarity. Reports indicated adenovirus-vectored Covid-19 vaccines may face efficacy issues if they are used again as boosters because the immune system would be able to recognize and debilitate the vector.
Now obviously the convenience of the pill trumps many concerns and gives VXRT an advantage. Some are not needing a cold chain protocol, as well as doing away with needles, syringes, and vials. Also, as Vaxart chief scientific officer Sean Tucker points out, the vaccine has the additional potential benefit of sidestepping unwanted antivector responses as expected with other adenovirus-vectored vaccines. Vaxart uses the adenovirus type 5 (Ad5) as its vector. In addition, there is preclinical data showing its oral vaccine could also prevent SARS-CoV-2 transmission to unvaccinated individuals.
Just a little over a month ago crap outlets like the Motley Fool were claiming that it was too little too late for Vaxart but here we are with covid spikes around the globe and a new variant starting to make its rounds. Markets are reeling and countries are back to implementing travel bans just as the holiday season is kicking off. Vaxart is in a prime space to carve out its own niche in the vaccine market. Vaxart’s oral vaccine is much more straightforward to investigate in a clinical trial than ones that require a needle and syringe.
So how is the pill supposed to work you may be wondering. Vaxart’s Covid-19 vaccine tablet has a coating that allows it to survive the low pH in the stomach. Once it reaches the lower small intestine, its adenovirus vectors are released to infect epithelial cells. Once the genetic code is delivered, the host cell manufactures the SARS-CoV-2 spike antigen, as well as a double-stranded hairpin turn adjuvant. Vaxart’s vaccine draws a stronger response in the lower small intestine potentially due to specific immune system cells in this region, as well as local digestive enzymes assisting with the response.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
From the covid pill to the flu vaccine Vaxart is making a name for itself as a revolutionary disruptor in the vaccine industry. Phase 2 clinical trials began in the third quarter for VXRT’s oral vaccine candidate with an expected completion date of spring 2022. Results from the Phase II human influenza challenge trial showed that those who were given VXA-A1.1 were better at providing protection against viral shedding compared to the injected inactivated influenza vaccine (IIV). All this while stock prices show a squeeze at the end of a pattern. Will Vaxart blow past resistance or crash through support? Let’s find out.
Welcome to Money Talk Sundayz. I’m your Investment Bro Stevie Bee. I hope you enjoyed my last VXRT episode. Run that like share and subscribe button. Let’s get to it.
A new study shows that there might be a way to protect against influenza infection without needing to stir up antibody response. Scientists from Stanford University investigated the effectiveness of an oral tablet flu vaccine called VXA-A1.1 by Vaxart, which uses cellular correlates of protection. Results from the Phase II human influenza challenge trial showed that those who were given VXA-A1.1 were better at providing protection against viral shedding compared to the injected inactivated influenza vaccine (IIV).
Those who received VXA-A1.1 were found with plasmablasts and hemagglutinin (HA+)-specific cells that contributed to protection from viral shedding after 90 days. This was not seen in those who got IIV or a placebo. On day 8, those who were given the oral drug demonstrated T cell expressing markers that suggested enhanced mucosal tissue homing.
Details of the VXA-A1.1 study are published in Cell Host and Microbe.
On the Covid front, the company began the first Phase II trial of their investigational COVID-19 oral tablet vaccine and dosed the first participants. The whole data set from this investigation is expected to be accessible in Q1 2022, according to Vaxart.
Published results by Duke University show that the company’s COVID-19 vaccine candidate reduced airborne transmission of the SARS-CoV-2 virus in a preclinical animal model. Vaxart also improved its research and manufacturing capacity, allowing it to move forward with the production of the vaccine candidate.
CEO Andrei Floroiu stated, “Vaxart made significant progress this quarter toward its goal of developing a next-generation oral tablet COVID-19 vaccine. We have started our United States Phase II trial and anticipate beginning international trials in the near future. This is an important milestone, as our candidate is the only oral COVID-19 vaccine to progress to Phase II trials in the U.S.”
Vaxart founder and Chief Scientific Officer Dr. Sean Tucker said The progress we made in our vaccine research this quarter was significant. We already learned from an earlier human influenza challenge study that our oral flu vaccine candidate inhibited the shedding of viral RNA better than injectable vaccines. In addition, our published hamster study showed that our vaccine candidate could reduce transmission of SARS-CoV-2, even when there is an infection breakthrough in a vaccinated subject. The implications are significant because existing injected vaccines do not always protect against viral shedding and transmission to other people.”
Vaxart Inc. stock is now 23.64% up from its year-to-date (YTD) trading value. VXRT Stock saw the intraday high of $7.29 and lowest of $6.77 per share.
Compared to the average trading volume of 3.53M shares, VXRT reached a trading volume of 5943937 in the most recent trading day, which is why market watchdogs consider the stock to be active.
With this latest performance, VXRT shares gained by 2.32% in over the last four-week period, additionally plugging by 5.37% over the last 6 months – not to mention a rise of 23.86% in the past year of trading.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Brief Summary:
Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or have received prior vaccination with an mRNA (messenger ribonucleic acid) vaccine for the prevention of COVID-19.
Part 2: This phase will assess the efficacy of prophylactic VXA-CoV2-1.1-S against confirmed COVID-19 occurring from 7 days after second dose with a repeat-dose vaccination schedule in healthy adults compared to placebo. Safety and immunogenicity of VXA-CoV2-1.1-S will also be evaluated in this phase.
As the weather gets cooler and winter approaches, doctors are predicting a spike in COVID-19 cases and more hospitalizations which could put emergency departments at risk of being overwhelmed again.
California has begun positioning equipment and locking in contracts with temporary health care workers in preparation for another possible winter surge of coronavirus cases, Gov. Gavin Newsom said Wednesday.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
VXRT’s earning reports are in and currently in phase 2 of their clinical trials for their Covid vaccine pill. Vaxart also rose 46.73% from its 52-week low and is up 20.67% year to date. While Covid numbers in the US are trending south, the rest of the world is still being ravaged. Do you buy, sell, or hold? Are we still bullish or are we now bearish? Let’s break it down in today’s episode of Money Talk Sundayz.
Thanks for tuning in to Money Talk Sundayz. I’m your investment Bro Stevie Bee. It’s been a few weeks since I last covered Vaxart so today we’re going to circle back and see what’s up with our favorite oral vaccine candidate stock. Hit that like button on your way in and let’s get started.
During the recent session, Vaxart Inc. (NASDAQ:VXRT)’s traded shares were 1.68 million, with the beta value of the company hitting 0.24. At the last check today, the stock’s price was $6.57, reflecting an intraday loss of -4.64% or -$0.32. The 52-week high for the VXRT share is $24.90, that puts it down -279.0 from that peak though still a striking 46.73% gain since the share price plummeted to a 52-week low of $3.50. The company’s market capitalization is $887.57M, and the average trade volume was 4.52 million shares over the past three months.
Vaxart Inc. (VXRT) is currently still a recommended Buy from analysts.
Vaxart Inc. (VXRT) registered a -4.64% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.64% in intraday trading to $6.57 this Thursday, 11/04/21, hitting a weekly high. The stock’s 5-day price performance is -0.14%, and it has moved by -2.96% in 30 days. Based on these gigs, the overall price performance for the year is 34.57%.
Per the CEO, VXRT’s oral vaccine candidate “is the only oral COVID-19 vaccine to progress to Phase II trials in the U.S.”
Vaxart recently brought online its own GMP manufacturing facility and is now producing vaccines at two GMP plants. This has allowed the Company to manufacture all of the COVID-19 vaccine oral tablets for the clinical trials started and planned to start this year, and to begin manufacturing vaccines for its upcoming norovirus Phase II trials.
Vaxart scaled up its research, quality and manufacturing capabilities, increasing its R&D employee headcount by more than 35% during the quarter.
Vaxart named Dr. James F. Cummings as its Chief Medical Officer. Dr. Cummings is a board-certified infectious disease physician with extensive experience in vaccine, drug and diagnostics development, and will help guide the Company’s development of its vaccines.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
I hate, rather deplore the term, meme stock. The connotation behind it in my opinion throws shade on actual stocks. Before “meme stocks” the black sheep of trading was penny stocks. Haters swore there was no money in penny stocks. From experience I can say that is not true. Since the GameStop and AMC craze earlier this year the media has adopted the term meme stock and the term isn’t going away. Hard to fight the corporate machine. Since we can’t shirk the side eye of trading meme stocks, we can certainly take control of the narrative and win trading these stocks. Here’s how.
Welcome to Money Talk Sundayz. I’m your Investment Bro Stevie Bee. Hit that like button on your way in. Let’s talk meme stocks.
I want to share with you 9 things to keep in mind when playing the meme stock game. If you keep these in mind you will undoubtedly acquire and maintain a winning portfolio and keep the money flowing in.
1 Nano Hands.
When I say nano hands, think Iron Man. His hands are capable of a variety of different actions from shooting lasers, jet propulsion, to coming off entirely. With meme stocks, your hands must be able to adapt with any situation that may arise. Therefore, forget the Diamond Hands nonsense and secure your profits whenever possible. You can sell and should sell when you feel comfortable. Do not, I repeat do not be pressured into holding onto a stock longer than you are comfortable with. If your gut is telling you, it’s time to cut it loose, CUT IT LOOSE! If you let the opinions and actions of others intimidate or enrage you, you are in the wrong game. Life is too short to be bothered with someone else’s opinions. Get your money and move on.
2 Risk Tolerance.
In other words, only trade what you can afford to lose. If you find yourself in a position where you must choose between paying your rent/mortgage or car note or any other base necessity for living and trading meme stocks, you’re doing it all wrong. Take care of your business. Yes there is big money to be made and can be made in minutes as we’ve seen with Digital World Acquisition Corp (DWAC), Phunware (PHUN) and more but there is just as much money to be lost in a matter of minutes. When trading meme stocks you must honestly ask yourself, are you ok with losing this money.
3 Meme Stock Volatility.
Meme stocks tend to be very volatile. So much so, at any given moment brokerages will halt trading on them as we’ve seen many times this year. Meme stocks swing faster than Brangelina at a swingers’ convention. Meme stocks move fast because they are heavily shorted and have an emotional component that hooks people in on a gut level. Meme stocks are also mostly owned by retail traders, so institutions have a smaller impact on movements.
4 Accept the Meme Stock Consequences.
Acknowledge the fact that these are meme stocks and along with assessing your risk tolerance know you’re playing a dangerous game. Indeed, with high risk comes big rewards but it can also go the other way. Accept this fact that you are chasing big payouts quickly. That is the cold hard facts.
5 Kill FOMO.
You missed out? Get over it. Don’t let FOMO drive your decisions. Perfect example is MARK or Remark Holdings. We talked about it last week. I also did a follow up to it. If you haven’t seen it check those two episodes out. MARK had a huge breakout in premarket last week Monday only to crash and burn. You need to accept when you’ve missed the boat. If you open your platform and that stock you were watching is up 300% from yesterday… let it go. By the time your jump in is in the books everyone else is taking their profits and running leaving you holding the bag. There will ALWAYS be another stock to trade.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Remark did as expected albeit after a quick and short lived run up in pre-market Monday morning. On Sunday during the podcast I reported that it was trading at 2.86. By the next morning it was well into the $6 range. The perfect time to play the put option, just as I mentioned during that episode. Let’s discuss what exactly happened with MARK.
Welcome to Money Talk Sundayz. Thanks for tuning in. Hit that like button on your way in the door and lets get started.
MARK was the big question for Monday. Sources from all walks of life were swearing by this stock as the one. But the more in premarket it rose the more inevitable the pullback or correction. And the pullback game was strong. Within 48 hours of the last episode Mark was down from over $6 to dipping below $2.
Some of you asked what happened. Why did it fall so much? The answer is pretty simple, human emotion. This stock like so many others is viewed as a meme stock. Investors in meme stocks for the most part are in it for the short term gains. A run up like what happened Monday morning is exactly what investors are looking for. They cash in quick and fast while like many of you who weren’t already invested catch on too late and buy up the shares they are selling overvalued thereby driving the price down.
One user told me that she bought in at $7 and was down $1100 by Monday afternoon. That is the game. Buy the news, sell the hype. Too many bought the hype aka the run up not realizing a swift fall was coming.
After being burned this way on a number of occasions, I offered up a suggestion on the podcast. I recommended a put option play banking that what happened was indeed going to happen. And it did! By close of business Monday my put option was up over 80%. I’m at work with multiple browser tabs open and one of the tabs was glued to the price of MARK as it fell. I eventually took my profits on that option play Wednesday being up 115%. It felt good being able to read the play… and with time and experience (losses) you will be able to do so too.
Funny thing is that Friday people were claiming that MARK was going to run up again on Friday claiming that the stock goes up on Fridays and ebbs on Mondays. Hype. Malarkey like Uncle Joe Biden says. I was skeptical of this but again I kept a close watch. It closed the day just over $2… about 2.04-05. So much for that run up lol. I will acknowledge that today it is trading at 2.11 so there was some gain but hardly enough to appease anyone who jumped in Monday morning above $5.
Anyway, I’m done watching MARK. On to the next mark no pun intended. Well maybe a little intended. Interested in what I have my eyes set on for this week? Subscribe to the podcast and get your notifications first on what the next play is going to be.
Happy trading bros nation.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Remark Holdings Inc (MARK) stock is trading at $2.86, a gain of $0.69 on high volume. Remark Holdings Inc delivers an integrated suite of AI solutions that enable businesses and organizations to solve problems, reduce risk and deliver positive outcomes. The company's easy-to-install AI products are being rolled out in a range of applications within the retail, financial, public safety, and workplace arenas. The company also owns and operates digital media properties that deliver relevant content and e-commerce solutions. The group operates in one segment namely Technology & Data Intelligence segment which provides products and services to customers based upon the data collected and processed by its proprietary data intelligence software. So what is pushing MARK?
Welcome to Money Talk Sundayz. I’m your investment bro Stevie Bee. Go ahead and drop a like on the video. Let’s talk MARK.
Redditors are currently pushing MARK as the play for Monday. During after hours it is currently sitting at 2.86 a share. There is the real possibility of it going up further. What’s bananas though is that on Friday it opened at 0.91 and ran as high as 2.45 before closing at 2.17. As of this recording like I mentioned it is sitting at 2.86.
Here is the conundrum many who are not already invested in it are debating, does it have more room to grow or is it going to run out of steam and begin to dip? We saw the dip on Friday after a meteoric rise but again over the weekend we saw MARK surge once more. Those who believe it still has room to grow will jump in first thing Monday morning and hope that the wave continues throughout the day.
Skeptics will note the rise and like the mantra says, after every rise comes a fall.
What do we here at Money Talk Sundayz think? The market can go either way. We don’t know what’s going on behind closed doors. We are not aware of any back channel deals that are being made. We can only go off what is made publicly available to us and use that information to make an educated or emotional guess as to the direction this stock will take.
But what if you could have it both ways? What if you could bet on a rise and a fall and come out with a bag still?
Going back to the heart of this podcast, this is the play that I’m considering for MARK. Remember, the heart of this podcast is cataloging, documenting, sharing the plays the Investment Bros make on our marathon to 100K.
With that being said, this is what I’m looking to do.
First off, I don’t want to miss out on an opportunity to swing this stock for some profit so I’m putting in an order to purchase 100 shares. Considering its at 2.86 as of this broadcast, if it goes up $1-2 over the next 48 hours I’m a happy camper and sell off before the inevitable decline in share price of MARK. This in fact is my FOMO play.
Now let’s say it doesn’t go the way expected in the first play. Part 2 of this play is buying a put option with a November 19thexpiration (since that was the earliest available expiration offered when I tried). I buy one put option contract and if MARK craters from the over hype again and I’m a happy camper.
On a side note, lets say MARK goes up on Monday and continues its ride for a couple days next week and begins to fall the week after, I get to have my cake and eat it too. I make my profits off the short swing (if I sell in time) and then also get to cash in on the fall with the put option. I’m hedging my bets you can say. Regardless of whatever play I decide or you decide I can agree it’s too late to jump in on this stock for a long swing. I learned that the hard way with BTX. I bought in at 12. It ran up to 30. I didn’t sell. Now it’s sitting around 9. I’m sitting on a loss but a part of me is refusing to sell at a loss and want to recoup at the least what I put in.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Ocugen ticker symbol OCGN. You saw the posts. You heard the VXRT naysayers saying dump the stock and switch to OCGN. Ocugen this and OCGN that. Overvalued and overhyped, people in fear of losing out on a supposed bull run jumped on the OCGN bandwagon and got another lesson in buy the news, sell the hype. For more on OCGN stay tuned.
Welcome to Money Talk Sundayz. Hit the like button if you will on your way in the door. I’ll give you a few moments to get that out the way. While you’re there go ahead and subscribe and click that notification bell depending on the platform you’re tuning in. Let’s talk Ocugen.
Out the gate let me say I opened a put option on OCGN Wednesday and I’m currently up 28%. Why the put option despite all the hype that was swirling online about Ocugen? The signs. One thing I picked up along the way since I’ve begun this investing journey is how to differentiate news from hype.
Ocugen (NASDAQ:OCGN) is a small biotech firm. For years, it tried unsuccessfully to commercialize therapies for eye diseases. However, in 2020, it ended a Phase 3 trial on that front and pivoted to Covid-19. Its first effort in that regard, Covid-19 testing, totally failed to take off. The company is nothing if not persistent, however, and has now tried to get into the Covid-19 vaccine race. OCGN stock has been volatile based on these events.
To help with their lofty goals of wining their vaccine race, OCGN partnered with an Indian firm that had already developed a Covid-19 vaccine. Ocugen is supposed to obtain Food and Drug Administration (FDA) approval for the vaccine and launch it in North America. But the FDA didn’t give Ocugen the green light yet, and the company ended up getting sued by shareholders.
Similar to Vaxart, OCGN made lofty vaccine claims that they couldn’t back up. In March, the company said it intended to advance its vaccine’s development toward an emergency use authorization and ultimately a biologics license in the United States.
In June, however, it said that based on feedback from the U.S. Food and Drug Administration, it was no longer pursuing an emergency use application and was instead pursuing a biologics license application, which required an additional clinical trial and “will extend our timelines.”
The lawsuit charges the company knew its statements had been “materially false and misleading” and that it violated federal securities law.
But wait, there’s more.
Demand for a vaccine is starting to wane some. Ever since Merck announced it had developed a highly-effective therapeutic for treating Covid-19, vaccine stocks have been in freefall. Moderna (NASDAQ:MRNA), for example, has tumbled from $497 to just $310. There’s also been a good deal of uncertainty around the merits of booster shots of the vaccines. Add the two up, and traders have been quickly taking profits in the vaccine names. Let’s not forget that Ocugen’s product, however, hasn’t yet found commercial success in North America. Additionally, it’s gotten embroiled in scandal overseas.
OCGN is in hot water now that its partner on the vaccine, Bharat, has run into a legal logjam. It has been alleged that Bharat bribed Brazilian officials to win distribution for the vaccine in Brazil. This came after Brazil questioned the vaccine due to its rushed approval process.
Brazil’s organized crime investigation unit has already gotten involved, and some politicians have suggested this could be an impeachable offense against that country’s president. Regardless, it’s not a good look for a vaccine that is struggling to gain commercial traction to get embroiled in this sort of controversy. What vaccine-skeptical person who passed on vaccines from credible firms will rush to take this one instead?
Additionally Ocugen’s bad luck with the FDA continues with the regulatory agency pushing back on Ocugen’s attempts to launch the Covaxin vaccine in the U.S.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Vaxart is a game changer in the fight against Covid but now many are wondering…. Is it too late? The national infection rate is in a downward trend. The number of people dying from Covid is also going down. Merck is lobbying the FDA to approve their “therapeutic” Covid drug for use. It’s been at least a month since we’ve heard anything about new variants Lambda and Mu, both of which are said to be more infectious and lethal than the Delta variant. Is the Covid race really over for VXRT? Let’s find out.
Thanks for tuning Bros Nation. Hit that like button below and let’s get into it.
Multiple outlets are speculating that the race may be over for VXRT. It's clear the company missed out on vaccinating during the height of the pandemic. Moderna, Pfizer, and Johnson & Johnson shared that market.
Recently, former U.S. Food and Drug Administration (FDA) chief Dr. Scott Gottlieb told CNBC he expects the authorization of a coronavirus treatment pill and vaccines for kids to mark the transition from a pandemic into an endemic phase. Merck is requesting authorization of its treatment pill candidate which should come soon. And Pfizer has requested authorization of its vaccine in kids ages five through 11. So a post-pandemic world may be only months away.
All that being said, there are still a few key points that keep VXRT in the running.
A recent study in hamsters showed VXRT’s vaccine candidate reduces airborne transmission of coronavirus. This echo results from Vaxart's phase 2 study of its investigational flu vaccine in humans. The flu candidate cut viral shedding more than an injectable flu vaccine.
Additionally, healthcare facilities will find it easier to store a room-temperature-stable tablet than an injectable vaccine. (For example, the Moderna and Pfizer vaccines require cold temperatures.)
On top of that, like I’ve said in previous coverage of Vaxart, users prefer a pill over a needle and would gladly avoid the long lines and wait times at vaccination sites and healthcare facilities and cop the pill at the local pharmacy.
And while Merck’s pill is meant to treat the infection, Vaxart’s pill is meant to prevent infection in the first place.
Finally, globally a temperature-controlled vaccine doesn’t stand a chance against the pill in under-developed countries. The tablet will have a much broader reach into rural areas and will be far easier administered as opposed to the injectable counterpart.
That being said, it’s not over for VXRT. The market is still there. The demand is still there. My question now is, will it still be there next spring/summer when the first part of phase 2 trials is over? Do we hope for another variant to spread around the globe or do we start promoting Vaxart’s other tablets? Ladies and gentlemen, time is of the essence. Is Vaxart running a sprint or a marathon? What do you think? Is it over for VXRT? Let me know in the comments.
And that’s it. Thanks for listening. If you’ve made it this far, please subscribe to the podcast if you haven’t done so already. Share this information with your friends and fellow investors. If you have any questions, go ahead and send them my way. I’m still bullish on VXRT and will remain so. VXRT to the moon baby!
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Is it time to buy JAGX? The company has an average price target of $14. Over the last month it has fallen 43.39% so it seems investors are less bullish about the stock than before. That’s all fine and dandy but for people first time hearing about this stock, can they make a quick buck with it? Let’s find out.
Welcome to Money Talk Sundayz. Click that thumbs up button below to check in. Share and subscribe if JAGX is something you’re interested in. Let’s rap Jaguar Health.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.
The stock closed yesterday at 2.05. Today it opened at 2.06 and is currently at 2.10. In the last 52 weeks JAGX was a low as 0.56 and as high as 13.41 with an average 100 day trading volume of 2,607,031.
Personally, I just came across this stock the other day while looking up something else. I figured I’d talk about it with you guys, bros nation, since at the heart, the core of this podcast, it’s about how two brothers play the market.
I’m intrigued about this stock mostly because of the low buy-in opportunity. After infusing thousands of my personal dollars into these market ventures, I’m shifting towards no longer having to use my dollars but rather the profits from swing and options trades to continue building my portfolio. Like they say, make your money make money.
Now, JAGX is set to release their earnings on 11/11/2021. During their last earnings release the company posted EPS of $-1.14.
Now as far as the charts are concerned, JAGX is down 27.42% over the last 30 days losing 0.7947 cents a share. Over the last 3 months, it is down 57.10% losing 2.77 per share. But again over the last year it is up 107.21% however it is trending downwards.
Based upon the chart patterns I’m seeing that it has more falling to do before we see another resurgence in price. By how much more I can’t say but I would ballpark it falling back down to 1.50. What I would do at this moment would be to add it to my watchlist and set alerts for a rapid rise as well as an alert for when it hits my expected floor. Once it bottoms out I’ll then hop in.
My recommendation is swinging this sucker the long way.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
It is high time that something is done about Goldman Sachs. The amount of corruption breeding from this giant is undeniable and yet we the people continue to turn a blind eye. The pattern of abuses by this bank and I use the term loosely is so profound but because of the cash flow and the number of hands in the pot they continue to be slapped with fines and lip service but no real change.
In the latest chapter for Goldman Sachs, alums of the fine institution, Carlos Watson and Samir Rao, founded Ozy Media and proceeded to acquire funding from good ole Goldman. Everything was going fine until investors is Ozy started sniffing around and asking questions. Apparently someone didn’t like what they found and now Ozy is being sued in California federal court alleging it knowingly failed to disclose among other things that one of its founders impersonated a YouTube executive and misrepresented Ozy's programming viewership.
But this isn’t the first time Goldman has been supposedly duped by Ozy. In the last month, insiders say David Solomon’s bank spent nearly $300,000 on a new advertising partnership with Ozy, which last week went up in flames over a series of scandals that also included lying about getting cash from Sharon and Ozzy Osbourne.
Six years ago, Goldman spent more than $20,000 to place ads in Ozy’s newsletter over the course of a month in the hopes of boosting the number of subscribers to the Goldman Sachs newsletter “Briefings,” the sources said.
The marketing team, the real workers, were skeptical about the promises made by Ozy and company but Goldman execs forced the team to move forward with Ozy. Ultimately that investment netted them maybe a dozen subscribers when Ozy claimed an influx of new subs would be had from their hundreds of thousands of subscribers.
But wait, there’s more!
In late October, the United States Department of Justice announced a major settlement with the global investment bank Goldman Sachs for its involvement in the 1MDB scandal, an international bribery scheme in which high-level Malaysian officials embezzled an estimated $4.5 billion from a fund designed to finance infrastructure and other economic development projects. Between 2012 and 2013, Goldman Sachs helped raise $6.5 billion for 1MDB in three bond sales, and at least two Goldman bankers aided Jho Low, an advisor to the fund, in embezzling much of the capital. As part of the settlement with DOJ, Goldman agreed to pay over $2.9 billion to authorities in the US, Hong Kong, UK, and Singapore. Of the nearly $3 billion in fines, approximately $1.85 billion will go to the United States, over $600 million to Malaysia (on top of a $3.9 billion settlement the Malaysian branch of Goldman reached with the country in July), and $440 million to financial regulators in other nations.
Goldman Sachs is ripe for corruption and greed. Since 2000 the bank has been fined a staggering $16,381,931,839. There are 64 recorded violations by the bank on the violation tracker website.
This bank can be fined this much but the US is on the verge of default if the debt ceiling isn’t raised. What’s really going on? I’ll let you be the judge.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Vaxart begins phase 2 clinical trials of Covid-19 vaccine tablet.
Brief Summary:
Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or have received prior vaccination with an mRNA (messenger ribonucleic acid) vaccine for the prevention of COVID-19.
Part 2: This phase will assess the efficacy of prophylactic VXA-CoV2-1.1-S against confirmed COVID-19 occurring from 7 days after second dose with a repeat-dose vaccination schedule in healthy adults compared to placebo. Safety and immunogenicity of VXA-CoV2-1.1-S will also be evaluated in this phase.
https://clinicaltrials.gov/ct2/show/NCT05067933?recrs=abdfm&cond=COVID-19&phase=1&draw=11&rank=95
Detailed Description:
Part 1: This is an open-label, dose-ranging phase of the study to determine the safety and immunogenicity of an orally administered adenoviral-vector based vaccine (VXA-COV2-1.1-S) expressing a SARS-CoV-2 antigen and dsRNA adjuvant. Post screening activities, healthy adult volunteers, either naïve or prior vaccinated with an mRNA COVID-19 vaccine, aged 18 - 55 yrs old, and then 56 - 75 yrs old, will be enrolled into the study in 8 subgroups. Participants will receive either a low or a high dose of an oral tableted vaccine at Days 1 and Day 29. The total study period will last ~ 2 months during the active phase, with a total 12 month safety follow-up period post last vaccination. Safety, reactogenicity and immunogenicity assessments will be performed at set times during the study active and follow-up periods. Subjects will be monitored for symptoms of COVID-19 throughout the duration of the study follow-up period. An independent data monitoring committee (IDMC) will provide safety oversight through the duration of the trial. Safety and immunogenicity data will inform on the dose selection for Part 2.
Part 2: This will be a placebo-controlled phase with the vaccine dose level selected from Part 1. Subjects will receive two doses of vaccine or placebo at Days 1 and 29. Subjects will be followed as in Part 1 for safety and immunogenicity. They will also be followed for 6 months for efficacy.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Bumpy September is out of the way and a race to the moon is on for the rest of the year folks. The race does come with its share of obstacles i.e., the debt ceiling issue that hasn’t been resolved as of yet. But crypto is still chugging along despite market volatility. BTC and ETH continue to be the mainstays in the field however a need for faster network speeds and lower transaction fees is pushing investors to alternative choices. For more on this you’re going to have to stick around.
Welcome to Money Talk Sundayz. Hit the like button on your way in. Let’s talk cryptocurrency.
Big dog Ethereum appears to be losing steam falling behind ETH killers Solana, Cardano and Polygon. Over the past year the value of Ethereum increased by 830% making it the second highest crypto by market value. During the month of September, the coin’s value dropped 16%. This decline was fueled not only by September uncertainty and hesitancy but also by the slow network speeds and high transaction fees plaguing the asset.
It is here where the altcoins shine. Solana has seen almost a 4800% growth since September of last year. Solana boasts cheaper fees and faster usage than Ethereum. But that’s not all. Solana has found a driver in the NFT and DeFi market. Solana is processing 50,000 transactions per second at only $0.00025 per transaction. Ethereum has not come up with a way to compete with that. Ethereum’s transaction speed is limited to 13 transactions per second with much higher fees than Solana.
Investors are catching on and while not completely leaving ETH outright, they are diversifying and giving a bigger piece of the crypto pie to alternative blockchains.
For example, Grayscale, a crypto asset manager, has added Solana and Uniswap to one of its funds per the Market Insider. The company said it had added the solana network's sol token and uniswaps' uni to its Digital Large Cap Fund, which has $494.6 million assets under management, according to its website. The weightings were adjusted so that bitcoin would have the largest weight followed by ether, ada, sol and then uni based on "quarterly reviews", Grayscale said.
If that wasn’t all, Solana-based NFT SolMonkey sold for $2 million. SolMonkey was the latest Solana-based non-fungible token to be sold at a very expensive price. Earlier this month, The Block Crypto reported that the SolMonkey was only sitting at more than $1 million value three weeks ago. Some people doubt Ethereum blockchain's dominance in the market since many NFTs are struggling to keep up there. However, the #1355 Solana Monkey, which depicts a skeletal monkey donning a colorful crown, has been bought for $2 million. In the collection, it was said to be the most unique NFT.
In more NFT/Solana news Genopets a Play-to-Earn NFT Game has announced its decision to build on the Solana ecosystem. According to the announcement, Genopets revealed that more than a million people actively played a Play-to-Earn blockchain game daily.
Also, the blockchain gaming platform revealed that its decision to build on Solana was due to its scalability, top-notch security, fast transactions, cheap costs, among others.
“[…] Solana is scalable and cost-efficient, so you don’t have to worry about growth on fragmented Layer 2 systems or sharded chains,” Genopets noted.
While I’m still on the fence when it comes to the lasting power of NFT’s this is affirmation that Solana itself is a great investment.
Another Solana convert is Bancambios. The long-awaited Bancambios DeFi initiative has finally begun. The token (ticker: BX) will be created over the Solana blockchain, and the foremost invitation to join will be sent to the Solana and DeFi communities. Bancambios is on course to meet its blueprint release deadline (Q4 2021 – Q2 2022).
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Bros Nation, I know, I know. I said we were going to be off this week for my birthday this weekend but news came across my desk about one of my favorite stocks, VXRT. This is good news/bad news depending on how you look at it but news nonetheless. The ongoing lawsuit with VXRT continues despite a much anticipated Sept 30 resolution date. The judge overseeing the case deals a blow to VXRT and investors respond in kind. For more on this stay tuned.
Welcome to the Money Talk Sundayz podcast. I’m your Investment Bro Stevie Bee. Do the channel a solid and hit that like button. If you’re not already subscribed you can do so now or at the end of the video. Finally, if you have friends that are invested in Vaxart or VXRT share this video. The latest VXRT news leaves me with mixed feelings but still bullish.
On September 30, 2021 Judge Vince Chhabria called Vaxart out on their dismissal claims accusing the biotech company and controlling owner, hedge fund Armistice Capital LLC of burying investors in an “avalanche of bs”. The judge did not outright rule that the defense were guilty of what they were being accused of but did go so far as to say that the allegations made against them were “plausible”.
Quick background as to the nature of the lawsuit. VXRT and Armistice are being sued for multiple materially misleading statements in June 2020 that claimed it was partnering with Attwill Medical Solutions Sterilflow LP to produce "a billion or more" COVID-19 vaccine doses per year, even though Attwill wasn't certified to produce the vaccines. Vaxart also claimed a day later that its Covid-19 vaccine had been "selected for the U.S. Government's Operation Warp Speed.” That wasn’t the case at all.
During a hearing held via Zoom, Judge Chhabria said it appears that the investors have plausibly alleged that Vaxart Inc. and its majority stockholder and controlling owner, hedge fund Armistice Capital LLC, intended to artificially prop up the price of the penny stock. It also appears that the investors have plausibly alleged that the defendants intended to make a series of misleading statements in order to prop up the stock price, the judge said.
"Is that what happened? I don't know," the judge said. "But I think that that has been plausibly alleged."
In VXRT’s defense, Riccardo DeBari of Thompson Hine LLP, argued that the allegations hinge on a mere "10 words" at the beginning of a press release that are unactionable, forward-looking statements that were aspirational and that only “nitwits” would have been duped by the numerous press statements released by Vaxart.
The judge disagreed pointing to the statements made back in June 2020 as seemingly credible intel for sophisticated investors. The judge went further revealing that at the time of the press statements Vaxart only had roughly 25 – 30 people working at the company making it highly unlikely they would have the capacity to produce billions of vaccines annually.
"It's just absurd," the judge said, adding that "clearly" the company should have known that they didn't have the capability to produce that many vaccines.
Now the judge did not issue a ruling at the end of the hearing instead asking both sides to submit additional case law citations for him to review before doing so.
Now from what I’ve read on the hearing an order date is not set so we’re playing the waiting game just like in the case of Ripple and XRP. What is notable is that shares of VXRT dropped to as low as 7.06 as of this recording. The drop is further fueled by another Covid-19 vaccine tablet shines in late stage trials from Merck & Co. Merk is leading the race in developing an oral pill for the virus with studies showing that their candidate greatly reduces chances of hospitalization or death among patients at risk of severe illness. Merk is currently trading at 81.40.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
China banned crypto again which sent the crypto market reeling but not for long. It’s not the first time that it happened and it won’t be the last. Don’t be fooled. You can only delay the inevitable but for so long before being overtaken by it. Crypto is the future of currency. Get in NOW!!!
Welcome to Money Talk Sundayz. I’m your Investment Bro, Stevie Bee. Hit that like share and subscribe button when you come in the door.
Lets talk Twitter!
Twitter announced that its 330m active users will soon be able to send bitcoin to each other instantly and for virtually zero cost – harnessing the Lightning network that’s been built on top of bitcoin’s primary layer and, many believe, will propel the cryptocurrency into the mainstream.
One bitcoin was worth $42,666 on the Bitstamp exchange at 16:00 EST Saturday, holding above its long-term moving averages and surpassing its value at the beginning of August.
The digital currency briefly dipped below $40,700 on Friday, when the so-called People's Bank of China – a Communist government-controlled central bank – declared that all cryptocurrency-related activities were “strictly prohibited” in the country. Beijing accused the cryptocurrency industry of “disrupting economic and financial order” and “endangering the safety of people's property”.
That clampdown triggered a 20% crash in bitcoin’s price, yet the latest, more draconian measure has moved the needle by less than 5%.
Bitcoin was almost completely unchanged on Saturday, having found strong support at its 200-day exponential moving average.
While everyone was freaking over the latest move by China, news coverage of the positive adoption by Twitter TWTR +0.8% was almost entirely restricted to financial outlets like Bloomberg and CNBC.
Twitter began integrating the Strike bitcoin Lightning wallet with its platform last week, enabling users to send and receive bitcoin as easily as tweeting out a thought.
Critics of bitcoin have long argued that the cryptocurrency can’t be scaled for mass adoption because of its high costs and slow processing times. Average transactions on bitcoin’s primary layer typically cost around $8 and take about 20 minutes to be validated, although fees and timeframes vary in-line with network demand.
Lightning solves this problem by processing transactions off-chain through a secondary layer that can, in theory, handle millions of payments a second (Visa, by comparison, processes about 1,700 payments a second).
Users interact with the Lightning network through purpose-built mobile wallets such as Strike and Muun. In El Salvador, which formally recognized bitcoin as legal tender this month, citizens are already making micro-payments for coffees and newspapers with their national digital wallet, Chivo.
Given the lack of media attention, it’s no surprise that the Lightning network remains small today: less than 3,000BTC is currently locked in the protocol. But its capacity has risen steadily this year and is likely to surge as Twitter completes its integration for all users over the coming weeks.
China is, undoubtedly, worried about bitcoin – but not because of money laundering, phishing scams or economic destabilization.
China is worried because bitcoin gives its citizens the freedom to teleport their wealth around the world instantly at the click of a button – side-stepping the short-sighted, arbitrary capital restrictions that Beijing is no doubt planning in response to the Evergrande debacle.
What does this mean for BTC, hiccups will come but the crypto is more than ready and capable to deal with all the hurdles that comes its way. Get you some if you haven’t done so already!
This is your investment bro Stevie Bee with Money Talk Sundayz. Again hit that like, share and subscribe button. We’re off this week. I’m celebrating my b-day so…. Yeah Libra Gang!
Happy trading folks!
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
So you want to know about SNDL. I’m not going to go into the back story of SNDL. If you’re asking about Sundial you already know what the company is about. Million dollar question is, do you invest or not. Simple answer, depends on how you’re investing. Let’s break it down.
Welcome to Money Talk Sundayz. Hit that like button on your way in the door. If you’re not already subscribed what re you waiting on? Let’s get his movement going. If you make it to the end of this episode please share. SNDL.
For the record I am not currently invested in SNDL but I was in the past. I swung it. Made some money when it broke a dollar and bounce out. That was several months ago. I haven’t jumped back in since BUT I have been keeping up with SNDL news for the most part in anticipation of another move. There hasn’t been any new recently that has motivated me to get back in but in the back of my head I do want to hop back in and I just might but only as a long swing trade.
Currently, the Canadian cannabis market is showing signs of saturation. That being said, SNDL is not looking as a market leader… yet. However the two pillar pivot is promising as it gives SNDL stable cashflow and a way to benefit from the saturation and legislative hurdles.
Sundial Growers' offerings center around adult cannabis use. They recently pivoted into what insiders call a ' two-pillar approach which is centered around the production of cannabis-related products and their investment arm Sunstream Bancorp.
Their production segment comprises inhalable products, such as pre-rolls, flowers, and vapes. Grasslands, Sundial Cannabis, Top Leaf, and Palmetto are the brands under which Sundial Growers offer their products.
Boasting a wide array of products in the cannabis space at multiple price points the company is still struggling to find consistency when it comes to profits. There is room for the company to focus its efforts on the more profitable sides of its business and the dried flower category has carried revenue for the company in the past accounting for more than 50% of revenue for the segment. The company is instead focusing on engaging its franchisees which is a positive. The company is also working on a Franchisee Advisory Council which will be tasked with flattening communications with franchisees so the company can dial into the growth dynamics the franchisees are seeing on the front line.
Sundial continues to invest heavily in streamlining the cultivation process and cost control. They also have an emphasis on vertical integration which jives well with their recent decision to Pivot into investment operations. Sundial seems focused on having positions all across the value stream end the Cannabis space which can be compelling or not depending on how you view the industry's prospects over the long term.
The challenge is the market saturation makes it difficult for the company to differentiate itself from its peers. The company hasn't really been able to find major success in this segment yet but as attrition thins out the competition in the Canadian market that may change. In the meantime, the company is focusing on increasing efficiency and improve its internal cost controls to protect its robust liquidity position which is prudent.
This is Stevie Bee for Money Talk Sundayz. If you haven’t done so already hit that like button. If you made it this far hit that subscribe and share button. I’m definitely open to you guys and hearing what you have to say so drop a comment or a dm. We’re going to do this. One love.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Welcome to Money Talks with your Investment Bro Stevie Bee. I just have one question to ask my viewers today… Are NFTs finally seeing the door? You know, that new fad that hopped on the scene in the last year called non-fungible tokens. From the jump I was extremely skeptical of its lasting power. In my opinion it was almost as ludicrous as paying any amount of money for an invisibly sculpture or for a banana taped to a canvas… but when you have money all bets are off I guess. Despite my skepticism there has been good money that has changed hands and I would be remiss to not secure a piece of that exchange. So I invested in YVR. I did a swing trade on YVR, made a couple hundred dollars and bailed out. That is the extent of my NFT experience.
But now signals are pointing to what many predicted. According to CointeleGraph, data shows that a majority of the lower-priced NFTs and lesser-known projects in the market do not accrue value and this means that the sector is rather illiquid. Using data from OpenSea, a recent report from Bloomberg found that 73.1% of NFT assets had only one transaction in the past 90 days.
While this may only be just a snapshot of the overall NFT market, the data itself raises eyebrows given that investors looking to buy NFTs on average pay well over $100 to mint a new NFT and cover the fees needed to transfer the asset.
In comments to Bloomberg, Gauthier Zuppinger, the COO of Nonfungible, said that “maybe 90% of collections minted today are totally useless and meaningless.”
Regarding 'successful' NFT investing, Zuppinger:
“Ninety-nine percent is about being in the right circle, having the right information at the right time. In the NFT space, you live with this constant frustration that you have missed a chance to make $1 billion.”
The number of sales being made on marketplaces has cooled off from its August highs as well. The number of daily sales across all NFT marketplaces has declined from a high of 138,109 on Aug. 30 to 42,372 on Sept. 21.
A similar chart pattern is seen across multiple NFT marketplace metrics including the dollar value of sales completed, active market wallets, primary market sales, secondary market sales, unique buyers and unique sellers.
In short, the NFT market is dying out. People are catching on and realizing it for the farce that it is. Yet another pump and dump in something that ultimately is worthless and in a lot of cases turns out to be fungible after all.
Fungible is defined as “being of such nature or kind as to be freely exchangeable or replaceable, in whole or in part, for another of like nature or kind.” Many of these NFTs are exchangeable and/or replaceable in whole or in part.
Thou hast been duped if thou hast partaken in the acquisition of most NFTs. To avoid this, I invested in the platform on which the exchanges occur. As the hype rose, so did the share price hence my swing trade. I hopped out just prior to the cool down and I must say it was a nice little quick run. Like SNDL for example, I jumped in when it was pennies on the dollar, rode it over that dollar mark and secured my profit and sent it packing. Since then, the stock has struggled to gain traction above 72 cents.
In summary, for the activity that is still occurring in the market, “the most actively traded 3% of collections accounted for 97% of all dollar volume,” according to Bloomberg, suggesting that the NFT market is behaving a lot like the wider altcoin market where a small percentage of the tokens receive a majority of the trading volume.
But this is just my take on NFTs. If you have a different experience with them share it with me. Im far from the brightest in the bunch and common sense is not all that common anymore so… help me see what I’m missing. It can’t really be that much being missed here. What do you think?
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
The market clearance sell continues today after last week’s quad witching. What that means for folks afflicted with FOMO (Fear of Missing Out), you once again have an opportunity to jump in at a good entry point stocks and crypto. So what are a couple promising plays? Stay tuned to find out.
Subscribe: https://anchor.fm/moneytalksundayz/subscribe
Let’s start off with the crypto market. The value of the world's cryptocurrencies plunged to a low of less than $1.9 trillion by 8:45 a.m. EDT on Monday, nearly 11% less than 24 hours prior and reflecting a loss of more than $250 billion, according to crypto-data website CoinMarketCap. Shout out to China for keeping the market on its toes and speculating. With the virus still dominating investor concerns, markets were jolted by news of Evergrande, a major Chinese real estate company that's teetering on the brink of default. China's potentially slowing economy, and Beijing's aggressive actions against key business sectors, have converged with worries about the global economy. Meanwhile, a fight is brewing in Washington over raising the U.S. debt limit per Yahoo! Finance.
Today, this somewhat obscure, overseas risk suddenly shook up financial markets from Asia to Europe and the U.S., where all three major benchmark stock indexes, the S&P 500 SPX, -1.70%, Dow industrials DJIA, -1.78% and Nasdaq Composite COMP, -2.19% appeared to be headed for the worst one-day drop in more than two months. Though it is certainly not the only reason U.S. stocks slid, Evergrande was a factor behind investors’ risk-off mood.
On one level, Evergrande—which reportedly faces at least $83.5 million in interest payments due on Thursday, with a 30-day grace period — is raising concerns about a liquidity crisis among all Chinese and Hong Kong property companies, as markets quickly turn off access to dollar funding. In a more macro way, the firm’s woes are bringing to the fore China’s wide-scale regulatory crackdown across most of its businesses, starting with technology giant Alibaba Group Holding Ltd. 9988, -2.19%, which is rattling confidence in the world’s second-largest economy.
You can’t really go wrong with BTC and ETH. The value of these coins right now are about as good as its going to get. Expecting the coins’ value to drop in half is wishful thinking so now is as good an entry point as any.
In fact, since hitting a September high of almost $53,000 after El Salvador officially introduced bitcoin as legal tender, the crypto unit is off by more than $8,000.
Aside from the obvious BTC and ETH, Solana and ATOM are really good choices to establish your position prior to the next run up. I’m a fervent believer in XRP and currently with it falling under a dollar, it’s another great option to get more bang for your buck. In the past I used to tout Dogecoin as the coin to buy BUTTTTT while I still believe it has its merits, I’m looking for plays that will pop off quicker, sooner than Doge.
In regards to stocks, now is a great time to jump on VXRT if you haven’t done so already. VXRT has seen its SMA50 which is now 1.12%. In looking the SMA 200 we see that the stock has seen a 11.17%. It’s also a good time to get in on OKE, ARKK, and SPG. With the market in the toilet people are selling off to hedge their losses which creates a wonderful buying opportunity for those with resources available to snatch up the sales. I for one had to go ahead and scoop up a few things while also running a couple option plays on Apple, NIO, and VXRT.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
We are literally chasing the coronavirus, the covid-19 virus like a hamster on a wheel. That is not just a saying, that is the truth of the matter when you look at rapidly emerging mutations of the covid-19 virus. While everyone is still focused on the delta strain, the lambda and the mu have already told Covid 1 to hold my beer. And of course, the propaganda machine wants to call it the pandemic of the unvaccinated while vaccinated people continue to catch the virus and in some cases die. But don’t get me wrong, this is not me making a case for or against vaccines. This is me making a case for a viable and feasible tool to help combat it. Ladies and gentlemen, Vaxart.
Subscribe: https://anchor.fm/moneytalksundayz/subscribe
Welcome to Money Talkz. If you’re new here, I’m your Investment Bro Stevie Bee. Leave a like, share, and or subscribe on your way in the door. If you’re feeling the episode and would like to see more, you can support the channel by clicking the link below. Let’s get into VXRT.
Vaxart Inc. (VXRT) is trending lower, roughly -4.57% in the recent trading with $8.19 being its most recent. The current price level is over -66.43% lower than the highest price of $24.90 over the past 52-weeks, but it is also 138.86% higher than the lowest price of $3.50 the company dropped to in the past 52-weeks. The latest news story on VXRT appeared in PR Newswire under the title “Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference”.
The conference was held over the last two days, and I’ll sum up what I’ve watched so far but before that, let’s talk charting.
VXRT in the last 30 days is trading almost 15% below its one month high and about 10% above its recorded lowest over the same time span. If you check the simple moving averages of VXRT, its 50-day-SMA is $8.27. It’s 5-day-SMA is 8.70. Vaxart’s 200-day-SMA is 7.55.
The stock’s 20-day average volume is at 4,041,925 shares and 50% of short-term indicators are suggesting the stock as Buy. Medium term indicators at an average of 100% are spotting the stock at Buy with its 50-day average volume of 7,578,720 shares. And to end, VXRT’s 100-day average volume is 15,462,688 shares with 100% of the long-term indicators pointing towards Buy for the stock.
In the bigger picture you can see it is trending higher overall.
Now it’s hard to say how well the stock will do in the long run. Investors like myself anxiously await the coveted pill that moves the needle as they say. I’m sure that the institutions holding VXRT shares are anxiously awaiting this pill as well since they own nearly 41%of the stock. The public owns 120.93 million shares and counting.
The latest SEC filings reveal that stock came across 7 new insider purchases involving 207,119 shares. On the other hand, VXRT has declared 272,958 shares sold in 9 insider transactions over the past three months.
How does Money Talkz feel about the stock? Just as bullish as ever. It’s a strong buy.
If you watched their presentation, you will see that their oral Covid vaccine candidate is backed by clinical data that the FDA found encouraging and promising enough to approve Vaxart to move on to Phase 2 clinical trials. That will being later this year. Considering that we’re already in mid-September and it hasn’t kicked off yet to our knowledge, I don’t expect the pill to be released by the end of the year. Maybe mid 2022 if we’re lucky.
While Covid is the hotly anticipated offering from VXRT however, the pipeline is focused on several oral tablets beyond the covid pill including norovirus, HPV, influenza & RSV.
But demand is super high for a Covid combatant and thus the focus is on their pill candidate. The pill promises a convenient mode of administration that is rapid and painless. No appointments, lines, or social distancing required.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
It’s that time of the season again. The witching hour is among us. Open contracts come to a close and either money is made or lost but the reset button has been pressed. All eyes will be on the mother of all squeezes in AMC and other so-called meme stocks like GME and other retail investor favorites. In crypto news, the market as a whole is in a bit of a slump over the past few days. One coin that remains resilient through the choppiness is again Solana, but this coin is looking to be SOL 2.0. Are you ready?
Subscribe: https://anchor.fm/moneytalksundayz/subscribe
Welcome to another episode of Money Talk Sundayz. I’m your Investment bro, Stevie Bee. You know the drill, hit that like share and subscribe and let’s jump right into it.
Crypto is ablaze and last week’s coin of the week is still holding ground. As other major coins tear Solana is ripping at a fraction. The Ethereum challenger has been seeing more interest from institutional players according to Sam Bankman-Fried, CEO of FTX exchange.
Solana is an enterprise-grade blockchain, which was created by Anatoly Yakovenko. It is backed by Alameda Research and FTX Exchange, which all fall under the watchful eye of crypto billionaire Sam Bankman-Fried. According to Bankman-Fried, Solana’s compelling long-term roadmap as a blockchain means that it will be able to support industrial uses of crypto. According to Bankman-Fried, NFTs, decentralized finance, and the launch of the Pyth Network market-data feed has contributed, at least in part, to Solana’s popularity. Bankman-Fried is busy with the development of the Serum derivatives exchange on top of Solana’s network.
Solana’s SOL token has seen its value soar in recent weeks, surpassing Dogecoin, as of September 7, 2021. It now sits sixth, at the time of this writing, at $182.56, surpassing XRP, which has not performed well this week, due in part to legal troubles.
As good as Solana is doing, this coin seems poised to usurp the Ethereum killer. Pseudonymous trader Inmortal tells his 66,600 Twitter followers that he’s looking at Cosmos (ATOM), a project that aims to help developers build different blockchains that can transact and exchange data, creating a decentralized internet of blockchains. According to the crypto analyst, Atom will be the next Solana (SOL), a crypto asset that has meteorically risen nearly 350% in the last 30 days, according to CoinGecko.
The crypto analyst is also looking at Cosmos in its Bitcoin pair ATOM/BTC). According to Inmortal, ATOM/BTC must flip 0.00055 ($25) resistance into support to ignite a parabolic rise in value.
ATOM is doing great and if it follows current projections the pair could rise to as high as 0.002 BTC ($91.14), which represents a potential upside of over 230% from its current price.
The ATOM coin indicates the formation of a rounded Bottom pattern in the daily timeframe. The key resistance level(neckline) for this pattern is situated at the $30 mark, which the price has currently broken. If the coin manages to provide a proper breakout from this neckline, the ATOM traders can grab an excellent long opportunity in this coin.
According to the EMA’s, the ATOM coin has a strong bullish trend with its price trading higher than the 20, 50, 100 and 200 EMA. Moreover, the 20 EMA provided strong dynamic support to the coin’s price.
The RSI value (BULLISH) is at 68, indicating a strong bullish trend in this coin. However, the RSI line shows substantial bearish divergence concerning the coin’s price, suggesting weakness in the bullish momentum.
After reviewing this coin I’ve opened up a position and started investing. I will continue to invest when it dips and watch it hit triple digits.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
It’s that time of the season again. The witching hour is among us. Open contracts come to a close and either money is made or lost but the reset button has been pressed. All eyes will be on the mother of all squeezes in AMC and other so-called meme stocks like GME and other retail investor favorites. In crypto news, the market as a whole is in a bit of a slump over the past few days. One coin that remains resilient through the choppiness is again Solana, but this coin is looking to be SOL 2.0. Are you ready?
Subscribe: https://anchor.fm/moneytalksundayz/subscribe
Welcome to another episode of Money Talk Sundayz. I’m your Investment bro, Stevie Bee. You know the drill, hit that like share and subscribe and let’s jump right into it.
Quadwiching is upon us again. Keep an eye on all of your open positions. I currently have a call option open on NNA based on some intel I came across and I’m currently down on it. If by Wednesday I don’t make at least a 30% profit than I’m out. NNA is Navios Maritime, a marine transportation business. It operates in Asia, Europe, and America. The firm owns fleets of crude oil, refined petroleum products, and chemical tankers.
I also have shares in MMAT, BBIG, BTX, VXRT and more. I anticipate a clearance sale this Friday so I’m saving to go holiday shopping come Black Friday.
There is one thing though that seems to be on the minds of many stonk traders, what’s going to happen with AMC? Are the institutions going to be able to cover their positions? The government is expected to hit their debt ceiling by mid-October. Naked shorts have flooded the market. Hurricane Ida as created a double whammy of a crisis in the gulf and the northeastern states. Billions of dollars have been poured into the economic recovery plan for this pandemic we’re almost 2 years in on. Threats of a market crash and serious correction are looming. People are nervous and wary as is the market performance over the past week.
Let’s say things go belly up. Will the institutions pay out to retail traders? Will the government bail out the banks again after over-leveraging? Well like I told another viewer last week, even if the hedgies are called to cover their bets they might not be able to. The amount of ghost shares currently out does need to be paid out but internally, a loophole, a bail out will be proffered. HODLers of AMC will not realize the fruits of their hactivism.
In a letter to congressional leaders Wednesday, Treasury Secretary Janet Yellen warned of a likely mid-October deadline to raise the debt ceiling. "The most likely outcome is that cash and extraordinary measures will be exhausted during the month of October," she wrote. She said that "waiting until the last minute" to tackle the issue could "cause serious harm to business and consumer confidence."
The cock fight continues between dems and republicans. Both agree that the debt ceiling needs to be raised but republicans want dems to do it without GOP support. That way, when it blows up they don’t have to take the blame.
I’m excited to see what happens Friday.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
What up Bros Nation! How is it going?! I don’t know about you but this past week has felt kind of long with no midweek Money Talkz check in. How has the market been treating you? In my case I had my shares of ups and downs but for the week I’m up several hundred dollars across various investments. On the crypto side of things I’d say about the same. I’m up over seven hundred dollars through various crypto investments. Slow and steady progress while waiting for that one breakout. Anyway, welcome to another episode of Money Talk Sundayz. It’s your big bro Stevie Bee. Hit that like share and subscribe button on your way in the door. Let’s get to the news.
In crypto news the market overall is experiencing an upswing. BTC being the biggest dog on the block all the other crypto are gunning for the top spot. Despite’s btc’s 50K sticker Solana (SOL) outperformed bitcoin. Solana ranked number 7, is a single chain, delegated proof of stake protocol whose focus is on delivering scalability without sacrificing decentralization or security.
Core to Solana’s scaling solution is a decentralized clock titled Proof-of-History (PoH), built to solve the problem of time in distributed networks where there is not a single, trusted, source of time. By using Verifiable Delay Functions, PoH allows each node to locally generate timestamps with SHA256 computations. This eliminates the need for the broadcasts of timestamps across the network, improving overall network efficiency.
Big moves from Solana have thrust it into the crypto limelight. Year-to-date gains come in at a whopping +6,100%, with a significant proportion of that coming over the last two weeks.
The Solana team states the technology employed in PoH enables the network, of 200 nodes, to sustain a throughput of 50,000 transactions a second with GPUs. They also claim the high scalability and quick transaction times have attracted a lot of institutional interest.
Solana's support for smart contracts enables it to be used for NFTs, decentralized finance and other blockchain-based applications—and has helped make it a popular competitor to Ethereum, even earning it the moniker "ETH killer," alongside tokens like Polkadot and Cardano. The blockchain claims to offer faster transaction speeds than Ethereum, but currently only handles about 6,000 transactions per second—a fraction of the more than 50,000 it claims to support.
Meanwhile, the price of Solana's native sol token hit an all-time high of $145.22 Friday morning, surging nearly 25%—the best-one day gain among top cryptocurrencies—to help it overcome meme token dogecoin as the world's seventh-largest cryptocurrency.
In a sign Solana may be gaining legitimacy as a long-term investment, Jonas Luethy, a sales trader at London-based digital asset broker GlobalBlock, said its token's price gains seemed to be driven by direct purchases without debt, as opposed to the speculative leveraged trading that's driven many of the gains in tokens like dogecoin.
One thing to watch for of course is the ever pressing need for regulation in the wild wild west of digital currency. Last month, Gary Gensler, chair of the Securities and Exchange Commission, identified decentralized finance, which offers cryptocurrency loans that bypass traditional financial intermediaries like banks, as one of the main areas in the industry that may warrant additional regulation. Over the weekend, the value of decentralized finance projects pinned to the Solana's blockchain surpassed $3 billion for the first time ever, nearly tripling this month alone.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
What up Bros Nation! How is it going?! I don’t know about you but this past week has felt kind of long with no midweek Money Talkz check in. How has the market been treating you? In my case I had my shares of ups and downs but for the week I’m up several hundred dollars across various investments. On the crypto side of things I’d say about the same. I’m up over seven hundred dollars through various crypto investments. Slow and steady progress while waiting for that one breakout. Anyway, welcome to another episode of Money Talk Sundayz. It’s your big bro Stevie Bee. Hit that like share and subscribe button on your way in the door. Let’s get to the news.
Vinco Ventures' (BBIG) stock price has remained very volatile in the last few days. On an overall basis, it has gained 160 percent in the last month or so. Since the beginning of 2021, BBIG stock is up by more than 480 percent.
Vinco Ventures is an acquisition company that focuses on the B.I.G. (buy, innovate, grow) strategy. It mainly works in the media and content space and tries to leverage the internal traffic platforms of Honey Badger and Social Pulse Media to determine the highest conversion traffic and target accordingly.
There have been many developments that have led to the wild ride for BBIG stock. First, BBIG and its joint venture partner Zash Global Media and Entertainment acquired a short-form video platform in July. Lomotif has more than 225 million app installations and over 31 million monthly active users worldwide. Since CCV's investment in 2018, the company has been among the fastest rising video-sharing social networking platforms, with 225+ million Lomotif app installations in over 200 international locations in 300+ languages. In accordance with outdoors monitoring providers, over 300 million movies are played on the platform monthly. Over 10 billion atomic UGC (User Generated Content) clips have been used to create greater than 750 million movies on the platform since its launch. In August, BBIG also launched a platform for music streaming and NFTs.
Another major catalyst for BBIG stock has been its rising popularity with social media sites, especially on Reddit and Stocktwits. The users are praying for a short squeeze and are buying the shares and call options with a potential short squeeze in mind.
The number of shares shorted is relatively small compared to the average trading volume of the stock. Therefore, the short squeeze catalyst might exhaust itself soon.
Recently, the company reported its second-quarter results, which were disappointing. Its operating loss for the second quarter was $4.97 million compared to $1.2 million in the second quarter of 2020. Its revenues for the second quarter of 2021 also declined by 48 percent YoY. Its financials haven't provided much strength to its fundamental investment case.
As far as valuation is concerned, BBIG stock is currently trading at a Last Twelve Months Enterprise Value-to-revenue multiple of 34.8x. According to Yahoo Finance, the industry average is 1.65x. Therefore, BBIG is trading at a much higher premium than the industry. A lot of optimism has already been priced into the stock with nearly 500 percent gains YTD.
The stock closed Friday at 7.98 well above its 20-day moving average of 4.24. it had a trading volume of 126.6 million shares indicating a high interest and lots of activity/volatility in this stock. The shares traded lower with abnormally high volume most likely attributed to retail investors raking in profits. According to data from Benzinga Pro, Vinco Ventures has a total share float of 60.01 million, of which 11.67 million shares are sold short, representing 19.44% of shares sold short.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
What up Bros Nation! How is it going?! I don’t know about you but this past week has felt kind of long with no midweek Money Talkz check in. How has the market been treating you? In my case I had my shares of ups and downs but for the week I’m up several hundred dollars across various investments. On the crypto side of things I’d say about the same. I’m up over seven hundred dollars through various crypto investments. Slow and steady progress while waiting for that one breakout. Anyway, welcome to another episode of Money Talk Sundayz. It’s your big bro Stevie Bee. Hit that like share and subscribe button on your way in the door. Let’s get to the news.
Call it the stock market’s version of the “sequel effect.” January’s meme stock runup was so enjoyable that investors can’t help but try short squeezes again. This week, the 15 most shorted stocks have risen 31%, wildly outperforming the S&P 500’s 0.76% gain over the same time. SPACs are just collateral damage of attention-deficit investors.
Vaxart, vaxart, vaxart. While doing my review of Vaxart for today’s episode I came across another biotech stock that’s competing with VXRT. That company is Oramed Pharmaceuticals. Oramed is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Its pipeline products are ORMD-0801 Type 1, ORM-0801 Type 2 and ORMD-0901. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule. It is anticipated for use as a complementary agent to insulin injections in the treatment of Type I diabetes Mellitus (T1DM) and T2Dm disease. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM.
Knowing there is another company working on a Covid pill how do they compare? Let’s start with the house favorite, VXRT.
Off rip, Vaxart has already obtained the FDA approval to begin phase 2 clinical trials with its tablet vaccine candidate. That trial will be commencing shortly. As of this recording VXRT is trading at 8.71. It closed Friday September 3rd 11 cents below it’s 20 day moving average with a trading volume of 2.89 million. The firm has a fifty day simple moving average of $8.17 and a 200-day simple moving average of $7.30. The company has a market capitalization of $1.10 billion.
Notably, Julie M. Cherrington joined VXRT Board of Directors. When Julie joined the board of Rakovina Therapeutics this is what they had to say about her.
"Julie M. Cherrington is an accomplished life science executive with a record of demonstrated success bringing drug candidates into human clinical trials and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products…”
She is a driving force for multiple products getting FDA approved and moved to market. She’s also served on the board of Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics to name a few.
Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco.
Her credentials are not to be effed with at all. With that being said, Vaxart is in a good place to make some real game changing moves.
Oramed on the other hand has a few factors tipping the scale in their favor. Oramed (ORMP) has outperformed even Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX), the established vaccine makers that have already received FDA authorization for their messenger-RNA-based shots.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Welcome to Money Talk Sundayz everybody. I’m your investment bro Stevie Bee. First off I just want to say to the people of Louisiana and everyone effected by Hurricane Ida, stay strong, stay safe, and keep your head up. I lived through Hurricane Andrew so I know tough times are ahead especially with Covid in the mix. First responders, you are not valued nearly as much as you should be until something catastrophic occurs but just know, we appreciate everything you do. Again, everyone in the path of the storm, stay safe, stay resilient, and this too shall pass.
Bros Nation, again thanks for tuning in. Have some pertinent info to cover today that you should keep in mind going into this week. We’re going to talk VXRT. Can’t get enough VXRT as we anticipate the next moves. We’re also going to talk about BBIG (Vinco Ventures). I was just introduced to this stock this morning and from what I’ve seen so far I want in. So you know the deal. Hit that like share and subscribe buttons. Let your peeps know you’re here. Let’s get to it!
Subscribe: https://anchor.fm/moneytalksundayz/subscribe
Before I jump into Vaxart, I have to clear up some miscommunication from yesterday’s episode on MMAT. In that broadcast I stated I bought in on MMAT around 2.50. I was “guesstimating” where I bought in at because I was more focused on doing the broadcast. Several viewers have pointed out that MMAT has never gone down to 2.50. While that is not true because it has fallen that low if you look at the chart history but at the time I bought in it was not that low. I bought in at 2.86. not 2.50. That is the actual amount and not an estimate.
Now VXRT. So much like the rest of you, when I initially bought in on VXRT I knew nothing about a lawsuit. I had no clue that the SEC was investigating claims that Vaxart embellished its role in Operation Warp Speed. I’m sure to many of you listening right now this is news so first here’s a quick summary.
Last summer, in June to be precise, the company claimed it was one of the few companies selected to participate in Operation Warp Speed and that their oral vaccine was the only one being evaluated. That announcement reportedly caused prices to go up to $17 from less than $3 previously. Days after that occurrence, Armistice Capital LLC, the hedge company that partly controls Vaxart, sold a large number of shares raking in over $200 million in profit.
The thing is Vaxart was not among the companies selected by the Trump Organization to receive funding to support their research.
In October of last year, VXRT revealed in a filing with the SEC that they were under investigation by the Feds and SEC over that announcement. Additionally, the filing revealed that there were several similar lawsuits filed in California and one in Delaware since August alleging these violations by Vaxart and a number of its officers and directors.
Now technically, these types of lawsuits are common when a company makes outrageous claims to self promote and elevate their worth. It is commonly referred to as a pump and dump scheme. When the market catches up with the bogus claims share prices plummet and shareholders lose loads of cash thus prompting lawsuits.
Now Vaxart denied the claims stating, “The Vaxart non-human primate challenge study was organized and funded by Operation Warp Speed, as stated in the June 26, 2020 company press release. The statements made in that press release are accurate and any allegation to the contrary is baseless."
Fast forward to April of this year, hedge fund Armistice and crew filed a motion to dismiss the lawsuit. The motion hearing was set for May 13th at 10 AM.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Meta Materials (MMAT) is making moves bros nation. I was THIS close to missing the squeeze but thanks to one viewer by the name of Kathy I’m already on the train. The stock is up nearly 21% and rising. Back in May this stock was trading around the $3-4 range to surging up to a high of more than $21 in June. It has since pulled back but its rearing for another go. So what is MMAT? Is now a good time to jump in? Buy the rumor and sell the news! Let’s get to it.
Subscribe: https://anchor.fm/moneytalksundayz/subscribe
Welcome to Money Talkz. I’m your investment bro Stevie Bee and thanks for tuning in to another episode. Today we’re going to talk about Meta Materials. Make sure you hit that like button. Share with anyone you know that’s looking into MMAT. Subscribe to the podcast or the youtube channel so you can always be up on the latest. Again thank you to all the viewers, all the listeners. Your engagement and interaction is doing so much more than you realize so THANK YOU!
Meta Materials, ticket symbol MMAT, engages in the manufacture and development of functional materials servicing various sectors and industries. Its technology platform enables the global brands to deliver products to customers in consumer electronics, 5G communications, health and wellness, aerospace, automotive, and clean energy. With such a diverse output its no wonder the benefits of meta is finally coming to light.
Meta was founded by George Palikaras and Themos Kallos on the 15th of August 2011. It is based in Nova Scotia, Canada. The company delivers previously unachievable performance across a range of applications by inventing designing, developing, and manufacturing sustainable, highly functional materials. This producer of high-performance nanocomposites and functional materials has seen a boon as a result of a variety of factors.
Factor 1: MMAT has formed a scientific advisory board. This group of award-winning scientists will be a catalyst the company hopes will drive future innovation. Indeed, as a company that is on the cutting edge of technological breakthroughs in the high-tech materials it produces, investors appear to be betting on a stronger and more diverse pipeline of prospective products in the future.
Additionally, one of the goals for this board to to assess new opportunities for mergers and acquisitions (M&A). Meta Materials has grown in a number of ways, and one has been through acquiring strategic technologies. The hope is that this group of experts can guide such decisions in a way that’s positive for shareholders.
The announcement of this board has investors looking past the hype of the stock and considering that actual soundness of the company. Investors can now focus on the science of MMAT and speculate about their innovative prowess. The more products Meta Materials can put in its pipeline, the greater the likelihood of explosive long-term growth.
Factor 2: Growth stocks in general are getting a lifeline from the Federal Reserve. Investors are factoring in the continuation of easy money policies, providing a more generalized boost to growth stocks.
Factor 3: Most importantly, MMAT is in the crosshairs of retail traders as a short-squeeze candidate. It has a relatively small float. The previous squeeze last quarter saw the share price go up nearly twenty dollars. Now trading around $4.15 per share, investors who are looking to take a flyer on a potential near-term winner appear to be piling into this speculative play.
As I mentioned before, I am invested in it. I don’t have nearly as many shares as I do VXRT or BTX but I have a good enough number starting off. Thanks again to Kathy for requesting a review of this stock.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Brooklyn ImmunoTherapeutics Inc (BTX) is a clinical stage biopharmaceutical company. BTX stock is higher by 28.44% over the past week up 4.69% while the S&P 500 is down -0.09% as of 10:09 AM on Thursday, Aug 26. BTX had its gamestopping moment in April, rising nearly 20x. Within a month after the company arrived in the stock market, the stock went up 1800%, and this fetal stage company suddenly had a market cap of nearly $2bn… but can it make a Gamestop type comeback? Let’s find out.
Subscribe: https://anchor.fm/moneytalksundayz/subscribe
Welcome to Money Talkz, my midweek broadcast for Money Talk Sundayz. It’s your investment bro Stevie Bee. You know the rules… shoot me a like, share, and subscribe if you haven’t done so already. I want to give you guys a special shout out for making the podcast numbers double this week. I was looking at the metrics and was pleasantly surprised so thank you very much. Let’s keep that same energy going. As always if you have a request, please drop it in the comments or send me a message and I will definitely get to it asap. Finally hit that support link in the description box and we can keep it moving.
If you haven’t figured it out already I have a thing for biotech/biopharma stocks. I[ve said it previously. I work in IT supporting the healthcare field so I have almost an insider view to certain takeaways when it comes to these stocks. Today, I want to talk BTX, or Brooklyn ImmunoTherapeutics Inc. Earlier this year I jumped in on this stock and made $300 in the first 30 minutes and bounced. It pulled back and then went for a bigger run (which I jumped in on as well) before collapsing under the weight of the short squeeze. Since then, I’ve been monitoring and occasionally buying up more shares in anticipation of another rally. But the question is:
Is there another rally in store in the near future for BTX?
Let’s look at how BTX got started.
That first short squeeze started off with a Bloomberg article on April 6, and it happened for a number of reasons:
BTX had a super ultra float, just about 1.12 million shares in March when it launched.
Its precursor company, NTN Buzztime, had a high short interest, and although there was absolutely no relation between the two businesses, the short interest carried through.
r/wallstreetbets and other retail social media hotspots were abuzz with an interest in squeezing the biopharma sector.
On April 5, 2 million shares of BTX were traded. On April 6, that number jumped to 44 million! All these things coalesced together to give BTX that tremendous boost. That rocket launch had absolutely nothing to do with the company's development profile or fundamentals. The fundamentals have been referred to as terrible at best. The company was very low on cash when they launched, and - based on just the science, the management, or the fundamentals - nobody seemed too interested in Brooklyn Therapeutics.
Out of nowhere, and with the help of publicity from the Bloomberg article people started taking notice including retail investors frequenting wallstreetbets’ reddit platform. The smart thing that the company did was to take advantage of the squeeze to issue and sell additional shares of its own. Within 2 weeks of the start of the squeeze, they entered into an agreement with Lincoln Park to sell $20 million worth of freshly issued shares to them. A month later, they amended the agreement to sell $40 million worth of shares. This raised the cash reserves of the company considerably, while adding to the shares outstanding, and eventually to the float. Currently, shares outstanding are 42 million, and the float is 28 million.
The biggest development for the company has been the $125mn deal to acquire Novellus Therapeutics. The deal consists of $17.4M in cash and $107.6M in Brooklyn shares.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
What up Bros Nation. How’s it going, how’s it going? Hope you’re having a good weekend and ready to get back to this money. It’s our first official Money Talk Sundayz livestream. Let’s see how this goes. On the agenda today: my latest update on Vaxart (VXRT). Anyway, you know the drill. Hit that like share and subscribe and don’t forget to hit that support link in the description box. Get your whiteboard or notebook ready. Let’s get to it. Drop the beat!
Support: https://anchor.fm/moneytalksundayz/support
Welcome again to Money Talk Sundays. Let’s talk VXRT. On Thursday the company announced the creation of an eight-member Scientific and Clinical Advisory Board. Interestingly enough, even though it was just recently announced, the board's first meeting occurred on July 24, 2021 and is comprised of medical and health care professionals who are vaccine, research, and academic experts in immunology, microbiology, and infectious diseases.
"We are excited to have such preeminent leaders in their fields joining our Scientific and Clinical Advisory Board," said Vaxart's Chief Executive Officer. "We believe their participation reflects the seriousness of our mission, our science, and the disruptive promise of our oral vaccines. We will benefit from access to their years of experience and deep expertise as we continue to advance our portfolio of programs."
"I am excited by the work Vaxart is doing and the promise its work holds for improving public health," said Advisory Board member Dr. Robert B. Belshe, Adorjan Endowed Professor Emeritus of Infectious Diseases and Immunology at Saint Louis University.
"A room-temperature stable pill has the promise to change how we vaccinate people both in the U.S. and abroad. An oral tablet vaccine could help vaccinate more people sooner in more corners of the world, and thus has the potential to make a major contribution to public health globally," Dr. Belshe added.
The eight leaders joining Vaxart's Scientific and Clinical Advisory Board are:
Ralph Baric, Ph.D.
Professor, Department of Epidemiology, Microbiology, and Immunology
Gillings School of Global Public Health University of North Carolina
Robert Belshe, M.D.
Professor Emeritus, Division of Infectious Diseases, Allergy, and Immunology,
Founder, Center for Vaccine Development
St. Louis University
Stefan Gravenstein, M.D.
Professor of Medicine,
Director, Division of Geriatrics and Palliative Care
Brown University
Gregory Gray, M.D.
Professor of Medicine, Division of Infectious Diseases
Duke University School of Medicine
Harry Greenberg, M.D.
Joseph D. Grant Professor in the School of Medicine,
Associate Dean for Research
Stanford University
Marion Pepper, Ph.D.
Associate Professor, Immunology
University of Washington
Stanley A. Plotkin, M.D.
Emeritus Professor, University of Pennsylvania
Adjunct Professor, Johns Hopkins University
Principal, Vaxconsult, LLC
George Siber, M.D.
Member, Board of Directors, Affinivax
Adjunct Professor, Johns Hopkins School of Medicine
Now word is making its rounds that VXRT isn’t going to be playing the waiting game and wait for Uncle Sam. My prediction for VXRT hasn’t changed. If you haven’t started investing do so now. It is currently trading at 8.34. Let’s see how it does in premarket trading in the am.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
What’s going on Bros Nation. I’m back again with another episode of Money Talkz. Today’s episode is by viewer request. We’re going to talk Atossa Therapeutics. Before we get into it you know the drill, show some love with that like share and subscribe. Click the link in the description box to support the channel. Let’s grow this channel and this community of marathoners and let’s get to it.
Support: https://anchor.fm/moneytalksundayz/support
Atossa Therapeutics, ticket symbol ATOS. I have shares of this stock. I started investing in this stock back on the first of June when it was 3.64. It is currently at 3.225 so I’m down just a tad…. But what is the outlook for this stock? What’s going on in the world with this stock? Who is Atossa Therapeutics?
Let’s tackle the who first. ATOS is a clinical-stage biotech company whose surge in 2021 soon proved to be unsustainable. It underwent a meteoric rise from $1.52 in April to a 52-week high of $9.80 in June. But now it’s back down to the $3.20 area.
According to Yahoo! Finance “Atossa Therapeutic … discovers and develops medicines in the areas of oncology and infectious diseases. The company’s lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer.”
This all sounds good and all but what is going on with the company? Good intentions aside is this a stock worth investing in?
Well, let’s take a look at a few factors.
ATOS is down 20% in a month. The company announced its Q2 2021 financial results and offered corporate updates on recent development.
In Q2, the company received final findings from the open-label Phase II clinical study of oral Endoxifen during the “window of opportunity” between breast cancer diagnosis and surgery. Endoxifen achieved the primary endpoint in the study with a 65.1% reduction of Ki-67, which is a common tumor cell activity measure. Also, Swedish regulators gave the company authorization to commence Phase 2 clinical trial of Endoxifen in mammographic breast density reduction.
In addition, Australian regulators approved the commencement of the AT-H201 clinical study being developed for COVID-19 treatment. Atossa released final data from the Phase 1 randomized, double-blinded, sham-controlled study using its novel drug candidate AT-301, developed as a nasal spray for home use for patients diagnosed with COVID-19. The company is witnessing progress in its COVID-19 and MD programs. So, with the progress, ATOS is worth watching in the coming months.
Also, the company joined the Russell 2000 and Russell 3000 Indexes fueling June’s price jump. Institutional investors and index funds had to buy the stock due to its inclusion in these major stock indexes.
But!
ATOS has had ZERO revenue. Nada. Zilch. So to continue operations ATOS is going to need to raise some cash. The most plausible option at this point would be for the company to issue more shares leading to stock dilution. And that just might be the case with the upcoming special meeting. This meeting is going to address the cash flow problem by voting on whether the total number of common shares of stock will be raised by 100 million. It would help fund the company’s growth but at the same time a stock dilution will hurt current investors. The company’s current cash flow stands at a $12.75 million loss. What is problematic about the stock is that the company is burning cash like a fire sale. In 2019 the free cash flow was -9.14 million. In 2020 it increased to -11.58 million. This year so far its at -12.75 million.
It’s not looking to good.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
What’s up Bros Nation. It’s your big bro Stevie Bee back with another episode of Money Talkz. I did not do a podcast yesterday for Money Talk Sundayz w/ the Investment Bros BUT I have some news for you today. It’s about none other than Vaxart (VXRT). Before we jump in, you know the drill and show some love. Hit that like button and don’t forget to subscribe. Support the channel by clicking the link in the description box. Finally, share the wealth with your peeps with that share button. Now let’s get to it.
Support: https://anchor.fm/moneytalksundayz/support
It’s Money Talkz! Drop the beat!
Welcome back again. Let’s talk VXRT. People have been reaching out after my last two videos on this stock and I definitely appreciate it. The exchange of information is a gold mine in and of itself. Keep it up! One user even put me onto game about some company movements that pushed me to go and look that up and indeed there are moves being made that we as shareholders should be aware of.
First off, earnings.
Vaxart raised $36.2 million in net proceeds from its $250 million at-the-market facility in the three months ended June 30, 2021. Vaxart last posted its quarterly earnings data on August 5th, 2021. The biotechnology company reported ($0.13) Earnings Per Share for the quarter, beating the consensus estimate of ($0.14) by $0.01. Vaxart has generated ($0.36) earnings per share over the last year (($0.47) diluted earnings per share). Earnings for Vaxart are expected to grow in the coming year, from ($0.68) to ($0.65) per share. Vaxart has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 11th, 2021 based off prior year's report dates.
Vaxart ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $198.9 million, compared to $177.3 million as of March 31, 2021. The increase was primarily due to net receipts of $36.2 million from the Company's $250 million at-the-market facility entered into in October 2020 and $0.9 million from the exercise of warrants and options, partially offset by $13.2 million of cash used in operations and $2.2 million spent on property and equipment.
Remember in the last two videos I mentioned that the company signed a deal with Altesa Biosciences allowing Altesa to develop and commercialize Vapendavir. Well! With that licensing agreement Vaxart receives milestone payments up to $130 million and royalties for GLOBAL Vapendavir sales.
Money in the bank!
Considering the progress Vaxart is making, Vaxart added to its management team and strengthened its research, clinical, and manufacturing groups and R&D infrastructure. The number of R&D employees grew by 36% in the quarter to 49 full-time employees.
On the Covid front, Vaxart broadened its research into the various COVID-19 strains while continuing its development of an oral tablet vaccine. Among the most significant developments in the second quarter:
The U.S. Food and Drug Administration cleared Vaxart to move to its next phase of COVID-19 testing with a study of its next generation S-1 construct.
Vaxart is manufacturing the vaccine necessary to start the Phase 2 clinical study of its S-Wuhan construct and expects to begin this study shortly.
A Non-Human Primate study of the S&N construct along with S-Wuhan and S-South Africa constructs showed optimal performance by the S-Wuhan construct and also cross reactivity against all variants tested. The decision was made to the S-Wuhan vaccine construct into Phase 2.
I hope you enjoyed this episode. I hope this information has emboldened you to HODL your VXRT. If you did, like, share and subscribe to the channel. Please support the channel by clicking the support link in the description box. This is your big bro Stevie Bee signing off for Money Talkz. The marathon continues. We in this bih!
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Big news on the Vaxart/vaccine front Bros Nation and I am here to kick that knowledge to you. You know what they say, “buy the rumor, sell the news”. I’m kicking it to you in a packaged deal right now. Hot off them presses it is time (well its been time) to load up and get ready for some action. Are you ready? Then hit that like button. Hit that subscribe button if you’re not already part of the team. If you care about anyone other than yourself, hit that share button so this rising tide can raise all boats and let’s get to it. Vaxart in the news.
Central Hub: https://linktr.ee/moneytalksundayz
Support: https://anchor.fm/moneytalksundayz/support
Welcome to Money Talk Sundayz. I think I’m going to shorten that name though for my midweek podcasts. Maybe just Money Talkz. Anyway, it’s your big bro Stevie Bee from the Investment Bros and I want to share with you some bomb information about Vaxart.
Last week I did a segment on Vaxart explaining what the company is, what they do, and so on. If you remember from that video, one of the driving factors for the company’s speculation was their manufacturing of a Covid vaccine pill.
Now who wouldn’t rather take a pill as opposed to a shot in the arm?
Now while the Covid vaccine pill isn’t the only thing this company has in the pipeline, there is a global demand that is driving the hype and the race to be first out with a successful vaccine. Don’t believe me? Compare Moderna, Pfizer, Astrazeneca, and Johnson & Johnson. Which one has the highest value shares right now? Moderna!
First comes with the biggest piece of the pie as long as the quality is there. In the electric car market it’s Tesla.
Now just two weeks ago market analysts were counting VXRT out of the Covid vaccine pill race. They were speculating that the company would not be able to get a viable candidate out to Phase 2 & 3 testing due to rapidly falling infection rate of Covid.
The delta variant said, HODL MY BEER!
Now Covid is spiking globally and threats of another shutdown are looming worldwide. Horrible news for the vulnerable and the ill. You couldn’t ask for better news if you’re Vaxart.
Why?
A press release from the company is making investors bullish on the company’s new orally administered vaccine. The company says its Investigational New Drug application has been cleared by the Food and Drug Administration (FDA). With this new approval, the company will be able to move forward with Phase Two testing of the vaccine going into the second half of 2021.
The tablet vaccine is the only product by the company that utilizes only S-proteins; most of the company’s products use S- and N-proteins. CSO Sean Tucker says the company is pushing this particular vaccine because clinical data suggests the S-only vaccine “produced much higher serum antibodies than the one expressing both S and N proteins.”
Stock prices have already surged in the wake of the news. Trading volume has already surpassed the daily average; over 14.6 million shares of VXRT are trading so far, against the stock’s average volume of 12.7 million.
I’m not a financial advisor. Not by a long shot BUT I know when something good is over the horizon.
Psst! Something great is over the horizon as we speak!
You want to invest in something that has a clear demand and a clear wide market? Jump in now on Vaxart. It is not too late. Invest what you can afford and continue to do so on a regular basis. When this pill comes to market the share price will explode, mark my words.
Again, this was your big bro Stevie Bee from the Investment Bros signing off for Money Talk Sundayz. Let’s get this moolah! The marathon continues Bros Nation. Peace!
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Welcome back to another episode of Money Talk Sundayz w/ your Investment Bro Stevie Bee. Today I want to chat for a minute about another stock that I’m invested in that I’m real bullish about. Before popping that cherry though you got to wine and dine me. Hit that like and subscribe button if you want the goodies. If you’re feeling the podcast you can support the mission by clicking the link in the description box. You can also find the central hub for all of the MTS social media channels in the second link in the description box. Ok. I’m done. Let’s get to it.
Click for social media: https://linktr.ee/moneytalksundayz
Click to support the mission: https://anchor.fm/moneytalksundayz/support
Bros nation let’s talk Vaxart, ticket symbol VXRT. VXRT is a clinical-stage California-based biotechnology company focused on developing oral vaccines that are administered via tablet as opposed to injection. Vaxart's programs are based on its proprietary oral vaccine platform called VAAST. I stumbled onto this stock earlier this year because of the pandemic and the option of an oral vaccine it was in the process of manufacturing seemed pragmatic. As vaccinations ramp back up with the Delta variant running amok, the choice of taking a pill as opposed to getting a shot is very appealing. It’s oral tablet vaccine candidate is VXA-CoV2-1. Convenience alone would market this pill. I believed in the concept. So much so I bought shares of the company. And have been doing so regularly since May. Honestly it is the largest holding I have in my WeBull account.
Consider the advantages of using a tablet instead of a needle for a Covid-19 vaccine:
Convenient mode of administration
Rapid and painless
No needles required
Self-administration is possible – may eliminate the need to make appointments and stand in lines
Could reduce some people’s fear or hesitancy towards getting vaccinated
Vaxart’s pills can be stored at room temperature
Thus, Vaxart’s primary appeal is the pill.
But a Covid pill is not the only thing this company has to offer. In fact, it’s closer to something else than releasing the Covid pill. There is built-in value in VXRT beyond the anticipated Covid pill. The company’s anti-viral product portfolio is making exceptional progress lately. Vaxart could be not only a moneymaker, but also a lifesaver.
Let me elaborate.
VXRT has another drug in the pipeline, its clinical-stage, broad-spectrum anti-viral known as Vapendavir. The tablet addresses a host of conditions including:
Epidemic hand, foot and mouth disease
HRV infection in chronic obstructive pulmonary disease (COPD) patients
Enteroviral infections (mainly relating to children)
Seasonal recurrent lower respiratory tract infection in preschoolers
Seasonal asthma exacerbation in school-age children
Also, the company recently signed an agreement with Altesa Biosciences allowing Altesa to develop and commercialize Vapendavir.
Ok, so what’s VXRT doing today you might be wondering.
Well…
Vaxart, Inc. (Nasdaq: VXRT) today announced that it has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier.
The stock price of Vaxart Inc (NASDAQ: VXRT) increased by over 10% pre-market. Investors are responding positively to the company announcing that it has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Hey everyone and welcome to Money Talk Sundayz. I’m your investment bruv Stevie Bee. As I do these podcasts and segments I’m constantly trying to improve, incorporate new things, test things, all to better serve the viewers. Today’s segment is going to run longer than normal for the podcast but I may break it up into sections for the YouTube channel. With that being said, I have a lot to cover today from the latest “jump” in crypto from the possible Amazon cosign to market reactions from Chinese interference. So if any of these topics interest you, stick around for the latest market news and forecasts.
Support: https://linktr.ee/moneytalksundayz
Over the weekend crypto caught its second or third wind after running on fumes for the last couple months. News broke of an Amazon adoption for crypto that shot Bitcoin up from 31K to 38K and change. As we all know, as Bitcoin goes so does the rest of the crypto market proportionately.
BUT!
Not long after that news broke, Amazon came out and denied that it would accept bitcoin as payment.
Here are a couple money moves you can make to make your dollar stretch like elastic.
From Covid to the past election cycle and everything in between the news has been crazy and sensational. Now you can actually get paid for watching the news. Now you're not going to get rich quick. Hell you won't even get rich BUT every cent counts and every dollar you make you can take it and invest in the market, crypto, real estate or whatever other side hustle you have going on.
In market news tech stocks took a hit today. The sector in general ate a gut punch while the rest of the market dodged and weaved China’s breakdown. Both Nasdaq and the S&P 500 fell from record levels ahead of big tech earnings. For those that had that put option in play, I hope you got your money. Congratulations.
Overall, all three major stock indexes snapped their 5-day-winning streak buckling under the anticipation of quarterly results from some of the most prominent names in the tech sector as well as Chinese regulatory crackdowns looming.
Before I go I want to tell you a few of the companies that are reporting earnings this week. They are:
Apple
AMD (Advanced Micro Device
Microsoft
Starbucks
Visa
Matttel
Norton Life Lock
Hawaiian Holdings
Paramount Group
Thanks for tuning into Money Talk Sundayz. I covered a lot of material in this episode. I hope you found some of it valuable. Again, please like, share and subscribe. Shoot me some feedback on what you’ve just heard. I enjoy hearing from you. I reply back to as many messages as I can. Don’t forget to check us out on Spotify and Apple Podcasts if you haven’t already. Subscribe to the YouTube page. You can click the link to take you to a central hub where you will find everything Money Talk Sundayz on social media. Let me hear from you. Until next time, the marathon continues.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
If you’re here, you already know what time it is. Mind your manners coming through the door and hit that Like button. It costs you less than a second to do it. I want to chop it up with you about a stock that I’m invested in that has been making quiet moves albeit very significant moves. You won’t find too much chatter about it surprisingly when you look at its growth over the past 12 months and its projected path. There are plenty of Bio tech stocks out there but this one is solid and continues to be so week to week month to month. That stock is Sesen Bio inc.
Support: https://linktr.ee/moneytalksundayz
Sesen Bio, or ticker symbol SESN, is up a whopping 417.72% over the last 12 months. It is currently trading at $4.13. I originally bought in at $2.96 back on May 26th of this year. In around a month and a half it’s approaching double its price. This is one of my long plays and quietly one of my favorites based upon it’s performance. The only downside in my opinion about this stock is that it doesn’t pay dividends so when my long play is over I will be dumping the stock and walking away with my profit. That is unless they switch it up and decide to pay dividends.
Across the market though, SESN is rated a strong buy. InvestorsObserver’s proprietary ranking system, gives SESN stock a score of 83 out of a possible 100. That rank is influenced by a long-term technical score of 98. SESN's rank also includes a fundamental score of 80.
Wall Street Zen as well as Tip Ranks also rate the stock a buy and are bullish about it. The general consensus is the same as far as the price target goes. All sources are in agreement at or around the $7-7.50 range. It is forecasted to hit that price mark in about 10-12 months. That gives you plenty of time to load up on shares and set your alerts for when it nears the price target to get ready to move out. But you will have to move fast.
So what is SESN and how is it doing in the news?
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in phase 3 clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate for use in the treatment of various types of EpCAM-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Today, Sesen Bio Inc (SESN) stock has risen 5.83% while the S&P 500 is up 0.65% as of 1:41 PM on Wednesday, Jul 21. SESN is up $0.23 from the previous closing price of $3.86 on volume of 3,254,475 shares. Over the past year the S&P 500 has risen 33.58% while SESN is up 417.72%. SESN's revenue has grown faster (73.99% per year) than the US market average (17.35%).
Institutions currently hold roughly 23% of the stock, 10% to insiders, and the rest to retail investors. Of the institutional investing, Vanguard Group Inc holds the most with 7,195,552 shares valued at $28.28 million.
Talk about M’s baby.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
What up Bros Nation. This your boy Stevie Bee coming back with another low cost option strategy you can use to triple and even quadruple your investment. Before we get started I need you guys to help me out. Hit that like and subscribe button. It helps the channel out tremendously. Also, if you’d like to be notified the moment a video drops hit that notification bell. Finally, you guys can check out the podcast on Spotify and support the movement by clicking the link (https://linktr.ee/moneytalksundayz) in the description box.
Ok let’s get to it.
So how can I 4 times my money and how much is it going to cost me?
Remember a couple weeks ago I did a video on tripling your money with the Long Call Condor Spread? If you didn’t see that video pause this video and go to the Money Talk Sundayz channel and check it out or click this link (https://youtu.be/flHYDWsdCCU?t=562).
The method is similar to the previous one but in this instance we are doing only PUT options. It is called the Long Put Condor Spread. Here is how it works. You want to select a stock that has been moving reliably for the past month or so roughly about a half a point to a point either up or down. So yes… we are dealing with stock that is moving sideways. A good example of that would be Apple stock. From month to month the stock price has moved steadily about a point and a half or so. Not volatile at all.
You don’t want to use this strategy on volatile stocks!
Again, you do not want to use this strategy on volatile stocks!
Moving on.
Once you have your stock selected it’s time to move on to your favorite trading app and put in the option play. Keep in mind this play is all put options. With that being said:
Step 1: Go to the options screen in your app and select Put. First thing we’re going to do is sell 2 puts.
Step 2: Select the sell put option right above the share price.
Step 3: Select the sell put option right above the previous put option.
Step 4. Switch over to the Buy option and select the buy put option right above the previous sell put option selected.
Step 5. Select the buy put option directly below the stock share price.
And you’re done.
Once you have those options selected, you’ll be able to see your max loss and max profits. As you can see your max loss is only the amount it cost you to make the play. On the flip side your max profit is 4 times or a little more than the money invested to make the play.
And just like that you’ve managed to still create income in a sideways market.
I hope you enjoyed this information and found it useful. If you did, please drop a like and subscribe. Leave a comment and let me know how it worked out for you. Now you don’t have to sit around and watch your portfolio tread water for weeks in a sideways market. You can now still make steady gains even while the market seems stagnant.
This has been Stevie Bee. Thanks for tuning in to the Money Talk Sundayz Channel with your Investment bro. I look forward to sharing more new tidbits that come my way with you all. Together we can do this. Let’s make the most of this market and get what’s ours. If you have a request for a how-to video let me know in the comments or dm me. Your video might be the next one I do! Until next time, the marathon continues.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
How is it going Bros’ nation? Welcome back to another episode. Today I want to chat for a bit about CLF, Cleveland Cliffs Inc. I stumbled across this stock today and I saw something promising, and I thought I would share. Before getting into it though, hit that like, share, and subscribe so new folks can be introduced to what we are doing here at Bros nation. I took a little family vacay, but I am back, and I have some extra free time on my hands due to quarantine so…. Market watching and playing is my focus until this quarantine is over. FYI I am covid negative for those that are wondering.
Support: https://linktr.ee/moneytalksundayz
Anyway, on to CLF.
It is currently ranked a strong buy on Tip Ranks with a prospective price target of 29.62 at the mid-range. On the high end its priced at $39 and $24 on the low end. Currently it is trading at 19.10. This morning the stock saw “unusual options activity” according to Benzinga. Now unusual options activity can be triggered by one of three things: 1. Exceptionally large trading volume which refers to the number of contracts traded over a given amount of time. 2. The trading of a contract with an expiration date in the distant future also marks unusual activity. Generally speaking, when it comes to options the farther out the expiration date of the contract, the higher the potential for it to reach the strike price and grow its time value. Time value in this respect is important because it represents the difference between the strike price and the value of the underlying asset. And finally, 3. Out of the money contracts are considered unusual because the contracts are purchased with a strike price that is far from the underlying asset price. Buyers and sellers attempt to take advantage of a large profit margin in these cases because they are banking on the value of the underlying asset to change dramatically in the future.
With these signatures coming into play, one would be hard pressed not to at least add this stock to their watch list. Its next earnings report date is this Thursday the 22nd. If I were to run an option play, I would probably play a call option and sell it right before close Wednesday afternoon.
Why?
Wall Street expects a year-over-year increase in earnings on higher revenues when Cleveland-Cliffs (CLF) reports results for the quarter ended June 2021. While this widely known consensus, outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on July 22, 2021, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it is worth handicapping the probability of a positive EPS surprise. Considering that I just transferred funds to my Webull account this morning, those funds are not available for options trading I am playing the long swing trade and purchased a significant number of shares to hold until I reach my target price before selling. CLF does not currently pay dividends, so I will not need to buy and hold this stock so once my swing trade is over, its on to the next play. One thing I am trying to do is clear the clutter that I have made with all the different stocks that I have plays in now. I am holding on to all my dividend paying stocks but for all the others, once I have made my profit, I am dumping them until another play presents itself.
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Hedgies and institutional investors are on their heels while corporate America is finally respecting the wishes of the common man and woman. So much so, we now have an actual say in the boardroom. Case in point is the latest resurrected cinema giant AMC. Think about it. Orange in chief ran on an America First platform while greedy capitalist tried to shutter American Movie Classic. Now that’s pretty commie of them. But alas, true patriots answered the call and the tree of liberty is flourishing in the blood money of tyrants.
https://linktr.ee/moneytalksundayz
A little over the top? Sue me. It’s Stevie Bee and welcome Bros nation to another check-in for Money Talk Sundayz hosted by the Investment Bros. Major deets on the AMC front but before I go further, hit that like button. Hit that subscribe button if you’re not already part of the team. Click that link in the description box and get plugged in because we’re about to be packing some major wattage. You can charge your batteries here and fill up on the latest.
AMC was looking to issue out 25 million new shares to capitalize on its meteoric rise since the beginning of the year. Normally when something like that happens that price of the stock reduces significantly but in this case, not only would that happen, it would also buy some wiggle room for the fascists looking to short America. Remarkably, AMC already issued more than 100 million new shares this year without losing upward momentum. In fact, the stock is nor 23 times higher than it was at the beginning of the year.
But we are coming to a crossroads because AMC has hit a roadblock since it’s company charter only allows it to issue 524 million shares of common stock. 513 are already outstanding. With that cap, the “meme stock” only has 11 million new shares it can issue before hitting its own ceiling. Seeing that hurdle, the CEO is asking shareholders to approve 25 million new shares.
According to Quartz, of the 80% held, many are activist investors looking to flip the playing field on its side and level it out. In the US, the 10 largest institutional investors, like hedge funds or endowments, make up 43% of the average public company’s ownership… but that is not the case for AMC. It is to the point where AMC CEO had to take notice. Meme traders voiced their opposition on Reddit to the new stock issuance to execute another short squeeze and drive the price up higher. Why?
Because the day of reckoning is nigh.
This is a huge win for those hodling AMC (such as myself.)
For a few high-profile stocks, historic roles have reversed: Individual traders coordinating online, armed with commission-free trading accounts, can supersede the wishes of management and institutional investors.
We own a major piece of the pie. About 80% or so. We OWN AMC.
When Aron decided to withdraw the stock issuance vote, the AMCStock subreddit applauded the decision. Bullish retail investors on Reddit forums, who call themselves “apes,” call CEO Adam Aron their “silverback” (the name for a dominant male gorilla). “For any apes that did not believe in our silverback or questioned his loyalty i think all those have been answered and there is absolutely no reason to doubt AA..,” wrote Reddit user 1Goalie29. “AMC as a company.. onward and upward ..AMC APES TOGETHER STRONG.
Support: https://linktr.ee/moneytalksundayz
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
Bitcoin & Crypto Consolidate, S&P 500 Big 1st Half, & Options Strategy for Beginners
Crypto wars continue with China’s continued crackdown and now US regulations are looming for cryptocurrency. Regulatory crackdowns and environmental issues continue to plague crypto so for the moment we remain in a consolidation phase. In the stock market, after a big first half, the wolves are circling the wagon expecting reversals to be forthcoming. And finally, for new option traders such as myself I introduce to you an option strategy to help you get your feet wet. Welcome to Money Talk Sundayz.
Crypto News.
China’s continued crackdown on Bitcoin mining and transactions continues hover like a dark cloud scaring novice investors, retail investors and more who were late to the party.
BTC traded lower on Friday struggling around the $35K range. As of this taping, BTC is trading around $32K up about $1K from Saturday morning. Some analysts predict continued weakness and charts are showing the same… possibly even more regression.
Also, China’s regulatory crackdown has accelerated the decline in bitcoin’s hashrate over the past month. The hashrate refers to the total combined computational power that is being used to mine and process transactions on the blockchain.
Another dark cloud on the horizon is the potential for tighter monetary policy in the US. You know with all the hacking and ransomware and ransom being paid in BTC, Uncle Sam is finally going to throw his hat in the ring. But don’t get it twisted. The US has its own coin it wants to promote just like China. The USDCoin is pegged to the US dollar and thus America is fiending the a dollar rally which will be another threat to the crypto space.
Bitcoin trading volumes on the LMAX Digital spot exchange have surged over the past year. Because LMAX Digital “facilitates trades for institutions only and already is among the leading bitcoin spot exchanges, this depicts the current institutionalization of the bitcoin market,” according to a report by Arcane Research and LMAX Digital published on Friday. 70% of the 77 institutional investors surveyed by LMAX Digital expect asset managers, funds, and banks to be the most significant contributors to trading volume in the next three years.
On to the stock market.
The S&P 500 posted one of the best first halves ever in history as June ends. Wall Street strategists, never ones to restrain their enthusiasm when it is warranted, warn that the gains have played out. Short sellers are circling, with wagers against the largest equity exchange-traded fund rising to the highest level this year.
Pushing against the wall of worries are the growing numbers of retail traders who bought the dip during the pandemic bear market and have since become the staunchest allies of this bull market. A week ago, when the S&P 500 dropped more than 1%, retail investors poured a record $2 billion into equities, according to data compiled by Vanda Research.
The fight is on ladies and gentlemen. Let’s get ready to RUMBLE!!!!!!
Finally, here is an option strategy I want to share with you guys. This strategy will allow you to double and triple your money in a week. It’s powerful, cheap and almost always brings you a return. It is the Long Call Condor Spread. It works by choosing a stock that has been trading sideways for a couple weeks and is not really expecting any volatile movement up or down. You go into this strategy betting that the stock will end the week around the same price it started the week. How do you implement the strategy?
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message
June 18th is right around the corner and the significance of that date is all options expire on that day. Those who are in a losing play and have not bailed by then will be force to cover those positions.... and if you're holding the bag at the time, that's one hot potato you're not going to be able to dump on someone else.
So what does that have to do with AMC and synthetic shares?
EVERYTHING!
Like. Share. Subscribe!
This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
Send in a voice message: https://anchor.fm/moneytalksundayz/message